MIME-Version: 1.0 X-Document-Type: Workbook Content-Type: multipart/related; boundary="----=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Workbook.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

This page should be opened with Microsoft Excel XP or newer.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet01.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Document and Entity Information (USD  $)	12 Months Ended
Dec. 31, 2010	Feb. 18, 2011	Jun. 30, 2010
Document and Entity Information
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec 31, 2010
Document Fiscal Year Focus	2010
Document Fiscal Period Focus	FY
Trading Symbol	gild
Entity Registrant Name	GILEAD SCIENCES INC
Entity Central Index Key	0000882095
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 25,450,411,375
Entity Common Stock, Shares Outstanding		795,264,644

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet02.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Balance Sheets (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Assets
Cash and cash equivalents	$ 907,879	$ 1,272,958
Short-term marketable securities	1,190,789	384,017
Accounts receivable, net of allowances of  $150,942 at December 31, 2010 and  $132,810 at December 31, 2009	1,621,966	1,389,534
Inventories	1,203,809	1,051,771
Deferred tax assets	279,339	295,080
Prepaid taxes	320,424	274,196
Prepaid expenses	67,632	78,111
Other current assets	116,244	66,891
Total current assets	5,708,082	4,812,558
Property, plant and equipment, net	701,235	699,970
Noncurrent portion of prepaid royalties	203,790	226,250
Noncurrent deferred tax assets	153,379	101,498
Long-term marketable securities	3,219,403	2,247,871
Intangible assets	1,425,592	1,524,777
Other noncurrent assets	181,149	85,635
Total assets	11,592,630	9,698,559
Liabilities and Stockholders' Equity
Accounts payable	803,025	810,544
Accrued government rebates	325,018	248,660
Accrued compensation and employee benefits	147,632	132,481
Income taxes payable	1,862	167,623
Other accrued liabilities	437,893	384,015
Deferred revenues	103,175	122,721
Current portion of convertible senior notes, net and other long-term obligations	646,345	5,587
Total current liabilities	2,464,950	1,871,631
Long-term deferred revenues	32,844	43,026
Convertible senior notes, net	2,838,573	1,155,443
Long-term income taxes payable	107,025	87,383
Other long-term obligations	27,401	35,918
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, par value  $0.001 per share; 5,000 shares authorized; none outstanding
Common stock, par value  $0.001 per share; 2,800,000 shares authorized; 801,998 and 899,753 shares issued and outstanding at December 31, 2010 and 2009, respectively	802	900
Additional paid-in capital	4,648,286	4,376,651
Accumulated other comprehensive income (loss)	30,911	(5,758)
Retained earnings	1,183,730	1,995,272
Total Gilead stockholders' equity	5,863,729	6,367,065
Noncontrolling interest	258,108	138,093
Total stockholders' equity	6,121,837	6,505,158
Total liabilities and stockholders' equity	$ 11,592,630	$ 9,698,559

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet03.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Balance Sheets (Parenthetical) (USD  $) In Thousands, except Share data	Dec. 31, 2010	Dec. 31, 2009
Consolidated Balance Sheets
Accounts receivable, allowances	$ 150,942	$ 132,810
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,800,000,000	2,800,000,000
Common stock, shares issued	801,998,000	899,753,000
Common stock, shares outstanding	801,998,000	899,753,000

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet04.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Statements of Income (USD  $) In Thousands, except Per Share data	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Revenues:
Product sales	$ 7,389,921	$ 6,469,311	$ 5,084,796
Royalty revenues	545,970	491,818	218,180
Contract and other revenues	13,529	50,254	32,774
Total revenues	7,949,420	7,011,383	5,335,750
Costs and expenses:
Cost of goods sold	1,869,876	1,595,558	1,127,246
Research and development	1,072,930	939,918	721,768
Selling, general and administrative	1,044,392	946,686	797,344
Purchased in-process research and development			10,851
Total costs and expenses	3,987,198	3,482,162	2,657,209
Income from operations	3,962,222	3,529,221	2,678,541
Interest and other income, net	60,287	42,397	59,401
Interest expense	(108,961)	(69,662)	(65,244)
Income before provision for income taxes	3,913,548	3,501,956	2,672,698
Provision for income taxes	1,023,799	876,364	702,363
Net income	2,889,749	2,625,592	1,970,335
Net loss attributable to noncontrolling interest	11,508	10,163	8,564
Net income attributable to Gilead	$ 2,901,257	$ 2,635,755	$ 1,978,899
Net income per share attributable to Gilead common stockholders - basic	$ 3.39	$ 2.91	$ 2.15
Shares used in per share calculation - basic	856,060	904,604	920,693
Net income per share attributable to Gilead common stockholders - diluted	$ 3.32	$ 2.82	$ 2.06
Shares used in per share calculation - diluted	873,396	934,109	958,825

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet05.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Statements of Stockholders' Equity (USD  $) In Thousands, except Share data	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance, shares at Dec. 31, 2007	932,484,000
Balance, value at Dec. 31, 2007	$ 932	$ 3,416,987	$ (4,363)	$ 198,775	$ 140,299	$ 3,752,630
Distributions to (from) noncontrolling interest					61,275	61,275
Net income (loss)				1,978,899	(8,564)	1,970,335
Unrealized gain (loss) on available-for-sale securities, net of tax			(15,316)			(15,316)
Foreign currency translation adjustment			(21,149)			(21,149)
Unrealized gain (loss) on cash flow hedges, net of tax			82,068			82,068
Comprehensive income						2,015,938
Issuances under employee stock purchase plan, shares	960,000
Issuances under employee stock purchase plan, value	1	30,385				30,386
Stock option exercises, net, shares	15,443,000
Stock option exercises, net, value	15	215,724				215,739
Tax benefits from employee stock plans		209,519				209,519
Stock-based compensation, shares	191,000
Stock-based compensation, value		153,269				153,269
Repurchases of common stock, shares	(39,259,000)
Repurchases of common stock, value	(38)	(95,775)		(1,877,360)		(1,973,173)
Balance, shares at Dec. 31, 2008	909,819,000
Balance, value at Dec. 31, 2008	910	3,930,109	41,240	300,314	193,010	4,465,583
Distributions to (from) noncontrolling interest					(44,754)	(44,754)
Net income (loss)				2,635,755	(10,163)	2,625,592
Unrealized gain (loss) on available-for-sale securities, net of tax			15,868			15,868
Foreign currency translation adjustment			8,459			8,459
Unrealized gain (loss) on cash flow hedges, net of tax			(71,325)			(71,325)
Comprehensive income						2,578,594
Issuances under employee stock purchase plan, shares	932,000
Issuances under employee stock purchase plan, value	1	34,872				34,873
Stock option exercises, net, shares	12,067,000
Stock option exercises, net, value	12	187,843				187,855
Tax benefits from employee stock plans		88,368				88,368
Stock-based compensation, shares	227,000
Stock-based compensation, value		181,530				181,530
Assumption of stock options in connection with acquisition		15,655				15,655
Repurchases of common stock, shares	(23,292,000)
Repurchases of common stock, value	(23)	(61,726)		(940,797)		(1,002,546)
Balance, shares at Dec. 31, 2009	899,753,000					899,753,000
Balance, value at Dec. 31, 2009	900	4,376,651	(5,758)	1,995,272	138,093	6,505,158
Distributions to (from) noncontrolling interest					131,523	131,523
Net income (loss)				2,901,257	(11,508)	2,889,749
Unrealized gain (loss) on available-for-sale securities, net of tax			7,020			7,020
Foreign currency translation adjustment			(8,416)			(8,416)
Unrealized gain (loss) on cash flow hedges, net of tax			38,065			38,065
Comprehensive income						2,926,418
Issuances under employee stock purchase plan, shares	1,110,000
Issuances under employee stock purchase plan, value	1	32,306				32,307
Stock option exercises, net, shares	10,671,000
Stock option exercises, net, value	11	188,906				188,917
Tax benefits from employee stock plans		82,086				82,086
Stock-based compensation, shares	461,000
Stock-based compensation, value		200,595				200,595
Purchases of convertible note hedges		(362,622)				(362,622)
Sale of warrants		155,425				155,425
Deferred tax assets on convertible note hedges		39,093				39,093
Equity portion of convertible notes, net of issuance costs of  $4,018		255,517				255,517
Repurchases of common stock, shares	(109,997,000)
Repurchases of common stock, value	(110)	(319,671)		(3,712,799)		(4,032,580)
Balance, shares at Dec. 31, 2010	801,998,000					801,998,000
Balance, value at Dec. 31, 2010	$ 802	$ 4,648,286	$ 30,911	$ 1,183,730	$ 258,108	$ 6,121,837

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet06.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010
Consolidated Statements of Stockholders' Equity
Equity portion of convertible notes, issuance costs	$ 4,018

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet07.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Consolidated Statements of Cash Flows (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Operating activities:
Net income	$ 2,889,749	$ 2,625,592	$ 1,970,335
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense	67,240	64,560	51,722
Amortization expense	198,237	148,384	103,888
Purchased in-process research and development expense			10,851
Stock-based compensation expenses	200,041	180,684	153,364
In-process research and development impairment	136,000
Excess tax benefits from stock-based compensation	(81,620)	(80,186)	(191,939)
Tax benefits from employee stock plans	82,086	88,368	209,519
Deferred income taxes	12,152	(42,013)	(24,969)
Other non-cash transactions	10,408	64,456	(11,257)
Changes in operating assets and liabilities:
Accounts receivable, net	(348,875)	(356,462)	(257,161)
Inventories	(161,190)	(75,266)	(330,726)
Prepaid expenses and other assets	(70,466)	(65,667)	9,719
Accounts payable	(4,453)	203,641	312,568
Income taxes payable	(185,733)	166,334	(23,887)
Accrued liabilities	120,065	109,026	136,276
Deferred revenues	(29,728)	48,603	25,081
Net cash provided by operating activities	2,833,913	3,080,054	2,143,384
Investing activities:
Purchases of marketable securities	(5,502,687)	(2,614,046)	(3,273,112)
Proceeds from sales of marketable securities	3,033,893	1,440,509	3,026,459
Proceeds from maturities of marketable securities	683,927	435,510	193,690
Acquisitions, net of cash acquired	(91,000)	(1,247,816)	(10,851)
Capital expenditures and other	(61,884)	(230,057)	(115,005)
Net cash used in investing activities	(1,937,751)	(2,215,900)	(178,819)
Financing activities:
Proceeds from issuances of convertible notes, net of issuance costs	2,462,500
Proceeds from sale of warrants	155,425
Purchases of convertible note hedges	(362,622)
Proceeds from credit facility	500,000	400,000
Repayments of credit facility	(500,000)	(400,000)
Proceeds from issuances of common stock	221,223	222,728	246,125
Repurchases of common stock	(4,022,593)	(998,495)	(1,969,582)
Extinguishment of long-term debt		(305,455)
Repayments of long-term obligations	(5,786)	(5,648)	(4,326)
Excess tax benefits from stock-based compensation	81,620	80,186	191,939
Distributions from (to) noncontrolling interest	131,523	(44,754)	61,275
Net cash used in financing activities	(1,338,710)	(1,051,438)	(1,474,569)
Effect of exchange rate changes on cash	77,469	940	1,220
Net change in cash and cash equivalents	(365,079)	(186,344)	491,216
Cash and cash equivalents at beginning of period	1,272,958	1,459,302	968,086
Cash and cash equivalents at end of period	907,879	1,272,958	1,459,302
Supplemental disclosure of cash flow information:
Interest paid	15,748	8,990	7,388
Income taxes paid	$ 1,129,577	$ 746,224	$ 495,544

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet08.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies	12 Months Ended
Dec. 31, 2010
Organization and Summary of Significant Accounting Policies
Organization and Summary of Significant Accounting Policies	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview Gilead Sciences, Inc. (Gilead, we, us or our), incorporated in Delaware on June 22, 1987, is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Our mission is to advance the care of patients suffering from life threatening diseases worldwide. Headquartered in Foster City, California, we have operations in North America, Europe and Asia Pacific. We market products in the HIV/AIDS, liver disease, respiratory and cardiovascular/metabolic therapeutic areas. Our product portfolio is comprised of Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), Truvada® (emtricitabine and tenofovir disoproxil fumarate), Viread® (tenofovir disoproxil fumarate) and Emtriva® (emtricitabine) for the treatment of human immunodeficiency virus (HIV) infection; Hepsera® (adefovir dipivoxil) and Viread for the treatment of chronic hepatitis B; AmBisome® (amphotericin B liposome for injection) for the treatment of severe fungal infections; Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension (PAH); Ranexa® (ranolazine) for the treatment of chronic angina; Vistide® (cidofovir injection) for the treatment of cytomegalovirus infection and Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). In addition, we also sell and distribute certain products through our corporate partners under royalty-paying collaborative agreements. For example, F. Hoffmann-La Roche Ltd (together with Hoffmann-La Roche Inc., Roche) markets Tamiflu® (oseltamivir phosphate) for the treatment and prevention of influenza; GlaxoSmithKline Inc. (GSK) markets Hepsera and Viread for the treatment of chronic hepatitis B in certain territories outside of the United States; GSK also markets Volibris® (ambrisentan) outside of the United States for the treatment of PAH; Astellas Pharma US, Inc. markets AmBisome for the treatment of severe fungal infections in the United States and Canada; Astellas US LLC markets Lexiscan® (regadenoson) injection in the United States for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI); Rapidscan Pharma Solutions, Inc. markets Rapiscan (regadenoson) in certain territories outside of the United States for the inducement of pharmacological stress and/or vasodilation of the coronary vasculature strictly for purposes of diagnosing cardiovascular disease; Menarini International Operations Luxembourg SA markets Ranexa in certain territories outside of the United States for the treatment of chronic angina; and Japan Tobacco Inc. (Japan Tobacco) markets Truvada, Viread and Emtriva in Japan. Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and our joint ventures with Bristol-Myers Squibb Company (BMS), for which we are the primary beneficiary. We record a noncontrolling interest in our Consolidated Financial Statements to reflect BMS's interest in the joint ventures. All intercompany transactions have been eliminated. The Consolidated Financial Statements include the results of companies acquired by us from the date of each acquisition for the applicable reporting periods. Consolidation of Variable Interest Entities On January 1, 2010, we adopted amended guidance for the consolidation of variable interest entities. The amended guidance eliminates a mandatory quantitative approach to determine whether a variable interest gives the entity a controlling financial interest in a variable interest entity in favor of a qualitatively focused analysis. Additionally, the amended guidance requires an ongoing reassessment of whether the entity is a primary beneficiary. We adopted the provisions of this guidance on a prospective basis for our joint ventures with BMS, which we consolidate because we are the primary beneficiary. The adoption of this guidance did not have any impact on our Consolidated Financial Statements.   Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, intangible assets, allowance for doubtful accounts, prepaid royalties, clinical trial accruals, our tax provision and stock-based compensation. We base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. Revenue Recognition Product Sales We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery to the customer has occurred, the price is fixed or determinable and collectability is reasonably assured. Upon recognition of revenue from product sales, provisions are made for government rebates such as Medicaid reimbursements, customer incentives such as cash discounts for prompt payment, distributor fees and expected returns of expired products, as appropriate. Items Deducted from Gross Product Sales Government Rebates We estimate reductions to our revenues for government-managed Medicaid programs as well as for certain other qualifying federal, state and foreign government programs based on contractual terms, historical utilization rates, new information regarding changes in these programs' regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and, for our U.S. product sales, channel inventory data obtained from our major U.S. wholesalers in accordance with our inventory management agreements. Government rebates that are invoiced directly to us are recorded in accrued government rebates on our Consolidated Balance Sheets. For qualified programs that can purchase our products through wholesalers at a lower contractual government price, the wholesalers charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as allowances against accounts receivable. Cash Discounts We estimate cash discounts based on contractual terms, historical utilization rates and our expectations regarding future utilization rates. Distributor Fees Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for the compliance of certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.   Product Returns We do not provide our customers with a general right of product return, but permit returns if the product is damaged or defective when received by the customer, or in the case of product sold in the Unites States and certain countries outside the United States, if the product has expired. We will accept returns for product that will expire within six months prior to or that have expired up to one year after their expiration dates. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns. Royalty Revenues Royalty revenue from sales of Lexiscan and AmBisome by Astellas US LLC and Astellas Pharma US, Inc., respectively, is recognized in the month following the month in which the corresponding sales occur. Royalty revenue from sales of our other products is generally recognized when received, which is generally in the quarter following the quarter in which the corresponding sales occur. Contract and Other Revenues Revenue from non-refundable up-front license fees and milestone payments such as under a development collaboration or an obligation to supply product, is recognized as performance occurs and our obligations are completed. In accordance with the specific terms of our obligations under these arrangements, revenue is recognized as the obligation is fulfilled or ratably over the development or manufacturing period. Revenue associated with substantive at-risk milestones is recognized based upon the achievement of the milestones as defined in the respective agreements. Advance payments received in excess of amounts earned are classified as deferred revenue on our Consolidated Balance Sheets.   Shipping and Handling Costs Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of goods sold in our Consolidated Statements of Income. Research and Development Expenses Major components of research and development (R&D) expenses consist of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (CROs), materials and supplies, licenses and fees, milestone payments under collaboration arrangements and overhead allocations consisting of various support and facilities related costs. We charge R&D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. We validate our accruals quarterly with our vendors and perform detailed reviews of the activities related to our significant contracts. Based upon the results of these validation processes, we assess the appropriateness of our accruals and make any adjustments we deem necessary to ensure that our expenses reflect the actual effort incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CRO and certain non-cancelable expenses incurred at any point of termination. Amounts paid in advance related to uncompleted services will be refunded to us if a contract is terminated. Some contracts may include additional termination payments that become due and payable if we terminate the contract. Such additional termination payments are only recorded if it becomes probable that a contract will be terminated. Advertising Expenses We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were  $116.5 million in 2010,  $108.1 million in 2009 and  $96.2 million in 2008. Net Income Per Share Attributable to Gilead Common Stockholders Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options, restricted stock units and performance shares and the assumed exercise of warrants relating to the convertible senior notes due in 2011 (2011 Notes), 2013 (2013 Notes), 2014 (2014 Notes) and 2016 (2016 Notes) (collectively, the Notes) are determined under the treasury stock method. Because the principal amount of the Notes will be settled in cash, only the conversion spread relating to the Notes is included in our calculation of diluted net income per share attributable to Gilead common stockholders. Our common stock resulting from the assumed settlement of the conversion spread of the Notes has a dilutive effect when the average market price of our common stock during the period exceeds the conversion prices of  $38.75,  $38.10,  $45.08 and  $45.41 for the 2011 Notes, 2013 Notes, 2014 Notes and 2016 Notes, respectively. For the years ended 2010, 2009 and 2008, the average market prices of our common stock exceeded the conversion prices of the 2011 and 2013 Notes and the dilutive effects are included in the accompanying table. Warrants relating to the 2011 Notes, 2013 Notes, 2014 Notes and 2016 Notes have a dilutive effect when the average market price of our common stock during the period exceeds the warrants' exercise prices of  $50.80,  $53.90,  $56.76 and  $60.10, respectively. The average market prices of our common stock during the years ended December 31, 2010, 2009 and 2008 did not exceed the warrants' exercise prices relating to any of the Notes; therefore, these warrants did not have a dilutive effect on our net income per share for those periods. Stock options to purchase approximately 22.5 million, 17.4 million and 11.4 million weighted-average shares of our common stock were outstanding during the years ended December 31, 2010, 2009 and 2008, respectively, but were not included in the computation of diluted net income per share attributable to Gilead common stockholders because their effect was antidilutive.   The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in thousands):        Year Ended December 31,        2010      2009      2008   Numerator:          Net income attributable to Gilead     $ 2,901,257        $ 2,635,755        $ 1,978,899                               Denominator:          Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders      856,060         904,604         920,693    Effect of dilutive securities:          Stock options and equivalents      16,606         23,850         30,727    Conversion spread related to the 2011 Notes      222         2,684         3,559    Conversion spread related to the 2013 Notes      508         2,971         3,846                               Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders      873,396         934,109         958,825                               Stock-Based Compensation Share-based payments to employees are recognized in the Consolidated Statements of Income based on their fair values and the benefit of tax deductions in excess of recognized compensation cost are reported in the Consolidated Statements of Cash Flows as a financing activity, rather than as an operating activity. The calculated pool of excess tax benefits is recorded as part of additional paid-in capital (APIC). Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three months or less on the purchase date to be cash equivalents. We may enter into overnight repurchase agreements (repos) under which we purchase securities with an obligation to resell them the following day. Securities purchased under agreements to resell are recorded at face value and reported as cash and cash equivalents. Under our investment policy, we may enter into repos with major banks and authorized dealers provided that such repos are collateralized by U.S. government securities with a fair value of at least 102% of the fair value of securities sold to us. Other eligible instruments under our investment policy that are included in cash equivalents include commercial paper, money market funds and other bank obligations. Marketable and Nonmarketable Securities We determine the appropriate classification of our marketable securities, which consist primarily of debt securities and which include auction rate securities and variable rate demand obligations, at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Interest and other income, net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline. As a result of entering into collaborations, from time to time, we may hold investments in non-public companies. We record these nonmarketable securities at cost in other noncurrent assets, less any amounts for other-than-temporary impairment. We regularly review our securities for indicators of impairment. Investments in nonmarketable securities are not material for the periods presented. Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate at December 31, 2010. Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application (NDA) filed with the U.S. Food and Drug Administration (FDA) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers were interrupted for any reason, we may be unable to ship our commercial products or to supply any of our product candidates for clinical trials.   Accounts Receivable Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government rebate programs, cash discounts for prompt payment, doubtful accounts and sales returns. Estimates for wholesaler chargebacks for government rebates, cash discounts and sales returns are based on contractual terms, historical trends and our expectations regarding the utilization rates for these programs. Estimates for our allowance for doubtful accounts is determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off have been insignificant and consistent with management's expectations.   Inventories Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of our inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the impairment is first recognized. Prepaid Royalties Prepaid royalties are capitalized at cost, which initially is equivalent to the present value of the future royalty obligation that we would expect to pay to the licensor on expected future levels of product sales incorporating the related technology. We review periodically the expected future sales levels of our products and any indicators that might require a write-down in the net recoverable value of our asset or a change in the estimated life of the prepaid royalty. We amortize our prepaid royalties to cost of goods sold over the remaining life of the underlying patent based on an effective royalty rate derived from forecasted future product sales incorporating the related technology. We review our effective royalty rate at least annually and prospectively adjust the effective rate based on significant new facts or circumstances that may arise from our review. Our prepaid royalties are primarily comprised of emtricitabine royalties we paid to Emory University (Emory) for the HIV indication when we and Royalty Pharma purchased the royalty interest owned by Emory in 2005. Under the terms of the transaction, we and Royalty Pharma paid 65% and 35%, respectively, of the total purchase price of  $525.0 million to Emory in exchange for the elimination of the emtricitabine royalties due to Emory on worldwide net sales of products containing emtricitabine. As a result of this transaction, we capitalized as prepaid royalties our 65% share of the  $525.0 million purchase price, or  $341.3 million. As of December 31, 2010 and 2009, we had an unamortized prepaid royalty asset of  $219.5 million and  $245.0 million, respectively. In 2010, 2009 and 2008,  $25.5 million,  $29.9 million and  $31.8 million were amortized to cost of goods sold, respectively. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows:   Description    Estimated Useful Life Buildings and improvements    20-35 Laboratory and manufacturing equipment    4-10 Office and computer equipment    3-7 Leasehold improvements    Shorter of useful life or lease term Office and computer equipment includes capitalized software. We had unamortized capitalized software costs of  $22.5 million and  $25.2 million on our Consolidated Balance Sheets as of December 31, 2010 and 2009, respectively. Leasehold improvements and capitalized leased equipment are amortized over the shorter of the lease term or the asset's useful life. Amortization of capitalized leased equipment is included in depreciation expense. Capitalized interest on construction in-progress is included in property, plant and equipment. Interest capitalized in 2010, 2009 and 2008 was not significant. Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Other intangible assets primarily related to marketed products and purchased in-process research and development (IPR&D) projects from our acquisitions of CGI Pharmaceuticals, Inc. (CGI) in July 2010 and CV Therapeutics, Inc. (CV Therapeutics) in April 2009, and are measured at their respective fair values as of the acquisition date. We do not amortize goodwill and other intangible assets with indefinite useful lives. We test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and in between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the assets below their carrying amounts. Intangible assets with finite useful lives are amortized over their estimated useful lives and are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. We amortize the intangible asset related to Ranexa, which we acquired from CV Therapeutics, over its estimated useful life using an amortization rate derived from our forecasted future product sales for Ranexa. Our product sales forecasts are prepared annually and determined using our best estimates of future activity and consider such factors as historical and expected future patient usage or uptake of our products, the introduction of complimentary or combination therapies or products and future product launch plans. If a previously unanticipated and significant change occurs to our sales forecasts, we will prospectively update the rate used to amortize our intangible asset related to Ranexa which may increase future cost of goods sold, as that is where we record the amortization expense. We amortize the intangible asset related to Lexiscan, which we also acquired from CV Therapeutics, over its estimated useful life to cost of goods sold on a straight-line basis. Given that current Lexiscan revenues consist of royalties received from a collaboration partner and our lack of ongoing access and visibility into that partner's future sales forecasts, we cannot make a reasonable estimate of the amortization rate using a forecasted product sales approach. Impairment of Long-Lived Assets The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts or circumstances both internally and externally that may suggest impairment. Specific potential indicators of impairment include a significant decrease in the fair value of an asset, a significant change in the extent or manner in which an asset is used or a significant physical change in an asset, a significant adverse change in legal factors or in the business climate that affects the value of an asset, an adverse action or assessment by the FDA or another regulator, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income producing asset. Should there be an indication of impairment, we will test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value will be recognized as an impairment loss. Foreign Currency Translation, Transactions and Contracts Adjustments resulting from translating the financial statements of our foreign subsidiaries into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Net foreign currency exchange transaction gains or losses are included in interest and other income, net, on our Consolidated Statements of Income. Net transaction losses totaled  $3.7 million,  $16.4 million and  $36.5 million in 2010, 2009 and 2008, respectively.   We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward and option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we limit the risk that counterparties to these contracts may be unable to perform. We also limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrecognized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes, nor do we hedge our net investment in any of our foreign subsidiaries. Fair Value of Financial Instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable, foreign currency exchange forward and option contracts, accounts payable, and short-term and long-term debt. Cash and cash equivalents, marketable securities and foreign currency exchange contracts that hedge accounts receivable and forecasted sales are reported at their respective fair values on our Consolidated Balance Sheets. The carrying value and fair value of the Notes were  $3.48 billion and  $3.97 billion, respectively, as of December 31, 2010. The carrying value and fair value of the Notes were  $1.16 billion and  $1.58 billion, respectively as of December 31, 2009. The fair value of the Notes was based on their quoted market values. The remaining financial instruments are reported on our Consolidated Balance Sheets at amounts that approximate current fair values. Income Taxes Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. Various factors may have favorable or unfavorable effects on our income tax rate. These factors include, but are not limited to, interpretations of existing tax laws, changes in tax laws and rates, our portion of the non-tax deductible pharmaceutical excise tax that we will be required to pay starting in 2011 as a result of the enactment of U.S. healthcare reform legislation, the accounting for stock options and other share-based payments, mergers and acquisitions, future levels of R&D spending, changes in accounting standards, changes in the mix of earnings in the various tax jurisdictions in which we operate, changes in overall levels of pre-tax earnings and resolution of federal, state and foreign income tax audits. The impact on our income tax provision resulting from the above mentioned factors may be significant and could have a negative impact on our consolidated net income. We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We do not believe any such uncertain tax positions currently pending will have a material adverse effect on our Consolidated Financial Statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.   Recent Accounting Pronouncements In October 2009, the Financial Accounting Standards Board (FASB) issued new standards for revenue recognition for agreements with multiple deliverables. These new standards impact the determination of when the individual deliverables included in a multiple element arrangement may be treated as separate units of accounting. Additionally, these new standards modify the manner in which the transaction consideration is allocated across the separately identified deliverables by no longer permitting the residual method of allocating arrangement consideration. These new standards are effective for us beginning in the first quarter of 2011; however, early adoption is permitted. The adoption of these standards will not have a material impact on our Consolidated Financial Statements. In December 2010, in response to the pharmaceutical excise tax mandated by healthcare reform legislation adopted in the United States, the FASB issued a new standard to address how pharmaceutical manufacturers should recognize and classify this tax in their income statements. Effective 2011, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the pharmaceutical excise tax, calculated based on select government sales for the preceding calendar year as a percentage of total industry government sales. The new standard clarifies that the pharmaceutical excise tax shall be presented as an operating expense and that the liability related to the tax shall be estimated and recorded in full upon the first qualifying sale with a corresponding deferred cost that is amortized to expense generally using a straight-line method of allocation. The new standard is effective for us beginning in the first quarter of 2011. We estimate the 2011 impact of the pharmaceutical excise tax to be between  $30– $50 million, which will be classified as selling, general and administrative expense in our Consolidated Financial Statements. Also in December 2010, the FASB issued an update to its existing standard for business combinations to address the pro forma financial disclosure requirements for business combinations. The updated standard specifies that if a public entity presents comparative financial statements, the entity should disclose pro forma revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period. The updated standard is effective for us beginning in the first quarter of 2011; however, early adoption is permitted. The adoption of this standard will not have a material impact on our Consolidated Financial Statements.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet09.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements	12 Months Ended
Dec. 31, 2010
Fair Value Measurements
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: Level 1 inputs which include quoted prices in active markets for identical assets or liabilities; Level 2 inputs which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and Level 3 inputs which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.   Certain amounts within debt securities have been re-categorized in the accompanying tables to conform to the current presentation. The following table summarizes, for assets or liabilities recorded at fair value, the respective fair value and the classification by level of input within the fair value hierarchy defined above (in thousands):       December 31, 2010     December 31, 2009       Level 1     Level 2     Level 3     Total     Level 1     Level 2     Level 3     Total   Assets:                 Debt securities:                 U.S. treasury securities    $ 1,355,437       $ —         $ —         $ 1,355,437       $ 289,790       $ —         $ —         $ 289,790    U.S.government agencies and FDIC guaranteed securities     —          1,296,110        —          1,296,110        —          1,086,082        —          1,086,082    Municipal debt securities     —          17,625        —          17,625        —          433,474        —          433,474    Non-U.S. government securities     —          278,610        9,594        288,204        —          75,524        —          75,524    Corporate debt securities     —          1,119,254        —          1,119,254        —          566,176        —          566,176    Residential mortgage and asset-backed securities     —          277,043        —          277,043        —          120,407        839        121,246    Student loan-backed securities     —          —          70,771        70,771        —          —          104,823        104,823                                                                    Total debt securities     1,355,437        2,988,642        80,365        4,424,444        289,790        2,281,663        105,662        2,677,115    Equity securities     4,631        —          —          4,631        3,470        —          —          3,470    Derivatives     —          64,461        —          64,461        —          26,198        —          26,198                                                                       $ 1,360,068       $ 3,053,103       $ 80,365       $ 4,493,536       $ 293,260       $ 2,307,861       $ 105,662       $ 2,706,783                                                                    Liabilities:                 Contingent consideration     —          —          11,100        11,100        —          —          —          —      Derivatives     —          38,553        —          38,553        —          47,688        —          47,688       $ —         $ 38,553       $ 11,100       $ 49,653       $ —         $ 47,688       $ —         $ 47,688                                                                    Marketable securities, measured at fair value using Level 2 inputs, are primarily comprised of U.S. government agencies and FDIC guaranteed securities and corporate debt securities. We review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.   The following table is a reconciliation of marketable securities measured at fair value using significant unobservable inputs (Level 3) (in thousands):        Year Ended December 31,        2010     2009   Balance, beginning of period     $ 105,662       $ 102,633    Total realized and unrealized gains (losses) included in:      Interest and other income, net      115        (29 )  Other comprehensive income, net      5,026        10,332    Sales of marketable securities      (40,032 )      (7,274 )  Transfers into Level 3      9,594        —                       Balance, end of period     $ 80,365       $ 105,662                     Total losses included in interest and other income, net attributable to the change in unrealized losses relating to assets still held at the reporting date     $ —         $ (29 )                   Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. Marketable securities, measured at fair value using Level 3 inputs, are substantially comprised of auction rate securities within our available-for-sale investment portfolio. The underlying assets of our auction rate securities consist of student loans. Although auction rate securities would typically be measured using Level 2 inputs, the failure of auctions and the lack of market activity and liquidity experienced since the beginning of 2008 required that these securities be measured using Level 3 inputs. The fair value of our auction rate securities was determined using a discounted cash flow model that considered projected cash flows for the issuing trusts, underlying collateral and expected yields. Projected cash flows were estimated based on the underlying loan principal, bonds outstanding and payout formulas. The weighted-average life over which the cash flows were projected considered the collateral composition of the securities and related historical and projected prepayments. The underlying student loans have a weighted-average expected life of four to eight years. The discount rates used in our discounted cash flow model were based on market conditions for comparable or similar term asset-backed and other fixed income securities, adjusted for an illiquidity discount. This resulted in an annual discount rate of 2.12%. Our auction rate securities reset every seven to 14 days with maturity dates ranging from 2025 through 2040 and have annual interest rates ranging from 0.43% to 1.19%. As of December 31, 2010, our auction rate securities continued to earn interest. Our auction rate securities were recorded in long-term marketable securities on our Consolidated Balance Sheets at December 31, 2010 and 2009. Although there continued to be failed auctions as well as lack of market activity and liquidity in 2010, we believe we had no other-than-temporary impairments on these securities as of December 31, 2010 because we do not intend to sell these securities and it is not more likely than not that we will be required to sell these securities before the recovery of their amortized cost basis.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet10.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities	12 Months Ended
Dec. 31, 2010
Available-For-Sale Securities
Available-For-Sale Securities	3. AVAILABLE-FOR-SALE SECURITIES The following table is a summary of available-for-sale debt and equity securities recorded in cash equivalents or marketable securities in our Consolidated Balance Sheets. Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services (in thousands):        Amortized Cost      Gross Unrealized Gains      Gross Unrealized Losses     Estimated Fair Value   December 31, 2010            Debt securities:            U.S. treasury securities     $ 1,349,348        $ 7,109        $ (1,020 )     $ 1,355,437    U.S. government agencies and FDIC guaranteed securities      1,284,654         11,919         (463 )      1,296,110    Municipal debt securities      17,543         103         (21 )      17,625    Non-U.S. government securities      286,410         1,880         (86 )      288,204    Corporate debt securities      1,112,976         8,040         (1,762 )      1,119,254    Residential mortgage and asset-backed securities      277,359         923         (1,239 )      277,043    Student loan-backed securities      75,900         —           (5,129 )      70,771                                       Total debt securities      4,404,190         29,974         (9,720 )      4,424,444    Equity securities      1,451         3,180         —          4,631                                       Total     $ 4,405,641        $ 33,154        $ (9,720 )     $ 4,429,075                                       December 31, 2009            Debt securities:            U.S. treasury securities     $ 289,055        $ 844        $ (109 )     $ 289,790    U.S. government agencies and FDIC guaranteed securities      1,077,910         9,116         (944 )      1,086,082    Municipal debt securities      429,583         3,986         (95 )      433,474    Non-U.S. government securities      74,756         874         (106 )      75,524    Corporate debt securities      557,116         9,563         (503 )      566,176    Residential mortgage and asset-backed securities      119,308         2,048         (110 )      121,246    Student loan-backed securities      115,400         —           (10,577 )      104,823                                       Total debt securities      2,663,128         26,431         (12,444 )      2,677,115    Equity securities      1,451         2,019         —          3,470                                       Total     $ 2,664,579        $ 28,450        $ (12,444 )     $ 2,680,585                                       The following table summarizes the classification of the available-for-sale debt and equity securities on our Consolidated Balance Sheets (in thousands):        December 31, 2010      December 31, 2009   Cash and cash equivalents     $ 18,883        $ 48,697    Short-term marketable securities      1,190,789         384,017    Long-term marketable securities      3,219,403         2,247,871                      Total     $ 4,429,075        $ 2,680,585                        The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):        December 31, 2010      December 31, 2009        Amortized Cost      Fair Value      Amortized Cost      Fair Value   Less than one year     $ 1,206,032        $ 1,209,672        $ 429,980        $ 432,714    Greater than one year but less than five years      3,022,744         3,044,114         1,878,589         1,898,183    Greater than five years but less than ten years      33,076         33,580         56,895         57,585    Greater than ten years      142,338         137,078         297,664         288,633                                        Total     $ 4,404,190        $ 4,424,444        $ 2,663,128        $ 2,677,115                                        The following table summarizes the gross realized gains and losses related to sales of marketable securities (in thousands):        Year Ended December 31,        2010     2009     2008   Gross realized gains on sales     $ 13,254       $ 10,373       $ 28,368    Gross realized losses on sales     $ (3,657 )     $ (1,405 )     $ (18,732 )  The cost of securities sold was determined based on the specific identification method.   The following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in thousands):        Less Than 12 Months      12 Months or Greater      Total        Gross Unrealized Losses     Estimated Fair Value      Gross Unrealized Losses     Estimated Fair Value      Gross Unrealized Losses     Estimated Fair Value                                 December 31, 2010                Debt securities:                U.S. treasury securities     $ (1,020 )     $ 531,184        $ —         $ —          $ (1,020 )     $ 531,184    U.S. government agencies and FDIC guaranteed securities      (463 )      226,176         —          —           (463 )      226,176    Municipal debt securities      (21 )      4,688         —          —           (21 )      4,688    Non-U.S. government securities      (86 )      44,317         —          —           (86 )      44,317    Corporate debt securities      (1,762 )      459,412         —          —           (1,762 )      459,412    Residential mortgage and asset-backed securities      (1,239 )      197,330         —          —           (1,239 )      197,330    Student loan-backed securities      —          —           (5,129 )      70,771         (5,129 )      70,771                                                       Total     $ (4,591 )     $ 1,463,107        $ (5,129 )     $ 70,771        $ (9,720 )     $ 1,533,878                                                       December 31, 2009                Debt securities:                U.S. treasury securities     $ (109 )     $ 97,871        $ —         $ —          $ (109 )     $ 97,871    U.S. government agencies and FDIC guaranteed securities      (944 )      223,901         —          —           (944 )      223,901    Municipal debt securities      (95 )      65,377         —          —           (95 )      65,377    Non-U.S. government securities      (106 )      30,924         —          —           (106 )      30,924    Corporate debt securities      (503 )      126,410         —          —           (503 )      126,410    Residential mortgage and asset-backed securities      (110 )      36,446         —          —           (110 )      36,446    Student loan-backed securities      —          —           (10,577 )      104,823         (10,577 )      104,823                                                       Total     $ (1,867 )     $ 580,929        $ (10,577 )     $ 104,823        $ (12,444 )     $ 685,752                                                       As of December 31, 2010 and 2009, approximately 34% and 32%, respectively, of the total number of securities were in an unrealized loss position. The gross unrealized losses for auction rate securities were caused by a higher discount rate used in the valuation of these securities as compared to the coupon rates of these securities. The gross unrealized losses for the other securities were primarily the result of an increase in the yield-to-maturity of the underlying securities. No significant facts or circumstances have arisen to indicate that there has been any deterioration in the creditworthiness of the issuers of these securities. Based on our review of these securities, we believe we had no other-than-temporary impairments on these securities as of December 31, 2010 and 2009 because we do not intend to sell these securities and it is not more likely than not that we will be required to sell these securities before the recovery of their amortized cost basis.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet11.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments	12 Months Ended
Dec. 31, 2010
Derivative Financial Instruments
Derivative Financial Instruments	4. DERIVATIVE FINANCIAL INSTRUMENTS We operate in foreign countries, which exposes us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the Euro. In order to manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward and option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we limit the risk that counterparties to these contracts may be unable to perform. We also limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrecognized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes, nor do we hedge our net investment in any of our foreign subsidiaries. We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities of our foreign subsidiaries that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in interest and other income, net on our Consolidated Statements of Income. We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturity dates of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess prospective hedge effectiveness using a regression analysis which calculates the change in cash flow as a result of the hedge instrument. On a monthly basis, we assess retrospective hedge effectiveness using a dollar offset approach. We exclude time value from our effectiveness testing and recognize changes in the time value of the hedge in interest and other income, net. The effective component of our hedge is recorded as an unrealized gain or loss on the hedging instrument in accumulated other comprehensive income (OCI) within stockholders' equity. When the hedged forecasted transaction occurs, the hedge is de-designated and the unrealized gains or losses are reclassified into product sales. The majority of gains and losses related to the hedged forecasted transactions reported in accumulated OCI at December 31, 2010 will be reclassified to product sales within 12 months. We had notional amounts on foreign currency exchange contracts outstanding of  $3.55 billion and  $3.45 billion at December 31, 2010 and 2009, respectively.   The following table summarizes information about the fair values of derivative instruments on our Consolidated Balance Sheets (in thousands):        As of December 31, 2010        Asset Derivatives      Liability Derivatives        Location      Fair Value      Location      Fair Value   Derivatives designated as hedges:             Foreign currency exchange contracts        Other current assets           $ 59,276           Other accrued liabilities           $ 36,493    Foreign currency exchange contracts        Other noncurrent assets            5,089           Other long-term obligations            2,022                            Total derivatives designated as hedges         64,365            38,515                            Derivatives not designated as hedges:             Foreign currency exchange contracts        Other current assets            96           Other accrued liabilities            38                            Total derivatives not designated as hedges         96            38                            Total derivatives        $ 64,461           $ 38,553                                 As of December 31, 2009        Asset Derivatives      Liability Derivatives        Location      Fair Value      Location      Fair Value   Derivatives designated as hedges:             Foreign currency exchange contracts        Other current assets           $ 16,183           Other accrued liabilities           $ 45,482    Foreign currency exchange contracts        Other noncurrent assets            10,010           Other long-term obligations            2,180                            Total derivatives designated as hedges         26,193            47,662                            Derivatives not designated as hedges:             Foreign currency exchange contracts        Other current assets            5           Other accrued liabilities            26                            Total derivatives not designated as hedges         5            26                            Total derivatives        $ 26,198           $ 47,688                            The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Statements of Income (in thousands):        Year Ended December 31        2010      2009   Derivatives designated as hedges:       Net gains (losses) recognized in OCI (effective portion)     $ 115,073        $ (29,698 )  Net gains reclassified from accumulated OCI into product sales (effective portion)     $ 73,720        $ 81,694    Net gains (losses) recognized in interest and other income, net (ineffective portion and amounts excluded from effectiveness testing)     $ 887        $ (14,493 )  Derivatives not designated as hedges:       Net gains (losses) recognized in interest and other income, net     $ 66,639        $ (11,981 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet12.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions	12 Months Ended
Dec. 31, 2010
Acquisitions
Acquisitions	5. ACQUISITIONS On January 1, 2009, we adopted guidance for recognizing and measuring assets acquired, liabilities assumed and any noncontrolling interests in the acquiree in a business combination. The guidance requires, for example, that IPR&D be capitalized at fair value as intangible assets at the time of acquisition and acquisition-related expenses and restructuring costs be recognized separately from the business combination. We adopted the provisions of this guidance on a prospective basis and applied it to our acquisitions of CGI in 2010 and CV Therapeutics in 2009, as discussed below. CGI Pharmaceuticals, Inc. In June 2010, we entered into an agreement to acquire CGI for up to  $120.0 million in cash, consisting of  $91.0 million as an upfront payment and up to  $29.0 million of contingent consideration payable based on the achievement of clinical development milestones. This transaction closed on July 8, 2010, at which time CGI became a wholly-owned subsidiary. CGI was a privately-held development stage pharmaceutical company based in Branford, Connecticut, primarily focused on small molecule chemistry and protein kinase biology. The lead preclinical compound from CGI's library of proprietary small molecule kinase inhibitors targets spleen tyrosine kinase (Syk) and could have unique applications for the treatment of serious inflammatory diseases, including rheumatoid arthritis. We believe the acquisition provides us with an opportunity to expand our research efforts in an interesting and promising area of drug discovery. The CGI acquisition was accounted for as a business combination. The results of operations of CGI since July 8, 2010 have been included in our Consolidated Statements of Income and were not significant. The acquisition-date fair value of the total consideration transferred to acquire CGI was  $102.1 million, and consisted of cash paid at or prior to closing of  $91.0 million and contingent consideration of  $11.1 million. The following table summarizes the fair value of the assets acquired and liabilities assumed at July 8, 2010 (in thousands):   Intangible assets—IPR&D     $ 26,630    Goodwill      70,111    Deferred tax assets      12,656    Deferred tax liabilities      (6,313 )  Other net liabilities assumed      (984 )           Total consideration transferred     $ 102,100             Intangible Assets Intangible assets associated with in-process research and development (IPR&D) projects relate to the preclinical Syk product candidate. Management estimated the acquisition-date fair value of intangible assets related to IPR&D to be  $26.6 million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. We estimated the fair value using a present value discount rate of 18%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of CGI. This is comparable to the estimated internal rate of return for CGI's operations and represents the rate that market participants would use to value the intangible assets. The projected cash flows from the IPR&D project was based on key assumptions such as: estimates of revenues and operating profits related to the project considering its stage of development; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a drug compound such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential alternative treatments in any future target markets. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis as well as between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Goodwill The excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed is  $70.1 million, which represents the goodwill amount resulting from the CGI acquisition. Management believes that the goodwill mainly represents the synergies expected from combining our research and development operations as well as acquiring CGI's assembled workforce and other intangible assets that do not qualify for separate recognition. We recorded the goodwill as an intangible asset in our Consolidated Balance Sheet as of the acquisition date. Goodwill is tested for impairment on an annual basis as well as between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the goodwill below its carrying amount. As we have elected to treat the CGI acquisition as an asset acquisition for California state tax purposes, the goodwill resulting from the acquisition is deductible for California state income tax purposes, although such amounts are not deductible for federal income tax purposes. We do not consider the CGI acquisition to be a material business combination and therefore have not disclosed the pro forma results of operations as required for material business combinations. CV Therapeutics, Inc. On April 15, 2009, we acquired CV Therapeutics through a cash tender offer under the terms of an agreement and plan of merger entered into in March 2009. CV Therapeutics was a publicly-held biopharmaceutical company based in Palo Alto, California, primarily focused on the discovery, development and commercialization of small molecule drugs for the treatment of cardiovascular, metabolic and pulmonary diseases. CV Therapeutics had two marketed products, Ranexa for the treatment of chronic angina and Lexiscan injection for use as a pharmacologic stress agent in radionuclide MPI in patients unable to undergo adequate exercise stress. CV Therapeutics also had several product candidates in clinical development for the treatment of cardiovascular, metabolic and pulmonary diseases. The CV Therapeutics acquisition was accounted for as a business combination. The results of operations of CV Therapeutics since April 15, 2009 have been included in our Consolidated Statements of Income. The acquisition date was determined to be April 15, 2009 as that is the date on which we acquired approximately 89% of the outstanding shares of common stock of CV Therapeutics and obtained effective control of the company. The acquisition was completed two days later on April 17, 2009, at which time CV Therapeutics became a wholly-owned subsidiary. The aggregate consideration transferred to acquire CV Therapeutics was  $1.39 billion, and consisted of cash paid for common stock and other equity instruments at or prior to closing of  $1.38 billion and the fair value of vested stock options assumed of  $15.7 million.   In accordance with the merger agreement, the number of Gilead stock options and restricted stock units into which assumed CV Therapeutics' stock options and restricted stock units were converted was determined based on an option conversion ratio. This conversion ratio was calculated by taking the per share acquisition price of  $20.00 and dividing it by the average closing price of our common stock for the five consecutive trading days immediately preceding (but not including) the closing date of April 17, 2009, which was  $46.24 per share. The fair value of stock options assumed was calculated using a Black-Scholes valuation model with the following assumptions: market price of  $44.54 per share, which was the closing price of our common stock on the acquisition date; expected term ranging from 0.1 to 5.2 years; risk-free interest rate ranging from 0.1% to 1.7%; expected volatility ranging from 37.4% to 43.2%; and no dividend yield. The fair value of restricted stock units assumed was calculated using the acquisition-date closing price of  $44.54 per share for our common stock.   We included the fair value of vested stock options assumed by us of  $15.7 million in the consideration transferred for the acquisition. We did not assume any vested restricted stock units. The estimated fair value of unvested stock options and restricted stock units assumed by us of  $11.2 million was not included in the consideration transferred and is being recognized as stock-based compensation expenses over the remaining future vesting period of the awards. The following table summarizes the assets acquired and liabilities assumed at April 15, 2009 (in thousands):   Intangible assets—marketed products     $ 951,200    Intangible assets—IPR&D      138,900    Goodwill      341,910    Deferred tax assets      413,816    Deferred tax liabilities      (426,861 )  Other assets/liabilities    Cash and cash equivalents      129,087    Marketable securities      116,363    Accounts receivable      9,136    Inventories      50,455    Prepaids and other current assets      60,671    Property, plant and equipment      11,672    Other assets      20,162    Accounts payable      (5,089 )  Accrued and other current liabilities      (87,898 )  Convertible senior notes      (303,060 )  Other liabilities      (27,906 )           Total other net liabilities      (26,407 )           Total consideration transferred     $ 1,392,558             Intangible Assets A substantial portion of the assets acquired consisted of intangible assets related to CV Therapeutics' two marketed products, Ranexa and Lexiscan, and CV Therapeutics' IPR&D projects. Management determined that the estimated acquisition-date fair values of the intangible assets related to the marketed products and IPR&D projects were  $951.2 million and  $138.9 million, respectively.   Of the  $951.2 million of intangible assets related to the marketed products,  $688.4 million related to Ranexa and  $262.8 million related to Lexiscan. We have determined that these intangible assets have finite useful lives and will be amortized over their respective useful lives, which we estimated to be the periods over which the associated product patents will expire as those are the periods over which the intangible assets are expected to contribute to the future cash flows of the related products. We are amortizing the intangible asset related to Ranexa over its estimated useful life using an amortization rate derived from our forecasted future product sales for Ranexa. We are amortizing the intangible asset related to Lexiscan over its estimated useful life on a straight-line basis. Given that current Lexiscan revenues consist of royalties received from a collaboration partner and our lack of ongoing access and visibility into that partner's future sales forecasts, we cannot make a reasonable estimate of the amortization rate using a forecasted product sales approach. The weighted-average amortization period for these intangible assets is approximately ten years. Of the  $138.9 million of intangible assets related to the IPR&D projects,  $93.4 million related to GS 9667 (formerly CVT-3619), a product candidate that was in Phase 1 clinical studies for the treatment of diabetes and hypertriglyceridemia. The remaining balance of the intangible assets related to IPR&D projects represented various other in-process projects with no single project comprising a significant portion of the total value. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. During the fourth quarter of 2010, we recorded  $136.0 million of impairment charges related to certain IPR&D assets acquired from CV Therapeutics which we had no future plans to develop and which were deemed to have no future use to us or other market participants. These charges related to the GS 9667, Adentri and tecadenoson programs and were recorded in R&D expense. The majority of the impairment charge related to our GS 9667 program, which was terminated in the fourth quarter of 2010 due to unfavorable results from pharmacokinetics and pharmacodynamics tests that demonstrated limited effectiveness of the compound in patients. Given these results, we do not believe it has alternative future uses for us or other market participants. As of December 31, 2010, we had  $2.9 million of IPR&D assets acquired from CV Therapeutics remaining on our Consolidated Balance Sheet. Deferred Tax Assets and Deferred Tax Liabilities The  $413.8 million of deferred tax assets resulting from the acquisition was primarily related to federal and state net operating loss and tax credit carryforwards. The  $426.9 million of deferred tax liabilities resulting from the acquisition was primarily related to the difference between the book basis and tax basis of the intangible assets related to the marketed products and IPR&D projects. We have concluded that it is more likely than not that we will not realize the benefit from deferred tax assets related to certain state net operating loss carryforwards. As a result, a valuation allowance of  $15.1 million was recorded related to those deferred tax assets. For presentation purposes, the  $426.9 million of deferred tax liabilities, all of which is of a noncurrent nature, has been netted against noncurrent deferred tax assets on our Consolidated Balance Sheet. As a result of the impairment charges recorded in the fourth quarter of 2010, we reduced the deferred tax liabilities related to IPR&D projects by  $49.7 million. Convertible Senior Notes As a result of the acquisition, we assumed convertible notes from CV Therapeutics consisting of 2.75% senior subordinated convertible notes due 2012, 3.25% senior subordinated convertible notes due 2013 and 2.0% senior subordinated convertible debentures due 2023. All of these convertible notes were recognized at their fair values at the acquisition date. In May 2009, we offered to repurchase these convertible notes in consideration for their par value plus accrued interest, as required under the terms of the respective convertible note agreements following the occurrence of a change in control or fundamental change as defined in the agreements. As of December 31, 2010, all of these convertible notes have been extinguished. Goodwill The excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed was  $341.9 million, which represents the goodwill amount resulting from the acquisition. Management believes that the goodwill mainly represents the synergies and economies of scale expected from combining our operations with CV Therapeutics. None of the goodwill is expected to be deductible for income tax purposes. We recorded the goodwill as an intangible asset in our Consolidated Balance Sheet as of the acquisition date. Goodwill is tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the goodwill below its carrying amount. Navitas Assets, LLC In May 2008, we executed an asset purchase agreement with Navitas Assets, LLC (Navitas) to acquire all of the assets related to its cicletanine business. We acquired the exclusive rights to regulatory data and filings for development of cicletanine as a monotherapy for PAH and for other indications in the United States. We are evaluating cicletanine, currently in Phase 2 clinical trials, as a potential treatment of PAH. The aggregate consideration transferred for the acquisition was  $10.9 million, and consisted primarily of cash paid. In addition, Navitas is entitled to potential additional purchase consideration, including payments contingent on future achievement of certain development and regulatory milestones. These amounts will be recorded when and if the related contingencies are resolved. The consideration transferred was allocated to IPR&D which represents the purchased IPR&D program for cicletanine that had not yet reached technological feasibility and had no alternative future uses as of the acquisition date, and therefore, was expensed upon acquisition within our Consolidated Statement of Income.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet13.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Restructuring	12 Months Ended
Dec. 31, 2010
Restructuring
Restructuring	6. RESTRUCTURING During the second quarter of 2010, we implemented a plan to close our research operations in Durham, North Carolina and consolidate our liver disease research activities in Foster City, California. The restructuring plan includes consolidation of the liver disease R&D organization and our exit from certain facilities. During the year, we recorded a total of  $14.6 million and  $10.4 million in SG&A expenses and R&D expenses, respectively, related to employee severance and facilities-related expenses under this plan. In December 2010, we closed our operations in Durham. We do not expect to incur any additional significant costs in connection with this plan. During the second quarter of 2009, we approved a plan to realize certain synergies as a result of the CV Therapeutics acquisition by re-aligning our cardiovascular operations and eliminating redundancies. The restructuring plan included consolidation and re-alignment of the cardiovascular R&D organization, our exit from certain facilities and the termination of certain contractual obligations. In 2010, we recorded  $10.6 million and  $3.4 million of restructuring expenses in SG&A and R&D expenses, respectively. Comparatively, in 2009, we recorded  $26.2 million and  $25.7 million in SG&A and R&D expenses, respectively. In both years, the expenses primarily related to employee severance, relocation, lease termination costs and other facilities-related expenses. Total costs incurred under this plan were  $36.8 million and  $29.1 million in SG&A and R&D expenses, respectively. We do not expect to incur any additional costs in connection with this plan. The following table summarizes the restructuring liabilities accrued for and changes in those amounts during the period for the restructuring plan related to our cardiovascular operations (in thousands):        Employee Severance and Termination Benefits     Facilities- Related Costs   Balance at December 31, 2008     $ —         $ —      Costs incurred during the period      33,797        9,880    Costs paid or settled during the period      (24,108 )      (545 )                   Balance at December 31, 2009     $ 9,689       $ 9,335    Costs incurred during the period      2,190        9,727    Costs paid or settled during the period      (11,445 )      (4,529 )                   Balance at December 31, 2010     $ 434       $ 14,533

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet14.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories	12 Months Ended
Dec. 31, 2010
Inventories
Inventories	7. INVENTORIES Inventories are summarized as follows (in thousands):        December 31,        2010      2009   Raw materials     $ 408,015        $ 333,582    Work in process      454,652         392,042    Finished goods      341,142         326,147                      Total inventories     $ 1,203,809        $ 1,051,771                      As of December 31, 2010 and 2009, the joint ventures formed by Gilead and BMS (see Note 10), which are included in our Consolidated Financial Statements, held  $811.9 million and  $667.8 million in inventory, respectively, of efavirenz active pharmaceutical ingredient purchased from BMS at BMS' estimated net selling price of efavirenz.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet15.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Property, Plant and Equipment	12 Months Ended
Dec. 31, 2010
Property, Plant and Equipment
Property, Plant and Equipment	8. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment are summarized as follows (in thousands):        December 31,        2010     2009   Property, plant and equipment, net:      Buildings and improvements (including leasehold improvements)     $ 501,401       $ 490,632    Laboratory and manufacturing equipment      168,711        176,362    Office and computer equipment      116,479        126,375    Capitalized leased equipment      10,865        15,232    Construction in progress      82,334        58,448                     Subtotal      879,790        867,049    Less accumulated depreciation and amortization (including  $10,451 and  $14,999 relating to capitalized leased equipment for 2010 and 2009, respectively)      (316,367 )      (304,888 )                   Subtotal      563,423        562,161    Land      137,812        137,809                     Total     $ 701,235       $ 699,970                     In January 2009, we completed the purchase of an office building and approximately 30 acres of land located in Foster City, California, for an aggregate purchase price of  $140.1 million. Based on the estimated relative fair values, the purchase price was allocated primarily to land of  $71.6 million, building of  $64.3 million, land improvements of  $2.7 million and office furniture and equipment of  $1.1 million.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet16.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets	12 Months Ended
Dec. 31, 2010
Intangible Assets
Intangible Assets	9. INTANGIBLE ASSETS The following table summarizes the carrying amount of our intangible assets (in thousands):        December 31,        2010      2009   Goodwill     $ 532,669        $ 462,558    Finite lived intangible assets      863,393         923,319    Indefinite lived intangible assets      29,530         138,900                      Total     $ 1,425,592        $ 1,524,777                        The following table summarizes the changes in the carrying amount of goodwill (in thousands):   Balance at December 31, 2009     $ 462,558    Goodwill resulting from the acquisition of CGI      70,111             Balance at December 31, 2010     $ 532,669               The following table summarizes our finite-lived intangible assets (in thousands):        December 31, 2010      December 31, 2009        Gross Carrying Amount      Accumulated Amortization      Gross Carrying Amount      Accumulated Amortization   Intangible asset—Ranexa     $ 688,400        $ 54,795        $ 688,400        $ 21,889    Intangible asset—Lexiscan      262,800         43,979         262,800         18,235    Other      22,095         11,128         22,095         9,852                                        Total     $ 973,295        $ 109,902        $ 973,295        $ 49,976                                        Amortization expense related to intangible assets was  $59.9 million for the year ended December 31, 2010, and was recorded in cost of goods sold in our Consolidated Statement of Income. Amortization expense related to intangible assets was  $43.4 million for the year ended December 31, 2009 and was recorded primarily in cost of goods sold in our Consolidated Statement of Income. Amortization expense related to intangible assets was  $2.8 million for the year ended December 31, 2008 and was recorded primarily in SG&A expenses in our Consolidated Statement of Income. The weighted-average amortization period for these intangible assets is approximately ten years. As of December 31, 2010, the estimated future amortization expense associated with our intangible assets for each of the five succeeding fiscal years is as follows (in thousands):   Fiscal Year    Amount   2011     $ 69,324    2012      75,776    2013      82,086    2014      90,940    2015      100,647             Total     $ 418,773             As of December 31, 2010, we had indefinite-lived intangible assets of  $29.5 million, which consisted of  $26.6 million and  $2.9 million of purchased IPR&D from our acquisitions of CGI and CV Therapeutics, respectively. During the fourth quarter of 2010, we recorded  $136.0 million of impairment charges related to certain IPR&D assets acquired from CV Therapeutics which we had no future plans to develop and which were deemed to have no future use to us or other market participants. These charges related to the GS 9667, Adentri and tecadenoson programs and were recorded in R&D expense. The majority of the impairment charge related to our GS 9667 program, a product candidate that was in Phase 1 clinical studies for the treatment of diabetes and hypertriglyceridemia, which was terminated in the fourth quarter of 2010 due to unfavorable results from pharmacokinetics and pharmacodynamics tests that demonstrated limited effectiveness of the compound in patients. Given these results, we do not believe it has alternative future uses for us or other market participants. As of December 31, 2009, we had indefinite-lived intangible assets of  $138.9 million related to purchased IPR&D from our acquisition of CV Therapeutics.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet17.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Collaborative Arrangements	12 Months Ended
Dec. 31, 2010
Collaborative Arrangements
Collaborative Arrangements	10. COLLABORATIVE ARRANGEMENTS As a result of entering into strategic collaborations from time to time, we may hold investments in non-public companies. We review our interests in our investee companies for consolidation and/or appropriate disclosure based on applicable guidance. As disclosed in Note 1, we determined that certain of our investee companies are variable interest entities; however, other than with respect to our joint ventures with BMS, we are not the primary beneficiary and therefore do not consolidate these investees. Bristol-Myers Squibb Company North America In December 2004, we entered into a collaboration arrangement with BMS in the United States to develop and commercialize a single tablet regimen containing our Truvada and BMS's Sustiva (efavirenz), which we sell as Atripla. The collaboration is structured as a joint venture and operates as a limited liability company named Bristol-Myers Squibb & Gilead Sciences, LLC, which we consolidate. The ownership interests of the joint venture and thus the sharing of product revenue and costs reflect the respective economic interests of BMS and Gilead and are based on the proportions of the net selling price of Atripla attributable to efavirenz and Truvada. Since the net selling price for Truvada may change over time relative to the net selling price of efavirenz, both BMS's and our respective economic interests in the joint venture may vary annually. We share marketing and sales efforts with BMS and both parties are obligated to provide equivalent sales force efforts for a minimum number of years. Starting in the second quarter of 2011, except for a limited number of activities that will be jointly managed, the parties will no longer coordinate detailing and promotional activities in the United States. The parties will continue to collaborate on activities such as manufacturing, regulatory, compliance and pharmacovigilance. We are responsible for accounting, financial reporting, tax reporting, manufacturing and product distribution for the joint venture. Both parties provide their respective bulk active pharmaceutical ingredients to the joint venture at their approximate market values. In July 2006, the joint venture received approval from the FDA to sell Atripla in the United States. In September 2006, we and BMS amended the joint venture's collaboration agreement to allow the joint venture to sell Atripla into Canada and in October 2007, the joint venture received approval from Health Canada to sell Atripla in Canada. As December 31, 2010 and 2009, the joint venture held efavirenz active pharmaceutical ingredient which it purchased from BMS at BMS's estimated net selling price of efavirenz in the U.S. market. These amounts are included in inventories on our Consolidated Balance Sheets. As of December 31, 2010 and 2009, total assets held by the joint venture were  $1.45 billion and  $1.40 billion, respectively, and consisted primarily of cash and cash equivalents, accounts receivable (including intercompany receivables with Gilead) and inventories. As of December 31, 2010 and 2009, total liabilities held by the joint venture were  $759.5 million and  $1.03 billion, respectively, and consisted primarily of accounts payable (including intercompany payables with Gilead) and other accrued expenses. These asset and liability amounts do not reflect the impact of intercompany eliminations that are included in our Consolidated Balance Sheets. Although we are the primary beneficiary of the joint venture, the legal structure of the joint venture limits the recourse that its creditors will have over our general credit or assets. Europe In December 2007, Gilead Sciences Limited (GSL), a wholly-owned subsidiary in Ireland, and BMS entered into a collaboration arrangement to commercialize and distribute Atripla in the European Union, Iceland, Liechtenstein, Norway and Switzerland (collectively, the European Territory). The parties formed a limited liability company which we consolidate, to manufacture Atripla for distribution in the European Territory using efavirenz that it purchases from BMS at BMS's estimated net selling price of efavirenz in the European Territory. We are responsible for product distribution, inventory management and warehousing. Through our local subsidiaries, we have primary responsibility for order fulfillment, collection of receivables, customer relations and handling of sales returns in all the territories where we co-promote Atripla with BMS. We are also responsible for accounting, financial reporting and tax reporting for the collaboration. In December 2007, the European Commission approved Atripla for sale in the European Union. As of December 31, 2010 and 2009, efavirenz purchased from BMS at BMS's estimated net selling price of efavirenz in the European Territory is included in inventories on our Consolidated Balance Sheets. The parties also formed a limited liability company to hold the marketing authorization for Atripla in Europe. We have primary responsibility for regulatory activities and we share marketing and sales efforts with BMS. In the major market countries, both parties have agreed to provide equivalent sales force efforts. Revenue and cost sharing is based on the relative ratio of the respective net selling prices of Truvada and efavirenz. PARI GmbH As a result of our acquisition of Corus Pharma, Inc. (Corus) in August 2006, we assumed all rights to the February 2002 development agreement between Corus and PARI GmbH (PARI) for the development of Cayston and development of an inhalation delivery device for this product. Under the terms of the agreement, we are obligated to pay PARI for services rendered, and subject to the achievement of specific milestones, we are obligated to pay certain milestone payments to PARI. In addition, we will make royalty payments based on net sales of Cayston. The agreement also provided us the right to reduce the royalty rate payable to PARI. In November 2007, we paid PARI  $13.5 million to reduce the royalty rate under the agreement. As Cayston had not yet been approved for commercialization at the time of the payment, we recorded this payment in R&D expenses in our Consolidated Statement of Income. In April 2008, pursuant to the February 2002 development agreement, we entered into a commercialization agreement with PARI which provides for the supply and manufacture of an inhalation delivery device and accessories for use with Cayston. Under the terms of this agreement, we are obligated to pay royalties on future net sales of these products pursuant to the 2002 development agreement. In February 2010, we received marketing approval from the FDA for Cayston as a treatment to improve respiratory symptoms in CF patients with P. aeruginosa. Cayston was conditionally approved in Europe and Canada in September 2009. Parion Sciences, Inc. In August 2007, we entered into a research collaboration and license agreement with Parion Sciences, Inc. (Parion) to research, develop and commercialize certain epithelial sodium channel (ENaC) inhibitors for the treatment of pulmonary diseases. The agreement granted us worldwide commercialization rights to GS 9411 (formerly P-680), an ENaC inhibitor discovered by Parion, for the treatment of pulmonary diseases, including CF, chronic obstructive pulmonary disease and non-CF bronchiectasis. In accordance with the terms of the agreement, we paid a  $5.0 million up-front license fee that was recorded in R&D expenses in our Consolidated Statement of Income as there was no future alternative use for this technology, and made a  $5.0 million investment in Parion in the form of convertible debt, which was recorded as other noncurrent assets in our Consolidated Balance Sheet. Under the collaboration agreement, we will lead all development and commercialization activities and provide funding of full time equivalent employees for certain research activities. In addition, we are obligated to make additional payments upon the achievement of certain milestones and pay royalties on future net sales of products that are developed and approved in relation to this collaboration. In August 2010, development of GS 9411 was terminated and the term of the research collaboration was extended to identify additional ENaC inhibitors for development. Roche In September 1996, we entered into a development and license agreement (the 1996 Agreement) with Roche to develop and commercialize therapies to treat and prevent viral influenza. Tamiflu, an antiviral oral formulation for the treatment and prevention of influenza, was co-developed by us and Roche. Under the 1996 Agreement, Roche has the exclusive right to manufacture and sell Tamiflu worldwide, subject to its obligation to pay us a percentage of the net revenues that Roche generates from Tamiflu sales, which, in turn, has been subject to reduction for certain defined manufacturing costs. In November 2005, we entered into a first amendment and supplement to the 1996 Agreement with Roche. The amended agreement provided for the formation of a joint manufacturing committee to review Roche's manufacturing capacity for Tamiflu and its global plans for manufacturing Tamiflu, a U.S. commercial committee to evaluate commercial plans and strategies for Tamiflu in the United States and a joint supervisory committee to evaluate Roche's overall commercial plans for Tamiflu on a global basis in each case, consisting of representatives of Roche and us. Under the amended agreement, we also have the option to provide a specialized sales force to supplement Roche's marketing efforts in the United States for Tamiflu. The royalties payable to us on net sales of Tamiflu sold by Roche remain the same under the amended agreement, which are as follows: (a) 14% of the first  $200.0 million in worldwide net sales in a given calendar year; (b) 18% of the next  $200.0 million in worldwide net sales during the same calendar year; and (c) 22% of worldwide net sales in excess of  $400.0 million during the same calendar year.The amended agreement revised the provision in the 1996 Agreement relating to the calculation of royalty payments such that in any given calendar quarter Roche will pay royalties based on the actual royalty rates applicable to such quarter. In addition, under the amended agreement, royalties payable by Roche to us will no longer be subject to a cost of goods sold adjustment that was provided in the 1996 Agreement. We recorded a total of  $386.5 million,  $392.7 million and  $155.5 million of Tamiflu royalties in 2010, 2009 and 2008, respectively. As a result of our acquisition of CV Therapeutics in April 2009, we assumed all rights to the agreement between CV Therapeutics and Roche under which we have an exclusive worldwide license to Ranexa. Under the license agreement, we paid an initial license fee and are obligated to make certain payments to Roche upon receipt of the first and second product approvals for Ranexa in any of the following major market countries: France, Germany, Italy, the United States and the United Kingdom. In January 2006, we received FDA approval for Ranexa for the treatment of chronic angina and paid  $11.0 million to Roche in accordance with the agreement. In July 2008, we received marketing authorization from the European Medicines Agency (EMEA) for Ranexa for the treatment of chronic angina in all 27 European Union member states and paid  $9.0 million to Roche related to this approval. This amount was capitalized as a noncurrent asset on our Consolidated Balance Sheet and is being amortized over its useful patent life, which is approximately 11 years, expiring in September 2019. In June 2006, we entered into an amendment to the agreement with Roche related to Ranexa. This amendment provided us with exclusive worldwide commercial rights to Ranexa for all potential indications in humans. Under the terms of the amendment, we made an upfront payment to Roche and are obligated to make royalty payments to Roche on worldwide net product sales of any licensed products. In addition, we are obligated to make additional milestone payments upon the achievement of certain regulatory approvals. Japan Tobacco Inc. In March 2005, Japan Tobacco Inc. (Japan Tobacco) granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor formerly known as GS 9137, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Under the terms of the agreement, we incurred an up-front license fee of  $15.0 million which was included in R&D expenses in 2005 as there was no future alternative use for this technology. In March 2006, we recorded  $5.0 million in R&D expenses related to a milestone we incurred as a result of dosing the first patient in a Phase 2 clinical study and in July 2008, we recorded  $7.0 million in R&D expenses related to a milestone we paid related to the dosing of the first patient in a Phase 3 clinical study. We are obligated to make additional payments upon the achievement of other milestones as well as pay royalties on any future product sales arising from this collaboration. GlaxoSmithKline Inc. In April 2002, we granted GSK the right to commercialize Hepsera, our oral antiviral for the treatment of chronic hepatitis B, in Asia, Latin America and certain other territories. Under the agreement, we retained rights to Hepsera in the United States, Canada, Europe, Australia, New Zealand and Turkey. GSK received exclusive rights to develop Hepsera solely for the treatment of chronic hepatitis B in all of its territories, the most significant of which include China, Japan, South Korea and Taiwan. GSK has full responsibility for the development and commercialization of Hepsera in its territories. Under the terms of the agreement, we received an up-front license payment of  $10.0 million and from 2002 to 2004, we received an aggregate of  $17.0 million in milestone payments related to the commercial approvals of Hepsera in various countries. In 2006, we received an aggregate of  $10.0 million in milestone payments from GSK for the achievement by GSK of four consecutive quarters of Hepsera gross sales exceeding  $75.0 million and the achievement of a certain drug status in China. The up-front license fee and milestone payments had been recorded as deferred revenue with a total of  $3.4 million and  $3.6 million being amortized into contract revenue in 2008 and 2007, respectively. During the first quarter of 2009, we terminated our supply agreement with GSK to allow GSK to assume all manufacturing and supply obligations for Hepsera for use in the GSK territories. As a result of the termination of this supply agreement, we recognized the remaining  $24.5 million balance of deferred revenue into contract revenue as of March 31, 2009. Under the terms of the agreement, GSK is also required to pay us royalties on net sales that GSK generates from sales of Hepsera and Epivir-HBV/Zeffix (GSK's hepatitis product) in the GSK territories. We recorded  $48.0 million,  $32.4 million and  $31.7 million of royalty revenues in 2010, 2009 and 2008, respectively. In November 2009, we entered into an agreement with GSK to commercialize Viread for the treatment of chronic hepatitis B in five countries in Asia. Under the agreement, we will retain exclusive rights for commercialization of Viread for chronic hepatitis B in Hong Kong, Singapore, South Korea and Taiwan. In China, GSK will have exclusive commercialization rights for Viread for chronic hepatitis B. Each company will pay royalties to the other on sales of Viread for chronic hepatitis B in their respective Asian territories. In September 2010, we granted GSK the exclusive right to commercialize tenofovir disoproxil fumarate for chronic hepatitis B in Japan. GSK will be required to pay us royalties on sales of tenofovir disoproxil fumarate for chronic hepatitis B in this territory. As a result of our acquisition of Myogen, Inc. (Myogen) in November 2006, we assumed all rights to the March 2006 license and distribution and supply agreements between Myogen and GSK. Under the terms of the license agreement, GSK has exclusive rights to market ambrisentan (the active pharmaceutical ingredient in Letairis) under the name Volibris for PAH in territories outside the United States. We received an up-front payment of  $20.0 million and, subject to the achievement of specific milestones, we are eligible to receive total additional milestone payments of  $80.0 million. In addition, we will receive royalties based on net sales of Volibris in the GSK territories. GSK has an option to negotiate from us an exclusive sublicense for additional therapeutic uses for Volibris in the GSK territories during the term of the license agreement. We will continue to conduct and bear the expense of all clinical development activities that we believe are required to obtain and maintain regulatory approvals for Letairis and Volibris in the United States, Canada and the European Economic Area, and each party may conduct additional development activities in its territories at its own expense. The parties may agree to jointly develop ambrisentan for new indications in the licensed field and each party will pay its share of external costs associated with such joint development. In 2007, we received a milestone payment of  $11.0 million from GSK for validation by the EMEA of the marketing authorization application for Volibris, and in 2008, we received a  $20.0 million milestone payment related to the European Commission marketing authorization approval for Volibris. The milestone and up-front license payments have been recorded as deferred revenue and are being amortized into contract revenue over the remaining period for which we have performance obligations under the agreement, which is approximately six years. We amortized  $8.7 million,  $8.3 million and  $5.0 million to contract revenue in 2010, 2009 and 2008, respectively. Astellas US LLC and Astellas Pharma US, Inc. (Astellas), as applicable As a result of our acquisition of CV Therapeutics in April 2009, we assumed all rights to the July 2000 collaboration agreement between CV Therapeutics and Astellas US LLC to develop and market second generation pharmacologic MPI stress agents. Under this agreement, Astellas received exclusive North American rights to Lexiscan and to a backup compound. In April 2008, we received FDA approval of Lexiscan for use as a pharmacologic stress agent in MPI studies in patients unable to undergo adequate exercise stress. Under the terms of the agreement, the product is marketed by Astellas and was launched in June 2008 in the United States. For the years ended December 31, 2010 and 2009, we recognized  $43.2 million and  $19.7 million, respectively, of royalty revenue from Astellas related to sales of Lexiscan. Since 1991, we have had an agreement with Astellas Pharma US, Inc. related to rights to market AmBisome. Under the terms of the agreement, Astellas is responsible for promotion of AmBisome in the United States and Canada. We have exclusive marketing rights to AmBisome in the rest of the world, subject to our obligation to pay royalties to Astellas in connection with sales in significant markets in Asia. We receive royalties from Astellas' sales of AmBisome in the Unites States and Canada. In connection with this agreement, we recorded royalty revenues of  $10.2 million,  $9.4 million and  $9.5 million in 2010, 2009 and 2008, respectively. Tibotec Pharmaceuticals In July 2009, we entered into a license and collaboration agreement with Tibotec Pharmaceuticals (Tibotec), a wholly-owned subsidiary of Johnson & Johnson, to develop and commercialize a fixed-dose combination of our Truvada and Tibotec's non-nucleoside reverse transcriptase inhibitor, TMC278 (25 mg rilpivirine hydrochloride), for which we currently have a pending marketing application. In January 2011, we received a "refuse to file" notification from the U.S. FDA. In its communication, the FDA requested additional information with respect to the Chemistry, Manufacturing and Controls section of the NDA submission. In February 2011, we re-filed our new drug application, which included the requested information, and are awaiting the FDA's response as to whether it is substantially complete to permit a substantive review. Under our license and collaboration agreement with Tibotec, we were granted an exclusive license to the combination product for administration to adults in a once daily, oral dosage form, worldwide excluding developing world countries and Japan. Neither party is restricted from combining its drug products with any other drugs. In accordance with the terms of the agreement, we will reimburse up to €71.5 million (approximately  $100.0 million) of development costs incurred by Tibotec for TMC278 through December 2011, and we are required to use commercially reasonable efforts to develop and formulate the combination product, including the completion of bioequivalence studies. For the years ended December 31, 2010 and 2009, we recorded €17.9 million (approximately  $22.1 million) and €35.7 million (approximately  $52.4 million), respectively, in reimbursable R&D expenses incurred by Tibotec in the development of TMC278. Tibotec is required to use commercially reasonable efforts to develop TMC278 and obtain its approval in the United States and Europe. We will manufacture the combination product and assume the lead role in registration, distribution and, subject to regulatory approval, commercialization of the combination product in the licensed countries. Tibotec will have the right to detail the combination product in the licensed countries, and, at its option, can request that it be the distributor of the combination product in a limited number of such countries. The price of the combination product is expected to be the sum of the prices of the Truvada and TMC278 components. We expect to recognize product sales revenue from future sales of the combination product if and when it is approved. The cost of TMC278 to be purchased by us from Tibotec for the combination product will approximate the market price of TMC278, less a specified percentage of up to thirty percent.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet18.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations	12 Months Ended
Dec. 31, 2010
Long-Term Obligations
Long-Term Obligations	11. LONG-TERM OBLIGATIONS Convertible Senior Notes The following table summarizes the carrying amount of our convertible senior notes (in thousands):        December 31,        2010      2009   2011 convertible senior notes     $ 638,991        $ 606,786    2013 convertible senior notes      576,884         548,480    2014 convertible senior notes      1,153,805         —      2016 convertible senior notes      1,107,884         —                        Total convertible senior notes, net      3,477,564         1,155,266    Less current portion (2011 convertible senior notes)      638,991         —                        Total non-current convertible senior notes, net     $ 2,838,573        $ 1,155,266                      2011 and 2013 Notes In April 2006, we issued  $650.0 million of convertible senior notes due in 2011 (2011 Notes) and  $650.0 million of convertible senior notes due in 2013 (2013 Notes) in a private placement pursuant to Rule 144A of the Securities Act of 1933, as amended. The 2011 Notes and the 2013 Notes were issued at par and bear interest rates of 0.50% and 0.625%, respectively. Debt issuance costs of  $23.8 million were recorded in other noncurrent assets and are being amortized to interest expense over the contractual terms of the 2011 and 2013 Notes. The initial conversion rate for the 2011 Notes is 25.8048 shares per  $1,000 principal amount of 2011 Notes (which represents an initial conversion price of approximately  $38.75 per share), and the initial conversion rate for the 2013 Notes is 26.2460 shares per  $1,000 principal amount of 2013 Notes (which represents an initial conversion price of approximately  $38.10 per share). The conversion rates are subject to customary anti-dilution adjustments. The 2011 and 2013 notes may be converted, subject to adjustment, only under the following circumstances: 1) during any calendar quarter beginning after September 30, 2006 if the closing price of our common stock for at least 20 trading days during the last 30 consecutive trading day period of the previous quarter is more than 130% of the applicable conversion price per share, 2) if we make specified distributions to holders of our common stock or if specified corporate transactions occur, or 3) during the last month prior to maturity of the applicable notes. Upon conversion, a holder would receive an amount in cash equal to the lesser of (i) the principal amount of the note or (ii) the conversion value for such note. If the conversion value exceeds the principal amount, we may also deliver, at our option, cash or common stock or a combination of cash and common stock for the conversion value in excess of the principal amount. If the 2011 and 2013 notes are converted in connection with a change in control, we may be required to provide a make whole premium in the form of an increase in the conversion rate, subject to a stated maximum amount. In addition, in the event of a change in control, the holders may require us to purchase all or a portion of their notes at a purchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any.   Concurrent with the issuance of the 2011 and 2013 notes, we purchased convertible note hedges in private transactions at a cost of  $379.1 million, which is tax deductible over the life of the notes. We also sold warrants in private transactions and received net proceeds of  $235.5 million from the sale of the warrants. The convertible note hedges and warrants are intended to reduce the potential economic dilution upon future conversions of the 2011 and 2013 notes by effectively increasing our conversion price to  $50.80 per share for the 2011 Notes and  $53.90 per share for the 2013 Notes. The net cost of  $143.7 million of the convertible note hedge and warrant transactions was recorded in stockholders' equity on our Consolidated Balance Sheets. The convertible note hedges cover, subject to customary anti-dilution adjustments, 33.8 million shares of our common stock at strike prices that initially correspond to the initial conversion prices of the 2011 and 2013 notes and are subject to adjustments similar to those applicable to the conversion price of the related notes. If the market value per share of our common stock at the time of conversion of the 2011 and 2013 notes is above the strike price of the applicable convertible note hedges, we will be entitled to receive from the counterparties in the transactions shares of our common stock or, to the extent we have made a corresponding election with respect to the related convertible notes, cash or a combination of cash and shares of our common stock, at our option, for the excess of the market value of the common stock over the strike price of the convertible note hedges. The convertible note hedges will terminate upon the maturity of the 2011 and 2013 notes or when none of the 2011 and 2013 notes remain outstanding due to conversion or otherwise. There are 33.8 million shares of our common stock underlying the warrants, subject to customary anti-dilution adjustments. The warrants have strike prices of  $50.80 per share (for the warrants expiring in 2011) and  $53.90 per share (for the warrants expiring in 2013) and are exercisable only on their respective expiration dates. If the market value of our common stock at the time of the exercise of the applicable warrants exceeds their respective strike prices, we will be required to net settle in cash or shares of our common stock, at our option, with the respective counterparties for the value of the warrants in excess of the warrant strike prices. Contemporaneously with the closing of the sale of the 2011 and 2013 notes, a portion of the net proceeds from the notes' issuance and the proceeds of the warrant transactions were used to repurchase 16.7 million shares of our common stock for  $544.9 million. Under current accounting guidance, we bifurcated the conversion option of the 2011 and 2013 notes from the debt instrument, classified the conversion option in equity and are accreting the resulting debt discount as interest expense. The following table summarizes information about the equity and liability components of the 2011 and 2013 notes (in thousands):        Carrying Value of Equity Component      Net Carrying Amount of Liability Component      Unamortized Discount of Liability Component        December 31,      December 31,      December 31,        2010      2009      2010      2009      2010     2009   2011 convertible senior notes     $ 147,481        $ 147,481        $ 638,991        $ 606,786        $ (10,996 )     $ (43,201 )  2013 convertible senior notes      193,231         193,231         576,884         548,480         (72,983 )      (101,387 )                                                       Total 2011 and 2013 convertible senior notes     $ 340,712        $ 340,712        $ 1,215,875        $ 1,155,266        $ (83,979 )     $ (144,588 )                                                       For the years ended December 31, 2010, 2009 and 2008, we recognized  $67.9 million,  $64.6 million and  $61.5 million, respectively, in interest expense related to the contractual coupon rates and amortization of the debt discount for the 2011 and 2013 notes. The effective interest rates on the liability components of the 2011 and 2013 notes were 5.7% and 5.8%, respectively. If the notes were converted as of December 31, 2010, the if-converted value would not exceed the principal amounts of the 2011 Notes and 2013 Notes. 2014 and 2016 Notes In July 2010, we issued  $1.25 billion of convertible senior notes due in 2014 (2014 Notes) and  $1.25 billion of convertible senior notes due in 2016 (2016 Notes) in a private placement pursuant to Rule 144A of the Securities Act of 1933, as amended. The 2014 and 2016 notes were issued at par and bear interest rates of 1.00% and 1.625%, respectively. Debt issuance costs are primarily comprised of  $37.5 million in bankers' fees, the majority of which were recorded in other noncurrent assets and are being amortized to interest expense over the contractual terms of the 2014 and 2016 notes. The aggregate principal amount of the 2014 and 2016 notes sold reflects the full exercise by the initial purchasers of their option to purchase additional notes to cover over-allotments. The initial conversion rate for the 2014 Notes is 22.1845 shares per  $1,000 principal amount (which represents an initial conversion price of approximately  $45.08 per share), and the initial conversion rate for the 2016 Notes is 22.0214 shares per  $1,000 principal amount (which represents an initial conversion price of approximately  $45.41 per share). The conversion rates are subject to customary anti-dilution adjustments. The 2014 and 2016 notes may be converted prior to April 1, 2014 and April 1, 2016, respectively, only under the following circumstances: 1) during any calendar quarter commencing after September 30, 2010, if the closing price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than 130% of the applicable conversion price on each applicable trading day, or 2) during the five business day period after any measurement period of ten consecutive trading days in which, for each trading day of such period, the trading price per  $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of Gilead common stock and the applicable conversion rate on such trading day, or 3) upon the occurrence of specified corporate transactions, such as the distribution of certain stock rights, cash amounts, or other assets to all Gilead shareholders or the occurrence of a change in control. On and after April 1, 2014, in the case of the 2014 Notes, and April 1, 2016, in the case of the 2016 Notes, holders may convert their notes at any time, regardless of the foregoing circumstances. Generally, upon conversion, a holder would receive an amount in cash equal to the lesser of (i) the principal amount of the note or (ii) the conversion value for such note, as measured under the indenture governing the relevant notes. If the conversion value exceeds the principal amount, we may also deliver, at our option, cash or common stock or a combination of cash and common stock for the conversion value in excess of the principal amount. If the 2014 and 2016 notes are converted in connection with a change in control, we may be required to provide a make whole premium in the form of an increase in the conversion rate, subject to a stated maximum amount. In addition, in the event of a change in control, the holders may require us to purchase all or a portion of their notes at a purchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any.   Concurrent with the issuance of the 2014 and 2016 notes, we purchased convertible note hedges in private transactions at a cost of  $362.6 million, which is tax deductible over the life of the notes. We also sold warrants in private transactions and received net proceeds of  $155.4 million from the sale of the warrants. The convertible note hedges and warrants are intended to reduce the potential economic dilution upon future conversions of the 2014 and 2016 notes by effectively increasing our conversion price to  $56.76 per share for the 2014 Notes and  $60.10 per share for the 2016 Notes. The net cost of  $207.2 million of the convertible note hedge and warrant transactions was recorded in stockholders' equity on our Consolidated Balance Sheets. The convertible note hedges cover, subject to customary anti-dilution adjustments, 55.3 million shares of our common stock at strike prices that initially correspond to the initial conversion prices of the 2014 and 2016 notes and are subject to adjustments similar to those applicable to the conversion price of the related notes. If the market value per share of our common stock at the time of conversion of the 2014 and 2016 notes is above the strike price of the applicable convertible note hedges, we will be entitled to receive from the counterparties in the transactions shares of our common stock or, to the extent we have made a corresponding election with respect to the related convertible notes, cash or a combination of cash and shares of our common stock, at our option, for the excess of the market value of the common stock over the strike price of the convertible note hedges. The convertible note hedges will terminate upon the maturity of the 2014 and 2016 notes or when none of the 2014 and 2016 notes remain outstanding due to conversion or otherwise. There are 55.3 million shares of our common stock underlying the warrants, subject to customary anti-dilution adjustments. The warrants have strike prices of  $56.76 per share (for the warrants expiring in 2014) and  $60.10 per share (for the warrants expiring in 2016) and are exercisable only on their respective expiration dates. If the market value of our common stock at the time of the exercise of the applicable warrants exceeds their respective strike prices, we will be required to net settle in cash or shares of our common stock, at our option, with the respective counterparties for the value of the warrants in excess of the warrant strike prices. We have used and will continue to use the net proceeds from the issuance of the convertible notes to repurchase shares of our common stock and repay existing indebtedness. Under current accounting guidance, we bifurcated the conversion option of the 2014 and 2016 notes from the debt instrument, classified the conversion option in equity and are accreting the resulting debt discount as interest expense. The following table summarizes information about the equity and liability components of the 2014 and 2016 notes (in thousands):        Carrying Value of Equity Component      Net Carrying Amount of Liability Component      Unamortized Discount of Liability Component        December 31, 2010      December 31, 2010      December 31, 2010   2014 convertible senior notes     $ 107,496        $ 1,153,805        $ (96,195 )  2016 convertible senior notes      152,039         1,107,884         (142,116 )                             Total 2014 and 2016 convertible senior notes     $ 259,535        $ 2,261,689        $ (238,311 )                             For the year ended December 31, 2010, we recognized  $34.9 million in interest expense related to the contractual coupon rates and amortization of the debt discount for the 2014 and 2016 notes. The effective interest rate on the liability components of the 2014 and 2016 notes was 3.5% and 4.0%, respectively. If the notes were converted as of December 31, 2010, the if-converted value would not exceed the principal amounts of the 2014 Notes and 2016 Notes. Credit Facility Under our amended and restated credit agreement, we, along with our wholly-owned subsidiary, Gilead Biopharmaceutics Ireland Corporation, may borrow up to an aggregate of  $1.25 billion in revolving credit loans. The credit agreement also includes a sub-facility for swing-line loans and letters of credit. Loans under the credit agreement bear interest at an interest rate of either LIBOR plus a margin ranging from 20 basis points to 32 basis points or the base rate, as described in the credit agreement. We may reduce the commitments and may prepay loans under the credit agreement in whole or in part at any time without penalty, subject to certain conditions. The credit agreement will terminate in December 2012 and all unpaid borrowings thereunder shall be due and payable at that time. In April 2009, in connection with the acquisition of CV Therapeutics, we borrowed  $400.0 million under the credit agreement to partially fund the acquisition. As of December 31, 2009, we had repaid the  $400.0 million under this credit agreement. In May 2010, we borrowed  $500.0 million under the credit agreement to fund our stock repurchases. In August 2010, we repaid the  $500.0 million borrowed under this credit agreement using proceeds from our convertible senior notes issued in July 2010. As of December 31, 2010, we had  $5.0 million in letters of credit outstanding under the  $1.25 billion credit agreement. We are required to comply with certain covenants under the credit agreement and as of December 31, 2010, we were in compliance with all such covenants.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet19.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Commitments and Contingencies	12 Months Ended
Dec. 31, 2010
Commitments and Contingencies
Commitments and Contingencies	12. COMMITMENTS AND CONTINGENCIES Lease Arrangements We have entered into various long-term non-cancelable operating leases for equipment and facilities. We lease facilities in Foster City, Palo Alto and San Dimas, California; Durham, North Carolina; Boulder, Colorado; Seattle, Washington; the Dublin and Cork areas of Ireland and the London area of the United Kingdom. We also have operating leases for sales, marketing and administrative facilities in Europe, Canada and Asia Pacific. Our leases expire on various dates between 2011 and 2029, with many of our leases containing options to renew. Certain facility leases also contain rent escalation clauses. Our most significant lease, related to a facility in Seattle, Washington, expires in 2020 and has a 10-year term. The lease provides us with three consecutive rights to extend the term of the lease through 2035 and contains an annual three percent rent escalation clause. The lease also requires us to pay additional amounts for operating expenses and maintenance. We also have leases for three corporate aircraft, with varying terms, with renewal options upon expiration of the lease terms. Lease expense under our operating leases was approximately  $41.7 million,  $37.3 million and  $29.3 million during the years ended December 31, 2010, 2009 and 2008, respectively. Aggregate non-cancelable future minimum rental payments under operating leases are as follows (in thousands):   2011     $ 45,887    2012      37,733    2013      29,648    2014      21,477    2015      19,078    Thereafter      57,344                 $ 211,167             Legal Proceedings On August 12, 2009, we received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa®. Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009. Following receipt of the subpoena, we cooperated with the government's inquiry. On December 13, 2010, the United States Department of Justice notified the United States District Court for the Northern District of California "of its decision not to intervene" in a False Claims Act lawsuit filed by a former employee of CV Therapeutics regarding the promotion of Ranexa. On December 16, 2010, the plaintiff-relator filed a notice of voluntary dismissal without prejudice of the underlying lawsuit, and the United States consented to the dismissal without prejudice. We are a party to various other legal actions that arose in the ordinary course of our business. We do not believe that any of these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.   Other Commitments In the normal course of business, we enter into various firm purchase commitments primarily related to active pharmaceutical ingredients and certain inventory related items. As of December 31, 2010, these commitments for the next five years were approximately  $640.3 million in 2011,  $149.3 million in 2012,  $57.5 million in 2013,  $20.2 million in 2014 and  $3.1 million in 2015. The amounts related to active pharmaceutical ingredients represent minimum purchase requirements. Actual payments for the purchases related to these active pharmaceutical ingredients were  $835.7 million,  $1.03 billion and  $1.04 billion during the years ended December 31, 2010, 2009 and 2008, respectively.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet20.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity	12 Months Ended
Dec. 31, 2010
Stockholders' Equity
Stockholders' Equity	13. STOCKHOLDERS' EQUITY Stock Repurchase Programs In October 2007, our Board authorized a program for the repurchase of our common stock in an amount of up to  $3.00 billion through open market and private block transactions pursuant to Rule 10b5-1 plans or privately negotiated purchases or other means, including accelerated stock repurchase transactions or similar arrangements. In 2007, we repurchased and retired 705,600 shares of our common stock at  $46.28 per share for an aggregate of  $32.7 million under the  $3.00 billion stock repurchase program. In February 2008, we entered into an accelerated share repurchase agreement with a financial institution to repurchase  $500.0 million of our common stock on an accelerated basis. Under the terms of this accelerated share repurchase agreement, we paid  $500.0 million to the financial institution to settle the initial purchase transaction and received 9,373,548 shares of our common stock at a price of  $53.34 per share. In June 2008, upon maturity of the agreement and in accordance with the share delivery provisions of the agreement, we received an additional 239,612 shares of our common stock based on the average of the daily volume weighted-average prices of our common stock during a specified period less a predetermined discount per share. As a result, the average purchase price of our common stock from the accelerated share repurchase was  $52.01 per share. We accounted for the accelerated share repurchase as two separate transactions: (a) as shares of common stock acquired in a treasury stock transaction recorded on the transaction date and (b) as a forward contract indexed to our own common stock. As such, we accounted for the 9,373,548 shares that we received as a repurchase of our common stock and retired those shares immediately for net income per share purposes. The 239,612 additional shares that we received upon maturity of the contract in June 2008 were also recorded in stockholders' equity. We determined that the forward contract indexed to our own common stock met all of the applicable criteria for equity classification, and therefore, the contract was not accounted for as a derivative. In October 2008, we entered into an accelerated share repurchase agreement with a financial institution to repurchase  $750.0 million of our common stock on an accelerated basis. Under the terms of the accelerated share repurchase agreement, we paid  $750.0 million to settle the initial purchase transaction and received 14,874,519 shares of our common stock at an initial price of  $50.42 per share. In March 2009, upon termination of the agreement and in accordance with the share delivery provisions of the agreement, we received an additional 1,356,337 shares of our common stock based on the average of the daily volume weighted-average prices of our common stock during a specified period less a predetermined discount per share. As a result, the total number of shares repurchased and retired under this accelerated share repurchase agreement was 16,230,856 shares at an average purchase price of  $46.21 per share. The accounting for this accelerated share repurchase was consistent with that of our previous accelerated share repurchase.   In 2008, in addition to the common stock repurchased under the two accelerated share repurchase transactions, we repurchased and retired 14,696,449 shares of our common stock at an average purchase price of  $48.94 per share, for an aggregate purchase price of  $719.3 million through open market transactions. In 2009, in addition to the additional shares that we received under the accelerated share repurchase agreement completed in March 2009, we repurchased and retired 21,845,929 shares of our common stock at an average purchase price of  $45.69 per share, for an aggregate purchase price of  $998.1 million through open market transactions. As of December 31, 2009, we completed share repurchases under our  $3.00 billion stock repurchase program. In January 2010, our Board authorized a new program for the repurchase of our common stock in an amount of up to  $1.00 billion through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated purchases or other means. We completed this plan in May 2010, at which time our Board authorized a new three-year,  $5.00 billion stock repurchase program. As of December 31, 2010, we have repurchased  $3.02 billion of our common stock under this program. As of December 31, 2010, the remaining authorized amount of stock repurchases that may be made under our  $5.00 billion repurchase program was  $1.98 billion. In 2010, we utilized a total of  $4.02 billion to repurchase and retire 109.9 million shares of our common stock, at an average purchase price of  $36.57 per share. In January 2011, our Board authorized an additional three-year,  $5.00 billion stock repurchase program which will commence upon the completion of our existing program authorized in May 2010. We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to APIC based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. As a result of our stock repurchases in 2008, we reduced common stock and APIC by an aggregate of  $95.8 million and charged  $1.88 billion to retained earnings. As a result of our stock repurchases in 2009, we reduced common stock and APIC by an aggregate of  $61.7 million and charged  $940.8 million to retained earnings. As a result of our stock repurchases in 2010, we reduced common stock and APIC by an aggregate of  $319.8 million and charged  $3.71 billion to retained earnings. Preferred Stock We have 5,000,000 shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. We have designated 800,000 shares of Series A Junior Participating Preferred Stock for potential issuance under our November 1994 rights agreement with BNY Mellon Investor Services, LLC (formerly known as ChaseMellon Shareholder Services, LLC), as amended (the Rights Plan). There was no preferred stock outstanding as of December 31, 2010 and 2009. Rights Plan The Rights Plan provides for the distribution of a preferred stock purchase right as a dividend for each share of our common stock. The purchase rights are not currently exercisable. Under certain conditions involving an acquisition or proposed acquisition by any person or group of 15% or more of our common stock, the purchase rights permit the holders (other than the 15% holder) to purchase our common stock at a 50% discount from the market price at that time, upon payment of a specified exercise price per purchase right. In addition, in the event of certain business combinations, the purchase rights permit the purchase of the common stock of an acquirer at a 50% discount from the market price at that time. Under certain conditions, the purchase rights may be redeemed by our Board in whole, but not in part, at a price of  $0.0025 per purchase right. The purchase rights have no voting privileges and are attached to and automatically trade with our common stock. In October 1999, October 2003 and May 2006, our Board approved amendments to the Rights Plan. The first amendment provided, among other things, for an increase in the exercise price of a right under the plan from  $15 to  $100 and an extension of the term of the plan from November 2004 to October 2009. The second amendment provides, among other things, for an increase in the exercise price of a right under the plan from  $100 to  $400 and an extension of the term of the Rights Plan to October 2013. The third amendment was a clarifying amendment entered into in connection with an increase in the designated number of shares of Series A Junior Participating Preferred Stock for potential issuance under the Rights Plan in May 2006. Stock Option Plans In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (the 2004 Plan). Stock options under the NeXstar Pharmaceuticals, Inc. (NeXstar), Triangle Pharmaceuticals, Inc. (Triangle), Corus, Myogen and CV Therapeutics stock option plans, which we assumed as a result of the acquisitions of NeXstar, Triangle, Corus, Myogen and CV Therapeutics have been converted into options to purchase our common stock effective with the closing of the respective acquisitions. The 2004 Plan is a broad based incentive plan that allows for awards to be granted to our employees, directors and consultants. The 2004 Plan provides for option grants designated as either non-qualified or incentive stock options. Prior to January 1, 2006, we granted both non-qualified and incentive stock options, but all stock options granted after January 1, 2006 have been non-qualified stock options. Under the 2004 Plan, employee stock options granted prior to 2011 generally vest over five years, are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the 2004 Plan's previously authorized and available pool of shares. In connection with the acquisition of CV Therapeutics, we assumed CV Therapeutics' 1994 Equity Incentive Plan, as amended and restated, Non-Employee Directors' Stock Option Plan, as amended and restated, 2000 Equity Incentive Plan, as amended and restated, 2000 Nonstatutory Incentive Plan, as amended and restated, and 2004 Employee Commencement Incentive Plan, as amended and restated (collectively, the CV Therapeutics Plans). The majority of options that were issued and outstanding under the CV Therapeutics Plans as of April 15, 2009 were converted into options to purchase approximately 1.8 million shares of our common stock and remain subject to their original terms and conditions. There are no shares available for future grant under the CV Therapeutics Plans. As of December 31, 2010, a total of 121,594,183 shares of common stock have been authorized for grant and 51,793,307 shares remain available for future grant under the 2004 Plan.   The following table summarizes activity under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date (shares in thousands):        Year Ended December 31,        2010      2009      2008        Shares     Weighted- Average Exercise Price      Shares     Weighted- Average Exercise Price      Shares     Weighted- Average Exercise Price   Outstanding, beginning of year      69,193       $ 28.09         76,811       $ 24.70         84,977       $ 20.33    Granted and assumed      4,836       $ 44.27         7,286       $ 48.87         9,807       $ 47.11    Forfeited      (2,348 )     $ 43.16         (2,393 )     $ 39.33         (2,471 )     $ 30.61    Expired      (759 )     $ 53.27         (440 )     $ 64.08         (59 )     $ 11.72    Exercised      (10,671 )     $ 17.68         (12,071 )     $ 15.56         (15,443 )     $ 13.97                                     Outstanding, end of year      60,251       $ 30.32         69,193       $ 28.09         76,811       $ 24.70                                     Exercisable, end of year      45,018       $ 25.92         47,090       $ 22.36         45,235       $ 17.29                                     Weighted-average grant date fair value of options granted during the year       $ 14.24          $ 17.00          $ 16.95    The total intrinsic value of options exercised during the years ended December 31, 2010, 2009 and 2008 was  $262.3 million,  $379.8 million and  $551.7 million, respectively. The total fair value of stock options that vested during the years ended December 31, 2010, 2009 and 2008 was  $124.6 million,  $162.9 million and  $169.2 million, respectively. As of December 31, 2010, the number of options outstanding that are expected to vest, net of estimated future option forfeitures was 13,302,022 with a weighted-average exercise price of  $43.12 per share, an aggregate intrinsic value of  $9.6 million and a weighted-average remaining contractual life of 7.62 years. The aggregate intrinsic value of stock options outstanding and stock options exercisable as of December 31, 2010 were  $564.2 million and  $554.0 million, respectively. As of December 31, 2010, the weighted-average remaining contractual life for options outstanding and options exercisable were 5.3 and 4.5 years, respectively. As of December 31, 2010, there was  $260.8 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.7 years. Performance Shares and Restricted Stock Awards Under the 2004 plan, we grant performance-based restricted stock awards which vest upon the achievement of specified market and performance goals relative to a pre-determined peer group. The actual number of common shares ultimately issued is calculated by multiplying the number of performance shares by a payout percentage ranging from 0% to 200%. Performance shares vest only when a committee (or subcommittee) of our Board has determined that we have achieved our specified market and performance goals. In January 2010, 2009 and 2008 we granted 412,505, 426,305 and 219,690 performance-based share awards (the 2010 performance shares, the 2009 performance shares and the 2008 performance shares, respectively). These awards will vest over a single three-year performance measurement and vesting period for each of the performance share awards. The fair value of each performance share grant is estimated at the grant date using a Monte Carlo valuation methodology. The weighted-average grant date fair values of the 2010, 2009 and 2008 performance shares were  $54.25,  $61.89 and  $56.61 per share, respectively. We recognized  $21.3 million,  $14.9 million and  $7.5 million of stock-based compensation expenses in 2010, 2009 and 2008, respectively, related to these performance shares. We have also granted performance-based restricted stock awards to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified performance goals. The number of these awards issued to date has not been significant. During 2010 we granted 2,189,903 time-based restricted stock awards to employees under the 2004 Plan. These awards vest annually over a five-year period. We recognized  $19.5 million of stock-based compensation expenses in 2010 related to time-based awards. Employee Stock Purchase Plan Under our Employee Stock Purchase Plan, as amended (ESPP), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a two-year look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP's previously authorized and available pool of shares. During 2010, 1,110,485 shares were issued under the ESPP for  $32.3 million. A total of 33,280,000 shares of common stock have been reserved for issuance under the ESPP, and there were 6,567,411 shares available for issuance under the ESPP as of December 31, 2010. As of December 31, 2010, there was  $22.1 million of unrecognized compensation cost related to the ESPP, which is expected to be recognized over an estimated weighted-average period of 1.0 year.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet21.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation	12 Months Ended
Dec. 31, 2010
Stock-Based Compensation
Stock-Based Compensation	14. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in our Consolidated Statements of Income (in thousands:        Year Ended December 31,        2010     2009     2008   Cost of goods sold     $ 10,180       $ 10,859       $ 10,312    Research and development expenses      84,048        82,893        66,523    Selling, general and administrative expenses      105,813        92,006        76,529                             Stock-based compensation expense included in total costs and expenses      200,041        185,758        153,364    Income tax effect      (52,331 )      (46,486 )      (40,565 )                           Stock-based compensation expense included in net income     $ 147,710       $ 139,272       $ 112,799                             During the years ended December 31, 2010, 2009 and 2008, we capitalized  $10.9 million,  $11.4 million and  $9.9 million of stock-based compensation costs to inventory, respectively. Stock-based compensation is recognized as expense over the requisite service periods in our Consolidated Statements of Income using a graded vesting expense attribution approach for unvested stock options granted prior to January 1, 2006, and using the straight-line expense attribution approach for stock options granted after our adoption of new guidance for share-based payments to employees and directors on January 1, 2006. As stock-based compensation expenses related to stock options recognized on adoption of the new guidance is based on awards ultimately expected to vest, gross expense has been reduced for estimated forfeitures. The guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimated forfeitures based on our historical experience. Prior to the adoption of this guidance, pro forma information that was required to be disclosed included forfeitures as they occurred. As a result of the guidance adopted on January 1, 2006, we only recognize a tax benefit from stock-based compensation in APIC if an incremental tax benefit is realized after all other tax attributes currently available to us have been utilized. In addition, we have elected to account for the indirect benefits of stock-based compensation on the research tax credit and the extraterritorial income deduction through the Consolidated Statements of Income rather than through APIC. Valuation Assumptions Fair values of awards granted under our stock option plans and ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. We used the following assumptions to calculate the estimated fair value of the awards:        Year Ended December 31,        2010      2009      2008   Expected volatility:          Stock options      31%         35%         34%    ESPP      35%         37%         31%    Expected term in years:          Stock options      5.4         5.3         5.3    ESPP      1.3         1.3         1.2    Risk-free interest rate:          Stock options      2.3%         2.1%         2.8%    ESPP      0.4%         0.7%         2.1%    Expected dividend yield      0%         0%         0%    The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet22.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income (Loss)	12 Months Ended
Dec. 31, 2010
Comprehensive Income (Loss)
Comprehensive Income (Loss)	15. COMPREHENSIVE INCOME (LOSS) Comprehensive income (loss) comprises net income and certain changes in stockholders' equity that are excluded from net income, such as changes in the fair value of our outstanding effective cash flow hedges, changes in unrealized gains and losses on our available-for-sale securities and changes in our cumulative foreign currency translation account. Comprehensive income (loss) for the years ended December 31, 2010, 2009 and 2008 is included in our Consolidated Statements of Stockholders' Equity. The components of comprehensive income (loss) are shown net of related taxes where the underlying assets or liabilities are held in jurisdictions that are expected to generate a future tax benefit or liability. The following reclassifications were recorded in connection with net realized gains (losses) on sales of securities and cash flow hedges that were previously included in comprehensive income (loss) (in thousands):        Year Ended December 31,        2010     2009     2008   Net unrealized gain (loss) related to available-for-sale securities, net of tax impact of  $(6,624),  $(11,724) and  $11,487 for 2010, 2009 and 2008, respectively     $ 13,450       $ 21,689       $ (21,607 )  Net unrealized gain (loss) related to cash flow hedges, net of tax impact of  $(9,149),  $10,682 and  $(40,681) for 2010, 2009 and 2008, respectively      105,924        (19,016 )      93,962    Reclassification adjustments, net of tax impact of  $9,028,  $32,532 and  $1,805 for 2010, 2009 and 2008, respectively      (74,289 )      (58,130 )      (5,603 )                           Other comprehensive income (loss)     $ 45,085       $ (55,457 )     $ 66,752                             The balance of accumulated other comprehensive income (loss), net of taxes, as reported on our Consolidated Balance Sheets consists of the following components (in thousands):        As of December 31,        2010     2009   Net unrealized gain on available-for-sale securities     $ 16,528       $ 9,509    Net unrealized gain (loss) on cash flow hedges      21,615        (16,450 )  Cumulative foreign currency translation adjustment      (7,232 )      1,183                     Accumulated other comprehensive income (loss)     $ 30,911       $ (5,758 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet23.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information	12 Months Ended
Dec. 31, 2010
Segment Information
Segment Information	16. SEGMENT INFORMATION We operate in one business segment, which primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. All products are included in one segment, because our major products, Atripla, Truvada and Viread, which together accounted for substantially all of our total product sales for each of the years ended December 31, 2010, 2009 and 2008, have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.   Product sales consist of the following (in thousands):        Year Ended December 31,        2010      2009      2008   Antiviral products:          Atripla     $ 2,926,579        $ 2,382,113        $ 1,572,455    Truvada      2,649,908         2,489,682         2,106,687    Viread      732,240         667,510         621,187    Hepsera      200,592         271,595         341,023    Emtriva      27,679         27,974         31,080                               Total antiviral products      6,536,998         5,838,874         4,672,432    AmBisome      305,856         298,597         289,651    Letairis      240,279         183,949         112,855    Ranexa      239,832         131,062         —      Other products      66,956         16,829         9,858                               Total product sales     $ 7,389,921        $ 6,469,311        $ 5,084,796                               The following table summarizes total revenues from external customers and collaboration partners by geographic region (in thousands). Product sales and product-related contract revenue are attributed to countries based on ship-to location. Royalty and non-product related contract revenue are attributed to countries based on the location of the collaboration partner.        Year Ended December 31,        2010      2009      2008   United States     $ 4,224,035        $ 3,599,313        $ 2,857,472    Outside of the United States:          Switzerland      458,606         448,203         193,314    France      519,700         468,314         395,672    Spain      456,647         451,115         356,607    United Kingdom      450,368         393,036         297,276    Italy      345,189         323,709         277,441    Germany      274,991         293,111         242,193    Other European countries      665,237         603,068         346,722    Other countries      554,647         431,514         369,053                               Total revenues outside of the United States      3,725,385         3,412,070         2,478,278                               Total revenues     $ 7,949,420        $ 7,011,383        $ 5,335,750                               The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a % of total revenues):        Year Ended December 31,        2010      2009      2008   Cardinal Health, Inc.      17%         18%         21%    McKesson Corp.      14%         13%         16%    AmerisourceBergen Corp.      12%         11%         11%      At December 31, 2010, the net book value of our property, plant and equipment in the United States, Ireland and Canada was  $519.4 million,  $112.2 million and  $53.9 million, respectively, which comprised approximately 98% of the total net book value of our property, plant and equipment. At December 31, 2009, the net book value of our property, plant and equipment in the United States, Ireland and Canada was  $510.0 million,  $115.3 million and  $57.0 million, respectively, which comprised approximately 97% of the total net book value of our property, plant and equipment.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet24.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes	12 Months Ended
Dec. 31, 2010
Income Taxes
Income Taxes	17. INCOME TAXES The provision for income taxes consists of the following (in thousands):        Year Ended December 31,        2010     2009     2008   Federal:        Current     $ 852,822       $ 719,777       $ 585,075    Deferred      (29,854 )      (47,608 )      6,099                                  822,968        672,169        591,174                             State:        Current      139,819        153,376        56,223    Deferred      17,464        9,150        24,333                                  157,283        162,526        80,556                             Foreign:        Current      43,094        42,860        38,738    Deferred      454        (1,191 )      (8,105 )                                43,548        41,669        30,633                             Provision for income taxes     $ 1,023,799       $ 876,364       $ 702,363                             Foreign pre-tax income was  $1.37 billion,  $1.33 billion and  $0.90 billion in 2010, 2009 and 2008, respectively. The cumulative unremitted foreign earnings that are considered to be permanently invested outside the United States and for which no U.S. taxes have been provided, were approximately  $4.48 billion and  $3.19 billion as of December 31, 2010 and 2009, respectively. The residual U.S. tax liability, if such amounts were remitted, would be approximately  $1.60 billion and  $1.14 billion as of December 31, 2010 and 2009, respectively. The difference between the provision for income taxes and the amount computed by applying the U.S. federal statutory income tax rate to income before provision for income taxes is as follows (in thousands):        Year Ended December 31,        2010     2009     2008   Income before provision for income taxes     $ 3,913,548       $ 3,501,956       $ 2,672,698                             Tax at federal statutory rate     $ 1,369,742       $ 1,225,685       $ 935,444    State taxes, net of federal benefit      106,250        111,095        58,166    Foreign earnings at different rates      (435,767 )      (399,993 )      (257,835 )  Research and other credits      (33,072 )      (43,045 )      (32,270 )  Net unbenefitted stock compensation      13,188        4,269        5,224    Other      3,458        (21,647 )      (6,366 )                           Provision for income taxes     $  1,023,799       $ 876,364       $ 702,363                               Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows (in thousands):        December 31,        2010     2009   Deferred tax assets:      Net operating loss carryforwards     $ 308,854       $ 377,058    Stock-based compensation      142,242        117,019    Reserves and accruals not currently deductible      109,806        90,760    Deferred revenue      49,194        67,389    Depreciation related      58,875        44,166    Research and other credit carryforwards      25,151        28,980    Capitalized intangibles      5,839        12,086    Other, net      88,669        64,881                     Total deferred tax assets before valuation allowance      788,630        802,339    Valuation allowance      (13,040 )      (1,078 )                   Total deferred tax assets      775,590        801,261                     Deferred tax liabilities:      Intangibles      (322,168 )      (384,480 )  Unremitted foreign earnings      (15,928 )      (15,928 )  Other      (20,774 )      (17,053 )                   Total deferred tax liabilities      (358,870 )      (417,461 )                   Net deferred tax assets     $ 416,720       $ 383,800                     The valuation allowance increased (decreased) by  $11.9 million,  $1.1 million and  $(23.5) million for the years ended December 31, 2010, 2009 and 2008, respectively. We have concluded, based on the standard set forth in the FASB Accounting Standards Codification related to Income Taxes, that it is more likely than not that we will not realize any benefit from the deferred tax assets related to certain state net operating loss and credit carryforwards. At December 31, 2010, we had U.S. federal net operating loss carryforwards of approximately  $732.5 million. The federal net operating loss carryforwards will start to expire in 2016, if not utilized. We also had federal tax credit carryforwards of approximately  $26.2 million which will start to expire in 2016, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately  $1.40 billion and  $3.3 million, respectively. The state net operating loss and tax credit carryforwards will start to expire in 2011 and 2016, respectively, if not utilized. Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses (NOLs) and credits before utilization. We file federal, state and foreign income tax returns in many jurisdictions in the United States and abroad. For federal income tax purposes, the statute of limitations is open for 2003 and onwards. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their NOLs and credits carried over from prior years. For California income tax purposes, the statute of limitations remains open for 2002 and onwards.   Our income tax returns are audited by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service (IRS) for the 2005, 2006 and 2007 tax years and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions. At December 31, 2010 and 2009, the total gross unrecognized tax benefits were  $126.5 million and  $106.5 million, respectively. Of the total unrecognized tax benefits,  $106.5 million and  $72.6 million at December 31, 2010 and 2009, respectively, if recognized, would reduce our effective tax rate in the period of recognition. We have continued to classify interest and penalties related to unrecognized tax benefits as part of our income tax provision in our Consolidated Statements of Income. As of December 31, 2010 and 2009, we had accrued interest and penalties related to unrecognized tax benefits of  $12.3 million and  $5.4 million, respectively. As of December 31, 2010, we believe it is reasonably possible that our unrecognized tax benefits will decrease by approximately  $6.0 million in the next 12 months as we expect to have clarification from the tax authorities around certain of our uncertain tax positions. With respect to the remaining unrecognized tax benefits, we are currently unable to make a reasonable estimate as to the period of cash settlement, if any, with the respective tax authorities. The following is a rollforward of our total gross unrecognized tax benefit liabilities for the years ended December 31, 2010 and 2009 (in thousands):        December 31,        2010     2009     2008   Balance, beginning of period     $ 106,506       $ 121,424       $ 115,087    Tax positions related to current year:        Additions      24,320        25,036        37,495    Reductions      (3,303 )      (8,380 )      —      Tax positions related to prior years:        Additions      25,581        37,014        4,298    Reductions      (23,474 )      (36,277 )      (23,307 )  Settlements      (2,160 )      (31,517 )      (10,252 )  Lapse of statute of limitations      (954 )      (794 )      (1,897 )                           Balance, end of period     $ 126,516       $ 106,506       $ 121,424

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet25.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Deferred Compensation Plans	12 Months Ended
Dec. 31, 2010
Deferred Compensation Plans
Deferred Compensation Plans	18. DEFERRED COMPENSATION PLANS We maintain a retirement savings plan under which eligible employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (Gilead Plan). Under the Gilead Plan, employees may contribute up to 60% of their eligible annual compensation, subject to IRS plan limits. We make matching contributions under the Gilead Plan. In 2010, 2009 and 2008, we contributed up to 50% of an employee's contributions up to an annual maximum match of  $5,000. Our total matching contribution expense under the Gilead Plan for the years ended December 31, 2010, 2009 and 2008 was  $11.2 million,  $10.2 million, and  $7.8 million, respectively. We maintain a deferred compensation plan under which our directors and key employees may defer compensation for income tax purposes. The deferred compensation plan is a non-qualified deferred compensation plan which is not subject to the qualification requirements under Section 401(a) of the Internal Revenue Code. Compensation deferred after December 31, 2004 is subject to the requirements of Section 409A of the Internal Revenue Code. Under the plan, officers and other senior grade level employees may contribute up to 70% of their annual salaries and up to 100% of their annual bonus while directors may contribute up to 100% of their annual retainer fee. Amounts deferred by participants are deposited in a rabbi trust and are recorded in other noncurrent assets in our Consolidated Balance Sheets. Beginning in 2004, directors may also elect to receive all or a portion of their annual cash retainer in phantom shares, which gives the participant the right to receive an amount equal to the value of a specified number of shares over a specified period of time and which will be payable in shares of our common stock (with fractional shares paid out in cash) as established by the plan administrator. As of December 31, 2010, we had 31,682 phantom shares outstanding. Participants can elect one of several distribution dates available under the plan at which they will receive their deferred compensation payment.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet26.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Subsequent Events	12 Months Ended
Dec. 31, 2010
Subsequent Events
Subsequent Events	19. SUBSEQUENT EVENTS Stock Repurchase Program In January 2011, our Board authorized an additional three-year,  $5.00 billion stock repurchase program which will commence upon the completion of our existing program authorized in May 2010. Acquisition of Arresto Biosciences, Inc. In December 2010, we entered into an agreement to acquire Arresto Biosciences, Inc. (Arresto) for  $225 million plus potential future payments based on achievement of certain sales levels. This transaction closed on January 14, 2011, at which time Arresto became a wholly-owned subsidiary. Arresto was a privately-held, development-stage biotechnology company based in Palo Alto, California, focused on developing antibodies for the potential treatment of fibrotic diseases and cancer. The company's lead product is GS 6224 (formerly AB0024), a humanized monoclonal antibody (mAb) targeting the human lysyl oxidase-like-2 (LOXL2) protein. In addition to an ongoing Phase 1 study of GS 6224 in patients with advanced solid tumors, a Phase 1 study had also been initiated to evaluate GS 6224 in patients with idiopathic pulmonary fibrosis. We believe that Arresto's pipeline and research and development expertise are well aligned with Gilead's areas of focus. Given the timing of the closing of this acquisition, we are currently in the process of valuing the assets acquired and liabilities assumed in the business combination. As a result, we are unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed and certain disclosures pertaining to contingent consideration. Acquisition of Calistoga Pharmaceuticals, Inc. In February 2011, we entered into an agreement to acquire Calistoga Pharmaceuticals, Inc. (Calistoga) for  $375 million plus potential payments of up to  $225 million based on the achievement of certain milestones. This transaction is expected to close in the second quarter of 2011. Calistoga is a privately-held, biotechnology company based in Seattle, Washington, focused on the development of medicines to treat cancer and inflammatory diseases. The company has a portfolio of proprietary compounds that selectively target isoforms of phosphoinositide-3 kinase (P13K). Calistoga's lead product candidate, CAL-101, is a first-in-class specific inhibitor of the P13K delta isoform. P13K delta is preferentially expressed in leukocytes involved in a variety of inflammatory and autoimmune diseases and hematological cancers.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet27.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Quarterly Results of Operations	12 Months Ended
Dec. 31, 2010
Quarterly Results of Operations
Quarterly Results Of Operations	20. QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) The following amounts are in thousands, except per share amounts:        1st Quarter      2nd Quarter      3rd Quarter      4th Quarter   2010 (1)             Total revenues     $ 2,085,853        $ 1,927,224        $ 1,937,656        $ 1,998,687    Gross profit on product sales     $ 1,347,633        $ 1,350,536        $ 1,387,975        $ 1,433,901    Net income     $ 852,094        $ 709,127        $ 702,163        $ 626,365    Net income attributable to Gilead     $ 854,901        $ 712,061        $ 704,876        $ 629,419    Net income per share attributable to Gilead common stockholders—basic     $ 0.95        $ 0.81        $ 0.85        $ 0.78    Net income per share attributable to Gilead common stockholders—diluted     $ 0.92        $ 0.79        $ 0.83        $ 0.76    2009             Total revenues     $ 1,530,460        $ 1,647,155        $ 1,801,389        $ 2,032,379    Gross profit on product sales     $ 1,118,166        $ 1,185,333        $ 1,239,255        $ 1,330,999    Net income     $ 586,576        $ 569,145        $ 670,478        $ 799,393    Net income attributable to Gilead     $ 589,112        $ 571,398        $ 673,033        $ 802,212    Net income per share attributable to Gilead common stockholders—basic     $ 0.65        $ 0.63        $ 0.75        $ 0.89    Net income per share attributable to Gilead common stockholders—diluted     $ 0.63        $ 0.61        $ 0.72        $ 0.87    (1) During 2010, we recorded  $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet28.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Schedule II Valuation and Qualifying Accounts	12 Months Ended
Dec. 31, 2010
Schedule II Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts	GILEAD SCIENCES, INC. Schedule II: Valuation and Qualifying Accounts        Balance at Beginning of Period      Additions/ Charged to Expense      Deductions      Balance at End of Period   Year ended December 31, 2010:             Accounts receivable allowances (1)     $ 132,810        $ 818,132        $ 800,000        $ 150,942    Valuation allowance for deferred tax assets (2)     $ 1,078        $ 12,127        $ 165        $ 13,040    Year ended December 31, 2009:             Accounts receivable allowances (1)     $ 90,694        $ 606,504        $ 564,388        $ 132,810    Valuation allowance for deferred tax assets (2)     $ —          $ 15,103        $ 14,025        $ 1,078    Year ended December 31, 2008:             Accounts receivable allowances (1)     $ 72,217        $ 500,037        $ 481,560        $ 90,694    Valuation allowance for deferred tax assets     $ 23,498        $ 965        $ 24,463        $ —      (1) Allowances are for doubtful accounts, sales returns, cash discounts and chargebacks.   (2) Valuation allowance for deferred tax assets includes  $9.9 million and  $1.1 million as of December 31, 2010 and 2009, respectively, related to our acquisitions.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet29.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies (Policy)	12 Months Ended
Dec. 31, 2010
Organization and Summary of Significant Accounting Policies
Basis of Presentation and Significant Accounting Policies, Estimates and Judgments	Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and our joint ventures with Bristol-Myers Squibb Company (BMS), for which we are the primary beneficiary. We record a noncontrolling interest in our Consolidated Financial Statements to reflect BMS's interest in the joint ventures. All intercompany transactions have been eliminated. The Consolidated Financial Statements include the results of companies acquired by us from the date of each acquisition for the applicable reporting periods. Consolidation of Variable Interest Entities On January 1, 2010, we adopted amended guidance for the consolidation of variable interest entities. The amended guidance eliminates a mandatory quantitative approach to determine whether a variable interest gives the entity a controlling financial interest in a variable interest entity in favor of a qualitatively focused analysis. Additionally, the amended guidance requires an ongoing reassessment of whether the entity is a primary beneficiary. We adopted the provisions of this guidance on a prospective basis for our joint ventures with BMS, which we consolidate because we are the primary beneficiary. The adoption of this guidance did not have any impact on our Consolidated Financial Statements.   Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, intangible assets, allowance for doubtful accounts, prepaid royalties, clinical trial accruals, our tax provision and stock-based compensation. We base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates.
Revenue Recognition	Revenue Recognition Product Sales We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery to the customer has occurred, the price is fixed or determinable and collectability is reasonably assured. Upon recognition of revenue from product sales, provisions are made for government rebates such as Medicaid reimbursements, customer incentives such as cash discounts for prompt payment, distributor fees and expected returns of expired products, as appropriate. Items Deducted from Gross Product Sales Government Rebates We estimate reductions to our revenues for government-managed Medicaid programs as well as for certain other qualifying federal, state and foreign government programs based on contractual terms, historical utilization rates, new information regarding changes in these programs' regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and, for our U.S. product sales, channel inventory data obtained from our major U.S. wholesalers in accordance with our inventory management agreements. Government rebates that are invoiced directly to us are recorded in accrued government rebates on our Consolidated Balance Sheets. For qualified programs that can purchase our products through wholesalers at a lower contractual government price, the wholesalers charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as allowances against accounts receivable. Cash Discounts We estimate cash discounts based on contractual terms, historical utilization rates and our expectations regarding future utilization rates. Distributor Fees Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for the compliance of certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.   Product Returns We do not provide our customers with a general right of product return, but permit returns if the product is damaged or defective when received by the customer, or in the case of product sold in the Unites States and certain countries outside the United States, if the product has expired. We will accept returns for product that will expire within six months prior to or that have expired up to one year after their expiration dates. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns. Royalty Revenues Royalty revenue from sales of Lexiscan and AmBisome by Astellas US LLC and Astellas Pharma US, Inc., respectively, is recognized in the month following the month in which the corresponding sales occur. Royalty revenue from sales of our other products is generally recognized when received, which is generally in the quarter following the quarter in which the corresponding sales occur. Contract and Other Revenues Revenue from non-refundable up-front license fees and milestone payments such as under a development collaboration or an obligation to supply product, is recognized as performance occurs and our obligations are completed. In accordance with the specific terms of our obligations under these arrangements, revenue is recognized as the obligation is fulfilled or ratably over the development or manufacturing period. Revenue associated with substantive at-risk milestones is recognized based upon the achievement of the milestones as defined in the respective agreements. Advance payments received in excess of amounts earned are classified as deferred revenue on our Consolidated Balance Sheets.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of goods sold in our Consolidated Statements of Income.
Research and Development Expenses	Research and Development Expenses Major components of research and development (R&D) expenses consist of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (CROs), materials and supplies, licenses and fees, milestone payments under collaboration arrangements and overhead allocations consisting of various support and facilities related costs. We charge R&D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. We validate our accruals quarterly with our vendors and perform detailed reviews of the activities related to our significant contracts. Based upon the results of these validation processes, we assess the appropriateness of our accruals and make any adjustments we deem necessary to ensure that our expenses reflect the actual effort incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CRO and certain non-cancelable expenses incurred at any point of termination. Amounts paid in advance related to uncompleted services will be refunded to us if a contract is terminated. Some contracts may include additional termination payments that become due and payable if we terminate the contract. Such additional termination payments are only recorded if it becomes probable that a contract will be terminated.
Advertising Expenses	Advertising Expenses We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were  $116.5 million in 2010,  $108.1 million in 2009 and  $96.2 million in 2008.
Net Income Per Share Attributable to Gilead Common Stockholders	Net Income Per Share Attributable to Gilead Common Stockholders Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options, restricted stock units and performance shares and the assumed exercise of warrants relating to the convertible senior notes due in 2011 (2011 Notes), 2013 (2013 Notes), 2014 (2014 Notes) and 2016 (2016 Notes) (collectively, the Notes) are determined under the treasury stock method. Because the principal amount of the Notes will be settled in cash, only the conversion spread relating to the Notes is included in our calculation of diluted net income per share attributable to Gilead common stockholders. Our common stock resulting from the assumed settlement of the conversion spread of the Notes has a dilutive effect when the average market price of our common stock during the period exceeds the conversion prices of  $38.75,  $38.10,  $45.08 and  $45.41 for the 2011 Notes, 2013 Notes, 2014 Notes and 2016 Notes, respectively. For the years ended 2010, 2009 and 2008, the average market prices of our common stock exceeded the conversion prices of the 2011 and 2013 Notes and the dilutive effects are included in the accompanying table. Warrants relating to the 2011 Notes, 2013 Notes, 2014 Notes and 2016 Notes have a dilutive effect when the average market price of our common stock during the period exceeds the warrants' exercise prices of  $50.80,  $53.90,  $56.76 and  $60.10, respectively. The average market prices of our common stock during the years ended December 31, 2010, 2009 and 2008 did not exceed the warrants' exercise prices relating to any of the Notes; therefore, these warrants did not have a dilutive effect on our net income per share for those periods. Stock options to purchase approximately 22.5 million, 17.4 million and 11.4 million weighted-average shares of our common stock were outstanding during the years ended December 31, 2010, 2009 and 2008, respectively, but were not included in the computation of diluted net income per share attributable to Gilead common stockholders because their effect was antidilutive.   The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in thousands):        Year Ended December 31,        2010      2009      2008   Numerator:          Net income attributable to Gilead     $ 2,901,257        $ 2,635,755        $ 1,978,899                               Denominator:          Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders      856,060         904,604         920,693    Effect of dilutive securities:          Stock options and equivalents      16,606         23,850         30,727    Conversion spread related to the 2011 Notes      222         2,684         3,559    Conversion spread related to the 2013 Notes      508         2,971         3,846                               Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders      873,396         934,109         958,825
Stock-Based Compensation	Stock-Based Compensation Share-based payments to employees are recognized in the Consolidated Statements of Income based on their fair values and the benefit of tax deductions in excess of recognized compensation cost are reported in the Consolidated Statements of Cash Flows as a financing activity, rather than as an operating activity. The calculated pool of excess tax benefits is recorded as part of additional paid-in capital (APIC).
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three months or less on the purchase date to be cash equivalents. We may enter into overnight repurchase agreements (repos) under which we purchase securities with an obligation to resell them the following day. Securities purchased under agreements to resell are recorded at face value and reported as cash and cash equivalents. Under our investment policy, we may enter into repos with major banks and authorized dealers provided that such repos are collateralized by U.S. government securities with a fair value of at least 102% of the fair value of securities sold to us. Other eligible instruments under our investment policy that are included in cash equivalents include commercial paper, money market funds and other bank obligations.
Marketable and Nonmarketable Securities	Marketable and Nonmarketable Securities We determine the appropriate classification of our marketable securities, which consist primarily of debt securities and which include auction rate securities and variable rate demand obligations, at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Interest and other income, net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline. As a result of entering into collaborations, from time to time, we may hold investments in non-public companies. We record these nonmarketable securities at cost in other noncurrent assets, less any amounts for other-than-temporary impairment. We regularly review our securities for indicators of impairment. Investments in nonmarketable securities are not material for the periods presented.
Concentrations of Risk	Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate at December 31, 2010. Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application (NDA) filed with the U.S. Food and Drug Administration (FDA) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers were interrupted for any reason, we may be unable to ship our commercial products or to supply any of our product candidates for clinical trials.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government rebate programs, cash discounts for prompt payment, doubtful accounts and sales returns. Estimates for wholesaler chargebacks for government rebates, cash discounts and sales returns are based on contractual terms, historical trends and our expectations regarding the utilization rates for these programs. Estimates for our allowance for doubtful accounts is determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off have been insignificant and consistent with management's expectations.
Inventories	Inventories Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of our inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the impairment is first recognized.
Prepaid Royalties	Prepaid Royalties Prepaid royalties are capitalized at cost, which initially is equivalent to the present value of the future royalty obligation that we would expect to pay to the licensor on expected future levels of product sales incorporating the related technology. We review periodically the expected future sales levels of our products and any indicators that might require a write-down in the net recoverable value of our asset or a change in the estimated life of the prepaid royalty. We amortize our prepaid royalties to cost of goods sold over the remaining life of the underlying patent based on an effective royalty rate derived from forecasted future product sales incorporating the related technology. We review our effective royalty rate at least annually and prospectively adjust the effective rate based on significant new facts or circumstances that may arise from our review. Our prepaid royalties are primarily comprised of emtricitabine royalties we paid to Emory University (Emory) for the HIV indication when we and Royalty Pharma purchased the royalty interest owned by Emory in 2005. Under the terms of the transaction, we and Royalty Pharma paid 65% and 35%, respectively, of the total purchase price of  $525.0 million to Emory in exchange for the elimination of the emtricitabine royalties due to Emory on worldwide net sales of products containing emtricitabine. As a result of this transaction, we capitalized as prepaid royalties our 65% share of the  $525.0 million purchase price, or  $341.3 million. As of December 31, 2010 and 2009, we had an unamortized prepaid royalty asset of  $219.5 million and  $245.0 million, respectively. In 2010, 2009 and 2008,  $25.5 million,  $29.9 million and  $31.8 million were amortized to cost of goods sold, respectively.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows:   Description    Estimated Useful Life Buildings and improvements    20-35 Laboratory and manufacturing equipment    4-10 Office and computer equipment    3-7 Leasehold improvements    Shorter of useful life or lease term Office and computer equipment includes capitalized software. We had unamortized capitalized software costs of  $22.5 million and  $25.2 million on our Consolidated Balance Sheets as of December 31, 2010 and 2009, respectively. Leasehold improvements and capitalized leased equipment are amortized over the shorter of the lease term or the asset's useful life. Amortization of capitalized leased equipment is included in depreciation expense. Capitalized interest on construction in-progress is included in property, plant and equipment. Interest capitalized in 2010, 2009 and 2008 was not significant.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Other intangible assets primarily related to marketed products and purchased in-process research and development (IPR&D) projects from our acquisitions of CGI Pharmaceuticals, Inc. (CGI) in July 2010 and CV Therapeutics, Inc. (CV Therapeutics) in April 2009, and are measured at their respective fair values as of the acquisition date. We do not amortize goodwill and other intangible assets with indefinite useful lives. We test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and in between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the assets below their carrying amounts. Intangible assets with finite useful lives are amortized over their estimated useful lives and are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. We amortize the intangible asset related to Ranexa, which we acquired from CV Therapeutics, over its estimated useful life using an amortization rate derived from our forecasted future product sales for Ranexa. Our product sales forecasts are prepared annually and determined using our best estimates of future activity and consider such factors as historical and expected future patient usage or uptake of our products, the introduction of complimentary or combination therapies or products and future product launch plans. If a previously unanticipated and significant change occurs to our sales forecasts, we will prospectively update the rate used to amortize our intangible asset related to Ranexa which may increase future cost of goods sold, as that is where we record the amortization expense. We amortize the intangible asset related to Lexiscan, which we also acquired from CV Therapeutics, over its estimated useful life to cost of goods sold on a straight-line basis. Given that current Lexiscan revenues consist of royalties received from a collaboration partner and our lack of ongoing access and visibility into that partner's future sales forecasts, we cannot make a reasonable estimate of the amortization rate using a forecasted product sales approach.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts or circumstances both internally and externally that may suggest impairment. Specific potential indicators of impairment include a significant decrease in the fair value of an asset, a significant change in the extent or manner in which an asset is used or a significant physical change in an asset, a significant adverse change in legal factors or in the business climate that affects the value of an asset, an adverse action or assessment by the FDA or another regulator, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income producing asset. Should there be an indication of impairment, we will test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value will be recognized as an impairment loss.
Foreign Currency Translation, Transactions and Contracts	Foreign Currency Translation, Transactions and Contracts Adjustments resulting from translating the financial statements of our foreign subsidiaries into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Net foreign currency exchange transaction gains or losses are included in interest and other income, net, on our Consolidated Statements of Income. Net transaction losses totaled  $3.7 million,  $16.4 million and  $36.5 million in 2010, 2009 and 2008, respectively.   We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward and option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we limit the risk that counterparties to these contracts may be unable to perform. We also limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrecognized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes, nor do we hedge our net investment in any of our foreign subsidiaries.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable, foreign currency exchange forward and option contracts, accounts payable, and short-term and long-term debt. Cash and cash equivalents, marketable securities and foreign currency exchange contracts that hedge accounts receivable and forecasted sales are reported at their respective fair values on our Consolidated Balance Sheets. The carrying value and fair value of the Notes were  $3.48 billion and  $3.97 billion, respectively, as of December 31, 2010. The carrying value and fair value of the Notes were  $1.16 billion and  $1.58 billion, respectively as of December 31, 2009. The fair value of the Notes was based on their quoted market values. The remaining financial instruments are reported on our Consolidated Balance Sheets at amounts that approximate current fair values.
Income Taxes	Income Taxes Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. Various factors may have favorable or unfavorable effects on our income tax rate. These factors include, but are not limited to, interpretations of existing tax laws, changes in tax laws and rates, our portion of the non-tax deductible pharmaceutical excise tax that we will be required to pay starting in 2011 as a result of the enactment of U.S. healthcare reform legislation, the accounting for stock options and other share-based payments, mergers and acquisitions, future levels of R&D spending, changes in accounting standards, changes in the mix of earnings in the various tax jurisdictions in which we operate, changes in overall levels of pre-tax earnings and resolution of federal, state and foreign income tax audits. The impact on our income tax provision resulting from the above mentioned factors may be significant and could have a negative impact on our consolidated net income. We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We do not believe any such uncertain tax positions currently pending will have a material adverse effect on our Consolidated Financial Statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.
Recent Accounting Pronouncements	In October 2009, the Financial Accounting Standards Board (FASB) issued new standards for revenue recognition for agreements with multiple deliverables. These new standards impact the determination of when the individual deliverables included in a multiple element arrangement may be treated as separate units of accounting. Additionally, these new standards modify the manner in which the transaction consideration is allocated across the separately identified deliverables by no longer permitting the residual method of allocating arrangement consideration. These new standards are effective for us beginning in the first quarter of 2011; however, early adoption is permitted. The adoption of these standards will not have a material impact on our Consolidated Financial Statements. In December 2010, in response to the pharmaceutical excise tax mandated by healthcare reform legislation adopted in the United States, the FASB issued a new standard to address how pharmaceutical manufacturers should recognize and classify this tax in their income statements. Effective 2011, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the pharmaceutical excise tax, calculated based on select government sales for the preceding calendar year as a percentage of total industry government sales. The new standard clarifies that the pharmaceutical excise tax shall be presented as an operating expense and that the liability related to the tax shall be estimated and recorded in full upon the first qualifying sale with a corresponding deferred cost that is amortized to expense generally using a straight-line method of allocation. The new standard is effective for us beginning in the first quarter of 2011. We estimate the 2011 impact of the pharmaceutical excise tax to be between  $30– $50 million, which will be classified as selling, general and administrative expense in our Consolidated Financial Statements. Also in December 2010, the FASB issued an update to its existing standard for business combinations to address the pro forma financial disclosure requirements for business combinations. The updated standard specifies that if a public entity presents comparative financial statements, the entity should disclose pro forma revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period. The updated standard is effective for us beginning in the first quarter of 2011; however, early adoption is permitted. The adoption of this standard will not have a material impact on our Consolidated Financial Statements.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet30.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
Dec. 31, 2010
Organization and Summary of Significant Accounting Policies
Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income Per Share	Year Ended December 31,        2010      2009      2008   Numerator:          Net income attributable to Gilead     $ 2,901,257        $ 2,635,755        $ 1,978,899                               Denominator:          Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders      856,060         904,604         920,693    Effect of dilutive securities:          Stock options and equivalents      16,606         23,850         30,727    Conversion spread related to the 2011 Notes      222         2,684         3,559    Conversion spread related to the 2013 Notes      508         2,971         3,846                               Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders      873,396         934,109         958,825
Estimated Useful Lives in Years	Description    Estimated Useful Life Buildings and improvements    20-35 Laboratory and manufacturing equipment    4-10 Office and computer equipment    3-7 Leasehold improvements    Shorter of useful life or lease term

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet31.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Tables)	12 Months Ended
Dec. 31, 2010
Fair Value Measurements
Summary of Assets and Liabilities Recorded at Fair Value and Classification by Level of Input	December 31, 2010     December 31, 2009       Level 1     Level 2     Level 3     Total     Level 1     Level 2     Level 3     Total   Assets:                 Debt securities:                 U.S. treasury securities    $ 1,355,437       $ —         $ —         $ 1,355,437       $ 289,790       $ —         $ —         $ 289,790    U.S.government agencies and FDIC guaranteed securities     —          1,296,110        —          1,296,110        —          1,086,082        —          1,086,082    Municipal debt securities     —          17,625        —          17,625        —          433,474        —          433,474    Non-U.S. government securities     —          278,610        9,594        288,204        —          75,524        —          75,524    Corporate debt securities     —          1,119,254        —          1,119,254        —          566,176        —          566,176    Residential mortgage and asset-backed securities     —          277,043        —          277,043        —          120,407        839        121,246    Student loan-backed securities     —          —          70,771        70,771        —          —          104,823        104,823                                                                    Total debt securities     1,355,437        2,988,642        80,365        4,424,444        289,790        2,281,663        105,662        2,677,115    Equity securities     4,631        —          —          4,631        3,470        —          —          3,470    Derivatives     —          64,461        —          64,461        —          26,198        —          26,198                                                                       $ 1,360,068       $ 3,053,103       $ 80,365       $ 4,493,536       $ 293,260       $ 2,307,861       $ 105,662       $ 2,706,783                                                                    Liabilities:                 Contingent consideration     —          —          11,100        11,100        —          —          —          —      Derivatives     —          38,553        —          38,553        —          47,688        —          47,688       $ —         $ 38,553       $ 11,100       $ 49,653       $ —         $ 47,688       $ —         $ 47,688
Reconciliation of Marketable Securities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	Year Ended December 31,        2010     2009   Balance, beginning of period     $ 105,662       $ 102,633    Total realized and unrealized gains (losses) included in:      Interest and other income, net      115        (29 )  Other comprehensive income, net      5,026        10,332    Sales of marketable securities      (40,032 )      (7,274 )  Transfers into Level 3      9,594        —                       Balance, end of period     $ 80,365       $ 105,662                     Total losses included in interest and other income, net attributable to the change in unrealized losses relating to assets still held at the reporting date     $ —         $ (29 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet32.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Tables)	12 Months Ended
Dec. 31, 2010
Available-For-Sale Securities
Summary of Available-for-Sale Debt and Equity Securities at Estimated Fair Value	Amortized Cost      Gross Unrealized Gains      Gross Unrealized Losses     Estimated Fair Value   December 31, 2010            Debt securities:            U.S. treasury securities     $ 1,349,348        $ 7,109        $ (1,020 )     $ 1,355,437    U.S. government agencies and FDIC guaranteed securities      1,284,654         11,919         (463 )      1,296,110    Municipal debt securities      17,543         103         (21 )      17,625    Non-U.S. government securities      286,410         1,880         (86 )      288,204    Corporate debt securities      1,112,976         8,040         (1,762 )      1,119,254    Residential mortgage and asset-backed securities      277,359         923         (1,239 )      277,043    Student loan-backed securities      75,900         —           (5,129 )      70,771                                       Total debt securities      4,404,190         29,974         (9,720 )      4,424,444    Equity securities      1,451         3,180         —          4,631                                       Total     $ 4,405,641        $ 33,154        $ (9,720 )     $ 4,429,075                                       December 31, 2009            Debt securities:            U.S. treasury securities     $ 289,055        $ 844        $ (109 )     $ 289,790    U.S. government agencies and FDIC guaranteed securities      1,077,910         9,116         (944 )      1,086,082    Municipal debt securities      429,583         3,986         (95 )      433,474    Non-U.S. government securities      74,756         874         (106 )      75,524    Corporate debt securities      557,116         9,563         (503 )      566,176    Residential mortgage and asset-backed securities      119,308         2,048         (110 )      121,246    Student loan-backed securities      115,400         —           (10,577 )      104,823                                       Total debt securities      2,663,128         26,431         (12,444 )      2,677,115    Equity securities      1,451         2,019         —          3,470                                       Total     $ 2,664,579        $ 28,450        $ (12,444 )     $ 2,680,585
Summary of the Classification of Available-For-Sale Debt and Equity Securities	December 31, 2010      December 31, 2009   Cash and cash equivalents     $ 18,883        $ 48,697    Short-term marketable securities      1,190,789         384,017    Long-term marketable securities      3,219,403         2,247,871                      Total     $ 4,429,075        $ 2,680,585
Summary of Available-For-Sale Debt Securities by Contractual Maturity	December 31, 2010      December 31, 2009        Amortized Cost      Fair Value      Amortized Cost      Fair Value   Less than one year     $ 1,206,032        $ 1,209,672        $ 429,980        $ 432,714    Greater than one year but less than five years      3,022,744         3,044,114         1,878,589         1,898,183    Greater than five years but less than ten years      33,076         33,580         56,895         57,585    Greater than ten years      142,338         137,078         297,664         288,633                                        Total     $ 4,404,190        $ 4,424,444        $ 2,663,128        $ 2,677,115
Summary of Gross Realized Gains and Losses Related to Marketable Securities	Year Ended December 31,        2010     2009     2008   Gross realized gains on sales     $ 13,254       $ 10,373       $ 28,368    Gross realized losses on sales     $ (3,657 )     $ (1,405 )     $ (18,732 )
Summary of Available-For-Sale Debt Securities that were in a Continuous Unrealized Loss Position but were not Deemed to be Other-Than-Temporarily Impaired	Less Than 12 Months      12 Months or Greater      Total        Gross Unrealized Losses     Estimated Fair Value      Gross Unrealized Losses     Estimated Fair Value      Gross Unrealized Losses     Estimated Fair Value                                 December 31, 2010                Debt securities:                U.S. treasury securities     $ (1,020 )     $ 531,184        $ —         $ —          $ (1,020 )     $ 531,184    U.S. government agencies and FDIC guaranteed securities      (463 )      226,176         —          —           (463 )      226,176    Municipal debt securities      (21 )      4,688         —          —           (21 )      4,688    Non-U.S. government securities      (86 )      44,317         —          —           (86 )      44,317    Corporate debt securities      (1,762 )      459,412         —          —           (1,762 )      459,412    Residential mortgage and asset-backed securities      (1,239 )      197,330         —          —           (1,239 )      197,330    Student loan-backed securities      —          —           (5,129 )      70,771         (5,129 )      70,771                                                       Total     $ (4,591 )     $ 1,463,107        $ (5,129 )     $ 70,771        $ (9,720 )     $ 1,533,878                                                       December 31, 2009                Debt securities:                U.S. treasury securities     $ (109 )     $ 97,871        $ —         $ —          $ (109 )     $ 97,871    U.S. government agencies and FDIC guaranteed securities      (944 )      223,901         —          —           (944 )      223,901    Municipal debt securities      (95 )      65,377         —          —           (95 )      65,377    Non-U.S. government securities      (106 )      30,924         —          —           (106 )      30,924    Corporate debt securities      (503 )      126,410         —          —           (503 )      126,410    Residential mortgage and asset-backed securities      (110 )      36,446         —          —           (110 )      36,446    Student loan-backed securities      —          —           (10,577 )      104,823         (10,577 )      104,823                                                       Total     $ (1,867 )     $ 580,929        $ (10,577 )     $ 104,823        $ (12,444 )     $ 685,752

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet33.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Tables)	12 Months Ended
Dec. 31, 2010
Derivative Financial Instruments
Summary of Information About the Fair Values of Derivative Instruments on Consolidated Balance Sheets	As of December 31, 2010        Asset Derivatives      Liability Derivatives        Location      Fair Value      Location      Fair Value   Derivatives designated as hedges:             Foreign currency exchange contracts        Other current assets           $ 59,276           Other accrued liabilities           $ 36,493    Foreign currency exchange contracts        Other noncurrent assets            5,089           Other long-term obligations            2,022                            Total derivatives designated as hedges         64,365            38,515                            Derivatives not designated as hedges:             Foreign currency exchange contracts        Other current assets            96           Other accrued liabilities            38                            Total derivatives not designated as hedges         96            38                            Total derivatives        $ 64,461           $ 38,553                                 As of December 31, 2009        Asset Derivatives      Liability Derivatives        Location      Fair Value      Location      Fair Value   Derivatives designated as hedges:             Foreign currency exchange contracts        Other current assets           $ 16,183           Other accrued liabilities           $ 45,482    Foreign currency exchange contracts        Other noncurrent assets            10,010           Other long-term obligations            2,180                            Total derivatives designated as hedges         26,193            47,662                            Derivatives not designated as hedges:             Foreign currency exchange contracts        Other current assets            5           Other accrued liabilities            26                            Total derivatives not designated as hedges         5            26                            Total derivatives        $ 26,198           $ 47,688
Summary of the Effect of Foreign Currency Exchange Contracts on Consolidated Statements of Income	Year Ended December 31        2010      2009   Derivatives designated as hedges:       Net gains (losses) recognized in OCI (effective portion)     $ 115,073        $ (29,698 )  Net gains reclassified from accumulated OCI into product sales (effective portion)     $ 73,720        $ 81,694    Net gains (losses) recognized in interest and other income, net (ineffective portion and amounts excluded from effectiveness testing)     $ 887        $ (14,493 )  Derivatives not designated as hedges:       Net gains (losses) recognized in interest and other income, net     $ 66,639        $ (11,981 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet34.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Tables)	0 Months Ended
Jul. 08, 2010	Apr. 15, 2009
Acquisitions
Summary of Assets Acquired and Liabilities Assumed, Stated at Fair Value	Intangible assets—IPR&D     $ 26,630    Goodwill      70,111    Deferred tax assets      12,656    Deferred tax liabilities      (6,313 )  Other net liabilities assumed      (984 )           Total consideration transferred     $ 102,100
Schedule of Assets Acquired and Liabilities Assumed		Intangible assets—marketed products     $ 951,200    Intangible assets—IPR&D      138,900    Goodwill      341,910    Deferred tax assets      413,816    Deferred tax liabilities      (426,861 )  Other assets/liabilities    Cash and cash equivalents      129,087    Marketable securities      116,363    Accounts receivable      9,136    Inventories      50,455    Prepaids and other current assets      60,671    Property, plant and equipment      11,672    Other assets      20,162    Accounts payable      (5,089 )  Accrued and other current liabilities      (87,898 )  Convertible senior notes      (303,060 )  Other liabilities      (27,906 )           Total other net liabilities      (26,407 )           Total consideration transferred     $ 1,392,558

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet35.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Restructuring (Tables)	12 Months Ended
Dec. 31, 2010
Restructuring
Schedule of Restructuring Reserve by Type of Cost	Employee Severance and Termination Benefits     Facilities- Related Costs   Balance at December 31, 2008     $ —         $ —      Costs incurred during the period      33,797        9,880    Costs paid or settled during the period      (24,108 )      (545 )                   Balance at December 31, 2009     $ 9,689       $ 9,335    Costs incurred during the period      2,190        9,727    Costs paid or settled during the period      (11,445 )      (4,529 )                   Balance at December 31, 2010     $ 434       $ 14,533

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet36.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Tables)	12 Months Ended
Dec. 31, 2010
Inventories
Schedule of Inventories	December 31,        2010      2009   Raw materials     $ 408,015        $ 333,582    Work in process      454,652         392,042    Finished goods      341,142         326,147                      Total inventories     $ 1,203,809        $ 1,051,771

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet37.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Property, Plant and Equipment (Tables)	12 Months Ended
Dec. 31, 2010
Property, Plant and Equipment
Property, Plant and Equipment	December 31,        2010     2009   Property, plant and equipment, net:      Buildings and improvements (including leasehold improvements)     $ 501,401       $ 490,632    Laboratory and manufacturing equipment      168,711        176,362    Office and computer equipment      116,479        126,375    Capitalized leased equipment      10,865        15,232    Construction in progress      82,334        58,448                     Subtotal      879,790        867,049    Less accumulated depreciation and amortization (including  $10,451 and  $14,999 relating to capitalized leased equipment for 2010 and 2009, respectively)      (316,367 )      (304,888 )                   Subtotal      563,423        562,161    Land      137,812        137,809                     Total     $ 701,235       $ 699,970

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet38.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Tables)	12 Months Ended
Dec. 31, 2010
Intangible Assets
Schedule of Carrying Amount of Intangible Assets	December 31,        2010      2009   Goodwill     $ 532,669        $ 462,558    Finite lived intangible assets      863,393         923,319    Indefinite lived intangible assets      29,530         138,900                      Total     $ 1,425,592        $ 1,524,777
Schedule of Changes in the Carrying Amount of Goodwill	Balance at December 31, 2009     $ 462,558    Goodwill resulting from the acquisition of CGI      70,111             Balance at December 31, 2010     $ 532,669
Schedule of Finite-Lived Intangible Assets	December 31, 2010      December 31, 2009        Gross Carrying Amount      Accumulated Amortization      Gross Carrying Amount      Accumulated Amortization   Intangible asset—Ranexa     $ 688,400        $ 54,795        $ 688,400        $ 21,889    Intangible asset—Lexiscan      262,800         43,979         262,800         18,235    Other      22,095         11,128         22,095         9,852                                        Total     $ 973,295        $ 109,902        $ 973,295        $ 49,976
Schedule of Estimated Future Amortization Expense	Fiscal Year    Amount   2011     $ 69,324    2012      75,776    2013      82,086    2014      90,940    2015      100,647             Total     $ 418,773

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet39.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Tables)	12 Months Ended
Dec. 31, 2010
Schedule of Carrying Amount of Convertible Senior Notes	December 31,        2010      2009   2011 convertible senior notes     $ 638,991        $ 606,786    2013 convertible senior notes      576,884         548,480    2014 convertible senior notes      1,153,805         —      2016 convertible senior notes      1,107,884         —                        Total convertible senior notes, net      3,477,564         1,155,266    Less current portion (2011 convertible senior notes)      638,991         —                        Total non-current convertible senior notes, net     $ 2,838,573        $ 1,155,266
2011 and 2013 Convertible Senior Notes [Member]
Schedule of Carrying Amount of Convertible Senior Notes	Carrying Value of Equity Component      Net Carrying Amount of Liability Component      Unamortized Discount of Liability Component        December 31,      December 31,      December 31,        2010      2009      2010      2009      2010     2009   2011 convertible senior notes     $ 147,481        $ 147,481        $ 638,991        $ 606,786        $ (10,996 )     $ (43,201 )  2013 convertible senior notes      193,231         193,231         576,884         548,480         (72,983 )      (101,387 )                                                       Total 2011 and 2013 convertible senior notes     $ 340,712        $ 340,712        $ 1,215,875        $ 1,155,266        $ (83,979 )     $ (144,588 )
2014 and 2016 Convertible Senior Notes [Member]
Schedule of Carrying Amount of Convertible Senior Notes	Carrying Value of Equity Component      Net Carrying Amount of Liability Component      Unamortized Discount of Liability Component        December 31, 2010      December 31, 2010      December 31, 2010   2014 convertible senior notes     $ 107,496        $ 1,153,805        $ (96,195 )  2016 convertible senior notes      152,039         1,107,884         (142,116 )                             Total 2014 and 2016 convertible senior notes     $ 259,535        $ 2,261,689        $ (238,311 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet40.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Commitments and Contingencies (Tables)	12 Months Ended
Dec. 31, 2010
Commitments and Contingencies
Future Minimum Rental Payments Under Operating Leases	2011     $ 45,887    2012      37,733    2013      29,648    2014      21,477    2015      19,078    Thereafter      57,344                 $ 211,167

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet41.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity (Tables)	12 Months Ended
Dec. 31, 2010
Stockholders' Equity
Schedule of Summary of Activity Under Stock Option Plans	Year Ended December 31,        2010      2009      2008        Shares     Weighted- Average Exercise Price      Shares     Weighted- Average Exercise Price      Shares     Weighted- Average Exercise Price   Outstanding, beginning of year      69,193       $ 28.09         76,811       $ 24.70         84,977       $ 20.33    Granted and assumed      4,836       $ 44.27         7,286       $ 48.87         9,807       $ 47.11    Forfeited      (2,348 )     $ 43.16         (2,393 )     $ 39.33         (2,471 )     $ 30.61    Expired      (759 )     $ 53.27         (440 )     $ 64.08         (59 )     $ 11.72    Exercised      (10,671 )     $ 17.68         (12,071 )     $ 15.56         (15,443 )     $ 13.97                                     Outstanding, end of year      60,251       $ 30.32         69,193       $ 28.09         76,811       $ 24.70                                     Exercisable, end of year      45,018       $ 25.92         47,090       $ 22.36         45,235       $ 17.29                                     Weighted-average grant date fair value of options granted during the year       $ 14.24          $ 17.00          $ 16.95

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet42.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation (Tables)	12 Months Ended
Dec. 31, 2010
Stock-Based Compensation
Schedule of Stock-Based Compensation Expenses Included in Consolidated Statement of Income	Year Ended December 31,        2010     2009     2008   Cost of goods sold     $ 10,180       $ 10,859       $ 10,312    Research and development expenses      84,048        82,893        66,523    Selling, general and administrative expenses      105,813        92,006        76,529                             Stock-based compensation expense included in total costs and expenses      200,041        185,758        153,364    Income tax effect      (52,331 )      (46,486 )      (40,565 )                           Stock-based compensation expense included in net income     $ 147,710       $ 139,272       $ 112,799
Schedule of Assumptions to Calculate the Estimated Fair Value of the Awards	Year Ended December 31,        2010      2009      2008   Expected volatility:          Stock options      31%         35%         34%    ESPP      35%         37%         31%    Expected term in years:          Stock options      5.4         5.3         5.3    ESPP      1.3         1.3         1.2    Risk-free interest rate:          Stock options      2.3%         2.1%         2.8%    ESPP      0.4%         0.7%         2.1%    Expected dividend yield      0%         0%         0%

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet43.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income (Loss) (Tables)	12 Months Ended
Dec. 31, 2010
Comprehensive Income (Loss)
Net Realized Gains (Losses) on Sale of Securities and Cash Flow Hedges	Year Ended December 31,        2010     2009     2008   Net unrealized gain (loss) related to available-for-sale securities, net of tax impact of  $(6,624),  $(11,724) and  $11,487 for 2010, 2009 and 2008, respectively     $ 13,450       $ 21,689       $ (21,607 )  Net unrealized gain (loss) related to cash flow hedges, net of tax impact of  $(9,149),  $10,682 and  $(40,681) for 2010, 2009 and 2008, respectively      105,924        (19,016 )      93,962    Reclassification adjustments, net of tax impact of  $9,028,  $32,532 and  $1,805 for 2010, 2009 and 2008, respectively      (74,289 )      (58,130 )      (5,603 )                           Other comprehensive income (loss)     $ 45,085       $ (55,457 )     $ 66,752
Accumulated Other Comprehensive Income (Loss), Net of Taxes	As of December 31,        2010     2009   Net unrealized gain on available-for-sale securities     $ 16,528       $ 9,509    Net unrealized gain (loss) on cash flow hedges      21,615        (16,450 )  Cumulative foreign currency translation adjustment      (7,232 )      1,183                     Accumulated other comprehensive income (loss)     $ 30,911       $ (5,758 )

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet44.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Tables)	12 Months Ended
Dec. 31, 2010
Segment Information
Schedule of Product Sales	Year Ended December 31,        2010      2009      2008   Antiviral products:          Atripla     $ 2,926,579        $ 2,382,113        $ 1,572,455    Truvada      2,649,908         2,489,682         2,106,687    Viread      732,240         667,510         621,187    Hepsera      200,592         271,595         341,023    Emtriva      27,679         27,974         31,080                               Total antiviral products      6,536,998         5,838,874         4,672,432    AmBisome      305,856         298,597         289,651    Letairis      240,279         183,949         112,855    Ranexa      239,832         131,062         —      Other products      66,956         16,829         9,858                               Total product sales     $ 7,389,921        $ 6,469,311        $ 5,084,796
Schedule of Total Revenues from External Customers and Collaboration Partners by Geographic Region	Year Ended December 31,        2010      2009      2008   United States     $ 4,224,035        $ 3,599,313        $ 2,857,472    Outside of the United States:          Switzerland      458,606         448,203         193,314    France      519,700         468,314         395,672    Spain      456,647         451,115         356,607    United Kingdom      450,368         393,036         297,276    Italy      345,189         323,709         277,441    Germany      274,991         293,111         242,193    Other European countries      665,237         603,068         346,722    Other countries      554,647         431,514         369,053                               Total revenues outside of the United States      3,725,385         3,412,070         2,478,278                               Total revenues     $ 7,949,420        $ 7,011,383        $ 5,335,750
Schedule of Revenues from Each Customer who Individually Accounted for 10% or More as a % of Total Revenues	Year Ended December 31,        2010      2009      2008   Cardinal Health, Inc.      17%         18%         21%    McKesson Corp.      14%         13%         16%    AmerisourceBergen Corp.      12%         11%         11%

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet45.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Tables)	12 Months Ended
Dec. 31, 2010
Income Taxes
Provision for Income Taxes	Year Ended December 31,        2010     2009     2008   Federal:        Current     $ 852,822       $ 719,777       $ 585,075    Deferred      (29,854 )      (47,608 )      6,099                                  822,968        672,169        591,174                             State:        Current      139,819        153,376        56,223    Deferred      17,464        9,150        24,333                                  157,283        162,526        80,556                             Foreign:        Current      43,094        42,860        38,738    Deferred      454        (1,191 )      (8,105 )                                43,548        41,669        30,633                             Provision for income taxes     $ 1,023,799       $ 876,364       $ 702,363
Difference Between the Provision for Income Taxes and Federal Statutory Income Tax Rate Before Income Tax	Year Ended December 31,        2010     2009     2008   Income before provision for income taxes     $ 3,913,548       $ 3,501,956       $ 2,672,698                             Tax at federal statutory rate     $ 1,369,742       $ 1,225,685       $ 935,444    State taxes, net of federal benefit      106,250        111,095        58,166    Foreign earnings at different rates      (435,767 )      (399,993 )      (257,835 )  Research and other credits      (33,072 )      (43,045 )      (32,270 )  Net unbenefitted stock compensation      13,188        4,269        5,224    Other      3,458        (21,647 )      (6,366 )                           Provision for income taxes     $  1,023,799       $ 876,364       $ 702,363
Components Deferred Tax Assets and Liabilities	December 31,        2010     2009   Deferred tax assets:      Net operating loss carryforwards     $ 308,854       $ 377,058    Stock-based compensation      142,242        117,019    Reserves and accruals not currently deductible      109,806        90,760    Deferred revenue      49,194        67,389    Depreciation related      58,875        44,166    Research and other credit carryforwards      25,151        28,980    Capitalized intangibles      5,839        12,086    Other, net      88,669        64,881                     Total deferred tax assets before valuation allowance      788,630        802,339    Valuation allowance      (13,040 )      (1,078 )                   Total deferred tax assets      775,590        801,261                     Deferred tax liabilities:      Intangibles      (322,168 )      (384,480 )  Unremitted foreign earnings      (15,928 )      (15,928 )  Other      (20,774 )      (17,053 )                   Total deferred tax liabilities      (358,870 )      (417,461 )                   Net deferred tax assets     $ 416,720       $ 383,800
Total Gross Unrecognized Tax Benefit Liabilities	December 31,        2010     2009     2008   Balance, beginning of period     $ 106,506       $ 121,424       $ 115,087    Tax positions related to current year:        Additions      24,320        25,036        37,495    Reductions      (3,303 )      (8,380 )      —      Tax positions related to prior years:        Additions      25,581        37,014        4,298    Reductions      (23,474 )      (36,277 )      (23,307 )  Settlements      (2,160 )      (31,517 )      (10,252 )  Lapse of statute of limitations      (954 )      (794 )      (1,897 )                           Balance, end of period     $ 126,516       $ 106,506       $ 121,424

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet46.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Quarterly Results Of Operations (Tables)	12 Months Ended
Dec. 31, 2010
Quarterly Results of Operations
Quarterly Results of Operations	1st Quarter      2nd Quarter      3rd Quarter      4th Quarter   2010 (1)             Total revenues     $ 2,085,853        $ 1,927,224        $ 1,937,656        $ 1,998,687    Gross profit on product sales     $ 1,347,633        $ 1,350,536        $ 1,387,975        $ 1,433,901    Net income     $ 852,094        $ 709,127        $ 702,163        $ 626,365    Net income attributable to Gilead     $ 854,901        $ 712,061        $ 704,876        $ 629,419    Net income per share attributable to Gilead common stockholders—basic     $ 0.95        $ 0.81        $ 0.85        $ 0.78    Net income per share attributable to Gilead common stockholders—diluted     $ 0.92        $ 0.79        $ 0.83        $ 0.76    2009             Total revenues     $ 1,530,460        $ 1,647,155        $ 1,801,389        $ 2,032,379    Gross profit on product sales     $ 1,118,166        $ 1,185,333        $ 1,239,255        $ 1,330,999    Net income     $ 586,576        $ 569,145        $ 670,478        $ 799,393    Net income attributable to Gilead     $ 589,112        $ 571,398        $ 673,033        $ 802,212    Net income per share attributable to Gilead common stockholders—basic     $ 0.65        $ 0.63        $ 0.75        $ 0.89    Net income per share attributable to Gilead common stockholders—diluted     $ 0.63        $ 0.61        $ 0.72        $ 0.87    (1) During 2010, we recorded  $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet47.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Schedule II Valuation and Qualifying Accounts (Tables)	12 Months Ended
Dec. 31, 2010
Schedule II Valuation and Qualifying Accounts
Schedule ll: Valuation and Qualifying Accounts	Schedule II: Valuation and Qualifying Accounts        Balance at Beginning of Period      Additions/ Charged to Expense      Deductions      Balance at End of Period   Year ended December 31, 2010:             Accounts receivable allowances (1)     $ 132,810        $ 818,132        $ 800,000        $ 150,942    Valuation allowance for deferred tax assets (2)     $ 1,078        $ 12,127        $ 165        $ 13,040    Year ended December 31, 2009:             Accounts receivable allowances (1)     $ 90,694        $ 606,504        $ 564,388        $ 132,810    Valuation allowance for deferred tax assets (2)     $ —          $ 15,103        $ 14,025        $ 1,078    Year ended December 31, 2008:             Accounts receivable allowances (1)     $ 72,217        $ 500,037        $ 481,560        $ 90,694    Valuation allowance for deferred tax assets     $ 23,498        $ 965        $ 24,463        $ —      (1) Allowances are for doubtful accounts, sales returns, cash discounts and chargebacks.   (2) Valuation allowance for deferred tax assets includes  $9.9 million and  $1.1 million as of December 31, 2010 and 2009, respectively, related to our acquisitions.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet48.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies (Narrative) (Details) (USD  $) Share data in Millions, except Per Share data, unless otherwise specified	1 Months Ended	12 Months Ended
Dec. 31, 2010	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2010 Warrants Expiring in 2011 [Member]	Dec. 31, 2010 Warrants Expiring in 2013 [Member]	Dec. 31, 2010 Warrants Expiring in 2014 [Member]	Dec. 31, 2010 Warrants Expiring in 2016 [Member]	Dec. 31, 2010 2011 Convertible Senior Notes [Member]	Apr. 30, 2006 2011 Convertible Senior Notes [Member]	Dec. 31, 2010 2013 Convertible Senior Notes [Member]	Apr. 30, 2006 2013 Convertible Senior Notes [Member]	Dec. 31, 2010 2014 Convertible Senior Notes [Member]	Jul. 31, 2010 2014 Convertible Senior Notes [Member]	Dec. 31, 2010 2016 Convertible Senior Notes [Member]	Jul. 31, 2010 2016 Convertible Senior Notes [Member]
Advertising expenses		$ 116,500,000	$ 108,100,000	$ 96,200,000
Conversion price of notes									38.75	38.75	38.1	38.1	45.08	45.08	45.41	45.41
Warrants strike price					$ 50.8	$ 53.9	$ 56.76	$ 60.1
Weighted-average shares of common stock outstanding excluded from the computation of diluted net income per share because their effect was antidilutive		22.5	17.4	11.4
Percentage of fair value of securities sold to us collateralized by U.S. government securities	102.00%	102.00%
Purchase cost of royalties interest paid	525,000,000	525,000,000
Percentage share cost of royalty interest paid		65.00%
Percentage share cost of royalty interest by Royalty Pharma		35.00%
Prepaid royalties capitalized	341,300,000	341,300,000
Unamortized prepaid royalty asset	219,500,000	219,500,000	245,000,000
Amortized to cost of goods sold		25,500,000	29,900,000	31,800,000
Unamortized capitalized software costs	22,500,000	22,500,000	25,200,000
Net transaction losses		3,700,000	16,400,000	36,500,000
Carrying value of notes	3,480,000,000	3,480,000,000	1,160,000,000
Fair value of the notes	3,970,000,000	3,970,000,000	1,580,000,000
Excise tax, minimum	30,000,000
Excise tax, maximum	$ 50,000,000
Use of estimates		The preparation of these Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, intangible assets, allowance for doubtful accounts, prepaid royalties, clinical trial accruals, our tax provision and stock-based compensation. We base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates.
Revenue recognition, product sales		We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery to the customer has occurred, the price is fixed or determinable and collectability is reasonably assured. Upon recognition of revenue from product sales, provisions are made for government rebates such as Medicaid reimbursements, customer incentives such as cash discounts for prompt payment, distributor fees and expected returns of expired products, as appropriate.
Revenue recognition, government rebates		We estimate reductions to our revenues for government-managed Medicaid programs as well as for certain other qualifying federal, state and foreign government programs based on contractual terms, historical utilization rates, new information regarding changes in these programs' regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and, for our U.S. product sales, channel inventory data obtained from our major U.S. wholesalers in accordance with our inventory management agreements. Government rebates that are invoiced directly to us are recorded in accrued government rebates on our Consolidated Balance Sheets. For qualified programs that can purchase our products through wholesalers at a lower contractual government price, the wholesalers charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as allowances against accounts receivable.
Revenue recognition, cash discounts		We estimate cash discounts based on contractual terms, historical utilization rates and our expectations regarding future utilization rates.
Revenue recognition, distributor fees		Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for the compliance of certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.
Revenue recognition, product returns		We do not provide our customers with a general right of product return, but permit returns if the product is damaged or defective when received by the customer, or in the case of product sold in the Unites States and certain countries outside the United States, if the product has expired. We will accept returns for product that will expire within six months prior to or that have expired up to one year after their expiration dates. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.
Revenue recognition, royalty revenues		Royalty revenue from sales of Lexiscan and AmBisome by Astellas US LLC and Astellas Pharma US, Inc., respectively, is recognized in the month following the month in which the corresponding sales occur. Royalty revenue from sales of our other products is generally recognized when received, which is generally in the quarter following the quarter in which the corresponding sales occur.
Revenue recognition, contract and other revenues		Revenue from non-refundable up-front license fees and milestone payments such as under a development collaboration or an obligation to supply product, is recognized as performance occurs and our obligations are completed. In accordance with the specific terms of our obligations under these arrangements, revenue is recognized as the obligation is fulfilled or ratably over the development or manufacturing period. Revenue associated with substantive at-risk milestones is recognized based upon the achievement of the milestones as defined in the respective agreements. Advance payments received in excess of amounts earned are classified as deferred revenue on our Consolidated Balance Sheets.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet49.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies (Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income Per Share) (Details) (USD  $) In Thousands	3 Months Ended	12 Months Ended
Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Mar. 31, 2009	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Net income attributable to Gilead	$ 629,419	[1]	$ 704,876	[1]	$ 712,061	[1]	$ 854,901	[1]	$ 802,212	$ 673,033	$ 571,398	$ 589,112	$ 2,901,257	$ 2,635,755	$ 1,978,899
Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders													856,060	904,604	920,693
Stock options and equivalents													16,606	23,850	30,727
Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders													873,396	934,109	958,825
2011 Convertible Senior Notes [Member]
Conversion spread													222	2,684	3,559
2013 Convertible Senior Notes [Member]
Conversion spread													508	2,971	3,846
[1]	During 2010, we recorded  $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet50.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Organization and Summary of Significant Accounting Policies (Estimated Useful Lives) (Details)	12 Months Ended
Dec. 31, 2010
Leasehold Improvements [Member]
Estimated Useful Lives	Shorter of useful life or lease term
Buildings and Improvements [Member]
Estimated Useful Lives, Minimum	20
Estimated Useful Lives, Maximum	35
Office and Computer Equipment [Member]
Estimated Useful Lives, Minimum	3
Estimated Useful Lives, Maximum	7
Laboratory and Manufacturing Equipment [Member]
Estimated Useful Lives, Minimum	4
Estimated Useful Lives, Maximum	10

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet51.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Narrative) (Details)	12 Months Ended
Dec. 31, 2010
Fair Value Measurements
Annual discount rate used in discounted cash flow model	2.12%
Auction rate reset, upper range, in days	14
Auction rate reset, lower range, in days	7
Auction rate securities annual interest rate, lower range	0.43%
Auction rate securities annual interest rate, higher range	1.19%
Lower limit for weighted average expected life of student loans, in years	4
Upper limit for weighted average expected life of student loans, in years	8

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet52.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Summary of Assets and Liabilities Recorded at Fair Value and Classification by Level of Input) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Assets [Member]
Fair value, total	$ 4,493,536	$ 2,706,783
Assets [Member] | Level 1 [Member]
Fair value, total	1,360,068	293,260
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | U.S. Treasury Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	1,355,437	289,790
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | Municipal Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | Non-U.S. Government Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | Residential Mortgage and Asset-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | Student Loan-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 1 [Member] | Debt Securities [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Measured on Recurring Basis, Investments	1,355,437	289,790
Assets [Member] | Level 1 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Equity securities	4,631	3,470
Fair Value, Assets Measured on Recurring Basis, Derivative Financial Instruments, Assets
Assets [Member] | Level 2 [Member]
Fair value, total	3,053,103	2,307,861
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | U.S. Treasury Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	1,296,110	1,086,082
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | Municipal Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	17,625	433,474
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | Non-U.S. Government Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	278,610	75,524
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | Residential Mortgage and Asset-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	277,043	120,407
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | Student Loan-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 2 [Member] | Debt Securities [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Measured on Recurring Basis, Investments	2,988,642	2,281,663
Assets [Member] | Level 2 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Equity securities
Fair Value, Assets Measured on Recurring Basis, Derivative Financial Instruments, Assets	64,461	26,198
Assets [Member] | Level 3 [Member]
Fair value, total	80,365	105,662
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | U.S. Treasury Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | Municipal Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | Non-U.S. Government Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	9,594
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | Residential Mortgage and Asset-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments		839
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | Student Loan-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	70,771	104,823
Assets [Member] | Level 3 [Member] | Debt Securities [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Measured on Recurring Basis, Investments	80,365	105,662
Assets [Member] | Level 3 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Equity securities
Fair Value, Assets Measured on Recurring Basis, Derivative Financial Instruments, Assets
Assets [Member] | Debt Securities [Member] | U.S. Treasury Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	1,355,437	289,790
Assets [Member] | Debt Securities [Member] | U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	1,296,110	1,086,082
Assets [Member] | Debt Securities [Member] | Municipal Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	17,625	433,474
Assets [Member] | Debt Securities [Member] | Non-U.S. Government Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	288,204	75,524
Assets [Member] | Debt Securities [Member] | Residential Mortgage and Asset-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	277,043	121,246
Assets [Member] | Debt Securities [Member] | Student Loan-Backed Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	70,771	104,823
Assets [Member] | Debt Securities [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Measured on Recurring Basis, Investments	4,424,444	2,677,115
Assets [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Equity securities	4,631	3,470
Fair Value, Assets Measured on Recurring Basis, Derivative Financial Instruments, Assets	64,461	26,198
Liabilities [Member]
Fair value, total	49,653	47,688
Business Acquisition, Contingent Consideration, at Fair Value	11,100
Liabilities [Member] | Level 1 [Member]
Fair value, total
Business Acquisition, Contingent Consideration, at Fair Value
Liabilities [Member] | Level 1 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Liabilities Measured on Recurring Basis, Derivative Financial Instruments, Liabilities
Liabilities [Member] | Level 2 [Member]
Fair value, total	38,553	47,688
Business Acquisition, Contingent Consideration, at Fair Value
Liabilities [Member] | Level 2 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Liabilities Measured on Recurring Basis, Derivative Financial Instruments, Liabilities	38,553	47,688
Liabilities [Member] | Level 3 [Member]
Fair value, total	11,100
Business Acquisition, Contingent Consideration, at Fair Value	11,100
Liabilities [Member] | Level 3 [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Liabilities Measured on Recurring Basis, Derivative Financial Instruments, Liabilities
Liabilities [Member] | Total Debt Securities, Equity Securities and Derivatives [Member]
Fair Value, Liabilities Measured on Recurring Basis, Derivative Financial Instruments, Liabilities	38,553	47,688
Level 1 [Member] | Debt Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Level 2 [Member] | Debt Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	1,119,254	566,176
Level 3 [Member] | Debt Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments
Debt Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Measured on Recurring Basis, Investments	$ 1,119,254	$ 566,176

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet53.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Reconciliation of Marketable Securities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)) (Details) (Level 3 [Member], USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Balance, beginning of period	$ 105,662	$ 102,633
Total realized and unrealized gains (losses) included in interest and other income, net	115	(29)
Total realized and unrealized gains (losses) included in other comprehensive income, net	5,026	10,332
Sales of marketable securities	(40,032)	(7,274)
Transfers into Level 3	9,594
Balance, end of period	80,365	105,662
Total losses included in interest and other income, net attributable to the change in unrealized losses relating to assets still held at the reporting date		$ (29)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet54.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Narrative) (Details)	Dec. 31, 2010	Dec. 31, 2009
Number of securities in an unrealized loss position, percentage of total	34.00%	32.00%

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet55.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary of Available-For-Sale Debt and Equity Securities at Estimated Fair Value) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Amortized cost	$ 4,405,641	$ 2,664,579
Gross unrealized gains	33,154	28,450
Gross unrealized losses	(9,720)	(12,444)
Estimated fair value	4,429,075	2,680,585
U.S. Treasury Securities [Member]
Amortized cost	1,349,348	289,055
Gross unrealized gains	7,109	844
Gross unrealized losses	(1,020)	(109)
Estimated fair value	1,355,437	289,790
U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Amortized cost	1,284,654	1,077,910
Gross unrealized gains	11,919	9,116
Gross unrealized losses	(463)	(944)
Estimated fair value	1,296,110	1,086,082
Municipal Debt Securities [Member]
Amortized cost	17,543	429,583
Gross unrealized gains	103	3,986
Gross unrealized losses	(21)	(95)
Estimated fair value	17,625	433,474
Non-U.S. Government Securities [Member]
Amortized cost	286,410	74,756
Gross unrealized gains	1,880	874
Gross unrealized losses	(86)	(106)
Estimated fair value	288,204	75,524
Corporate Debt Securities [Member]
Amortized cost	1,112,976	557,116
Gross unrealized gains	8,040	9,563
Gross unrealized losses	(1,762)	(503)
Estimated fair value	1,119,254	566,176
Residential Mortgage and Asset-Backed Securities [Member]
Amortized cost	277,359	119,308
Gross unrealized gains	923	2,048
Gross unrealized losses	(1,239)	(110)
Estimated fair value	277,043	121,246
Student Loan-Backed Securities [Member]
Amortized cost	75,900	115,400
Gross unrealized gains
Gross unrealized losses	(5,129)	(10,577)
Estimated fair value	70,771	104,823
Equity Securities [Member]
Amortized cost	1,451	1,451
Gross unrealized gains	3,180	2,019
Gross unrealized losses
Estimated fair value	4,631	3,470
Debt Securities [Member]
Amortized cost	4,404,190	2,663,128
Gross unrealized gains	29,974	26,431
Gross unrealized losses	(9,720)	(12,444)
Estimated fair value	$ 4,424,444	$ 2,677,115

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet56.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary of the Classification of Available-For-Sale Debt and Equity Securities) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Available For Sale Securities	$ 4,429,075	$ 2,680,585
Cash and Cash Equivalents [Member]
Available-for-sale debt and equity securities	18,883	48,697
Short-Term Marketable Securities [Member]
Available-for-sale debt and equity securities	1,190,789	384,017
Long-Term Marketable Securities [Member]
Available-for-sale debt and equity securities	$ 3,219,403	$ 2,247,871

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet57.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary of Available-For-Sale Debt Securities by Contractual Maturity) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Available-For-Sale Securities
Less than one year, amortized cost	$ 1,206,032	$ 429,980
Greater than one year but less than five years, amortized cost	3,022,744	1,878,589
Greater than five years but less than ten years, amortized cost	33,076	56,895
Greater than ten years, amortized cost	142,338	297,664
Total, amortized cost	4,404,190	2,663,128
Less than one year, fair value	1,209,672	432,714
Greater than one year but less than five years, fair value	3,044,114	1,898,183
Greater than five years but less than ten years, fair value	33,580	57,585
Greater than ten years, fair value	137,078	288,633
Total, fair value	$ 4,424,444	$ 2,677,115

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet58.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary of Gross Realized Gains and Losses Related to Marketable Securities) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Available-For-Sale Securities
Gross realized gains on sales	$ 13,254	$ 10,373	$ 28,368
Gross realized losses on sales	$ (3,657)	$ (1,405)	$ (18,732)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet59.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary of Available-For-Sale Debt Securities that were in a Continuous Unrealized Loss Position but were not Deemed to be Other-Than-Temporarily Impaired) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Less than 12 months, gross unrealized losses	$ (4,591)	$ (1,867)
Less than 12 months, estimated fair value	1,463,107	580,929
12 months or greater, gross unrealized losses	(5,129)	(10,577)
12 months or greater, estimated fair value	70,771	104,823
Total, gross unrealized losses	(9,720)	(12,444)
Total, estimated fair value	1,533,878	685,752
U.S. Treasury Securities [Member]
Less than 12 months, gross unrealized losses	(1,020)	(109)
Less than 12 months, estimated fair value	531,184	97,871
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(1,020)	(109)
Total, estimated fair value	531,184	97,871
U.S. Government Agencies and FDIC Guaranteed Debt Securities [Member]
Less than 12 months, gross unrealized losses	(463)	(944)
Less than 12 months, estimated fair value	226,176	223,901
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(463)	(944)
Total, estimated fair value	226,176	223,901
Municipal Debt Securities [Member]
Less than 12 months, gross unrealized losses	(21)	(95)
Less than 12 months, estimated fair value	4,688	65,377
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(21)	(95)
Total, estimated fair value	4,688	65,377
Non-U.S. Government Securities [Member]
Less than 12 months, gross unrealized losses	(86)	(106)
Less than 12 months, estimated fair value	44,317	30,924
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(86)	(106)
Total, estimated fair value	44,317	30,924
Corporate Debt Securities [Member]
Less than 12 months, gross unrealized losses	(1,762)	(503)
Less than 12 months, estimated fair value	459,412	126,410
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(1,762)	(503)
Total, estimated fair value	459,412	126,410
Residential Mortgage and Asset-Backed Securities [Member]
Less than 12 months, gross unrealized losses	(1,239)	(110)
Less than 12 months, estimated fair value	197,330	36,446
12 months or greater, gross unrealized losses
12 months or greater, estimated fair value
Total, gross unrealized losses	(1,239)	(110)
Total, estimated fair value	197,330	36,446
Student Loan-Backed Securities [Member]
Less than 12 months, gross unrealized losses
Less than 12 months, estimated fair value
12 months or greater, gross unrealized losses	(5,129)	(10,577)
12 months or greater, estimated fair value	70,771	104,823
Total, gross unrealized losses	(5,129)	(10,577)
Total, estimated fair value	$ 70,771	$ 104,823

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet60.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Narrative) (Details) (USD  $) In Billions	Dec. 31, 2010	Dec. 31, 2009
Derivative Financial Instruments
Notional amounts on foreign currency exchange forward contracts outstanding	$ 3.55	$ 3.45

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet61.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Summary of Information About the Fair Values of Derivative Instruments on Consolidated Balance Sheets) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Asset derivatives designated as hedges	$ 64,365	$ 26,193
Liability derivatives designated as hedges	38,515	47,662
Asset derivatives not designated as hedges	96	5
Liability derivatives not designated as hedges	38	26
Total derivatives, asset derivatives	64,461	26,198
Total derivatives, liability derivatives	38,553	47,688
Foreign Currency Exchange Contracts [Member] | Other Current Assets [Member]
Asset derivatives designated as hedges	59,276	16,183
Asset derivatives not designated as hedges	96	5
Foreign Currency Exchange Contracts [Member] | Other Noncurrent Assets [Member]
Asset derivatives designated as hedges	5,089	10,010
Foreign Currency Exchange Contracts [Member] | Other Accrued Liabilities [Member]
Liability derivatives designated as hedges	36,493	45,482
Liability derivatives not designated as hedges	38	26
Foreign Currency Exchange Contracts [Member] | Other Long-Term Obligations [Member]
Liability derivatives designated as hedges	$ 2,022	$ 2,180

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet62.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Summary of the Effect of Foreign Currency Exchange Contracts on Consolidated Statements of Income) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Derivative Financial Instruments
Net gains (losses) recognized in OCI (effective portion)	$ 115,073	$ (29,698)
Net gains reclassified from accumulated OCI into product sales (effective portion)	73,720	81,694
Net gains (losses) recognized in interest and other income, net (ineffective portion and amounts excluded from effectiveness testing)	887	(14,493)
Net gains (losses) recognized in interest and other income, net	$ 66,639	$ (11,981)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet63.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Narrative) (Details) (USD  $)	12 Months Ended				3 Months Ended					0 Months Ended		0 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010 Marketed Products [Member]	Apr. 15, 2009 Marketed Products [Member] CV Therapeutics, Inc. [Member]	Dec. 31, 2010 IPR&D [Member] CV Therapeutics, Inc. [Member]	Apr. 15, 2009 IPR&D [Member] CV Therapeutics, Inc. [Member]	Dec. 31, 2010 Ranexa [Member]	Dec. 31, 2010 Lexiscan [Member]	May 31, 2008 Navitas Assets, LLC [Member]	Apr. 15, 2009 GS 9667 [Member] CV Therapeutics, Inc. [Member]	Apr. 15, 2009 2.75% Senior Subordinated Convertible Notes Due 2012 [Member] CV Therapeutics, Inc. [Member]	Apr. 15, 2009 3.25% Senior Subordinated Convertible Notes Due 2013 [Member] CV Therapeutics, Inc. [Member]	Apr. 15, 2009 2.0% Senior Subordinated Convertible Debentures Due 2023 [Member] CV Therapeutics, Inc. [Member]	Jul. 08, 2010 CGI Pharmaceuticals [Member]	Jun. 30, 2010 CGI Pharmaceuticals [Member]	Apr. 15, 2009 CV Therapeutics, Inc. [Member]	Dec. 31, 2010 CV Therapeutics, Inc. [Member]
Maximum consideration of acquisition														$ 120,000,000
Total cash paid for acquisition															91,000,000	1,380,000,000
Maximum value of contingent consideration														29,000,000
Total consideration paid in connection with the acquisition									10,900,000					102,100,000		1,392,558,000
Contingent consideration paid														11,100,000
Fair value of intangible assets related to IPR&D						138,900,000				93,400,000				26,630,000
Present value discount rate	2.12%													18.00%
Intangible assets related to the marketed products			951,200,000	951,200,000			688,400,000	262,800,000
Asset impairment charges	136,000,000				136,000,000
Intangible assets - IPR&D	29,530,000	138,900,000
Business acquisition, effective date of acquisition																April 15, 2009
Percentage of shares acquired on outstanding shares of common stock																89.00%
Fair value of vested stock options																15,700,000
Business Acquisition, Equity Interest Issued or Issuable, Basis for Determining Value																In accordance with the merger agreement, the number of Gilead stock options and restricted stock units into which assumed CV Therapeutics' stock options and restricted stock units were converted was determined based on an option conversion ratio. This conversion ratio was calculated by taking the per share acquisition price of  $20.00 and dividing it by the average closing price of our common stock for the five consecutive trading days immediately preceding (but not including) the closing date of April 17, 2009, which was  $46.24 per share. The fair value of stock options assumed was calculated using a Black-Scholes valuation model with the following assumptions: market price of  $44.54 per share, which was the closing price of our common stock on the acquisition date; expected term ranging from 0.1 to 5.2 years; risk-free interest rate ranging from 0.1% to 1.7%; expected volatility ranging from 37.4% to 43.2%; and no dividend yield. The fair value of restricted stock units assumed was calculated using the acquisition-date closing price of  $44.54 per share for our common stock.
Estimated fair value of unvested stock options and restricted stock units assumed																11,200,000
Deferred tax assets resulting from the acquisition primarily related to federal and state net operating loss and tax credit carryforwards														12,656,000		413,816,000
Deferred tax liabilities resulting from the acquisition primarily related to the difference between the book basis and tax basis of the intangible assets														6,313,000		426,861,000
Deferred tax liability reduced as result of impairment charges																	49,700,000
Valuation allowance related to deferred tax assets	13,040,000	1,078,000														15,100,000
Senior subordinated convertible notes - interest rate											2.75%	3.25%	2.00%
Senior subordinated convertible notes - maturity date											Dec 31, 2012	Dec 31, 2013	Dec 31, 2023
Goodwill resulting from the acquisition of CGI														70,111,000		341,910,000
Aggregate consideration transferred for the acquisition									$ 10,900,000					$ 102,100,000		$ 1,392,558,000

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet64.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Summary of Assets Acquired and Liabilities Assumed, Stated at Fair Value) (Details) (CGI Pharmaceuticals [Member], USD  $) In Thousands	Jul. 08, 2010
Intangible assets - IPR&D	$ 26,630
Goodwill	70,111
Deferred tax assets	12,656
Deferred tax liabilities	(6,313)
Other net liabilities assumed	(984)
Total consideration transferred	$ 102,100

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet65.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Schedule of Assets Acquired and Liabilities Assumed) (Details) (CV Therapeutics, Inc. [Member], USD  $) In Thousands	Apr. 15, 2009
Goodwill	$ 341,910
Deferred tax assets	413,816
Deferred tax liabilities	(426,861)
Cash and cash equivalents	129,087
Marketable securities	116,363
Accounts receivable	9,136
Inventories	50,455
Prepaids and other current assets	60,671
Property, plant and equipment	11,672
Other assets	20,162
Accounts payable	(5,089)
Accrued and other current liabilities	(87,898)
Convertible senior notes	(303,060)
Other liabilities	(27,906)
Total other net liabilities	(26,407)
Total consideration transferred	1,392,558
Marketed Products [Member]
Intangible assets	951,200
IPR&D [Member]
Intangible assets - IPR&D	$ 138,900

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet66.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Restructuring (Narrative) (Details) (USD  $) In Millions	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
CVT/Cardiovascular Restructuring [Member] | Selling, General and Administrative Expenses [Member]
Restructuring and related cost	$ 10.6	$ 26.2
Total amount to be incurred in connection with our restructuring plan	36.8
CVT/Cardiovascular Restructuring [Member] | Research Development Expenses [Member]
Restructuring and related cost	3.4	25.7
Total amount to be incurred in connection with our restructuring plan	29.1
Durham Restructuring [Member] | Selling, General and Administrative Expenses [Member]
Restructuring and related cost	14.6
Durham Restructuring [Member] | Research Development Expenses [Member]
Restructuring and related cost	$ 10.4

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet67.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Restructuring (Schedule of Restructuring Reserve by Type of Cost) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Employee Severance and Termination Benefits [Member]
Costs incurred during the period	$ 2,190	$ 33,797
Costs paid or settled during the period	(11,445)	(24,108)
Balance	434	9,689
Facilities Related Costs [Member]
Costs incurred during the period	9,727	9,880
Costs paid or settled during the period	(4,529)	(545)
Balance	$ 14,533	$ 9,335

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet68.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Narrative) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Total inventory	$ 1,203,809	$ 1,051,771
Joint Venture, Gilead and BMS [Member]
Total inventory	$ 811,900	$ 667,800

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet69.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Summary of Inventories) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Inventories
Raw materials	$ 408,015	$ 333,582
Work in process	454,652	392,042
Finished goods	341,142	326,147
Total inventories	$ 1,203,809	$ 1,051,771

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet70.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Property, Plant and Equipment (Narrative) (Details) (USD  $) In Millions, unless otherwise specified	Jan. 31, 2009
Number of acres of land purchased	30
Purchase cost of office building and land located in Foster city	$ 140.1
Land [Member]
Purchase cost of office building and land located in Foster city	71.6
Land Improvements [Member]
Purchase cost of office building and land located in Foster city	2.7
Building [Member]
Purchase cost of office building and land located in Foster city	64.3
Office and Computer Equipment [Member]
Purchase cost of office building and land located in Foster city	$ 1.1

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet71.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Property, Plant and Equipment (Property, Plant and Equipment) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010 Buildings and Improvements [Member]	Dec. 31, 2009 Buildings and Improvements [Member]	Dec. 31, 2010 Laboratory and Manufacturing Equipment [Member]	Dec. 31, 2009 Laboratory and Manufacturing Equipment [Member]	Dec. 31, 2010 Office and Computer Equipment [Member]	Dec. 31, 2009 Office and Computer Equipment [Member]	Dec. 31, 2010 Capital Lease Equipment [Member]	Dec. 31, 2009 Capital Lease Equipment [Member]	Dec. 31, 2010 Construction in Progress [Member]	Dec. 31, 2009 Construction in Progress [Member]	Dec. 31, 2010 Property Plant and Equipment [Member]	Dec. 31, 2009 Property Plant and Equipment [Member]	Dec. 31, 2010 Land [Member]	Dec. 31, 2009 Land [Member]
Subtotal			$ 501,401	$ 490,632	$ 168,711	$ 176,362	$ 116,479	$ 126,375	$ 10,865	$ 15,232	$ 82,334	$ 58,448	$ 879,790	$ 867,049	$ 137,812	$ 137,809
Less accumulated depreciation and amortization (including  $10,451 and  $14,999 relating to capitalized leased equipment for 2010 and 2009, respectively)													(316,367)	(304,888)
Property, plant and equipment, net	701,235	699,970											563,423	562,161
Depreciation on capitalized leased equipments									$ 10,451	$ 14,999

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet72.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Narrative) (Details) (USD  $)	12 Months Ended			3 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2010 CGI Pharmaceuticals [Member] IPR&D [Member]	Dec. 31, 2010 CV Therapeutics [Member] IPR&D [Member]	Dec. 31, 2009 CV Therapeutics [Member] IPR&D [Member]	Dec. 31, 2010 IPR&D Related to CVT [Member]
Amortization expense	$ 59,900,000	$ 43,400,000	$ 2,800,000
Weighted-average amortization period for intangible assets, in years	10
Indefinite-lived intangible assets	29,530,000	138,900,000		26,600,000	2,900,000	138,900,000
Impairment charges							$ 136,000,000

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet73.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule of Carrying Amount of Intangible Assets) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Intangible Assets
Goodwill	$ 532,669	$ 462,558
Finite lived intangible assets	863,393	923,319
Intangible assets - IPR&D	29,530	138,900
Total	$ 1,425,592	$ 1,524,777

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet74.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule of Changes in the Carrying Amount of Goodwill) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009	Jul. 08, 2010 CGI Pharmaceuticals [Member]
Year end balance	$ 532,669	$ 462,558
Goodwill resulting from the acquisition of CGI			$ 70,111

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet75.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule of Finite-Lived intangible Assets) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Gross carrying amount	$ 973,295	$ 973,295
Accumulated amortization	109,902	49,976
Ranexa [Member]
Gross carrying amount	688,400	688,400
Accumulated amortization	54,795	21,889
Lexiscan [Member]
Gross carrying amount	262,800	262,800
Accumulated amortization	43,979	18,235
Other Intangible Assets [Member]
Gross carrying amount	22,095	22,095
Accumulated amortization	$ 11,128	$ 9,852

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet76.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule of Estimated Future Amortization Expense) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010
Intangible Assets
2011	$ 69,324
2012	75,776
2013	82,086
2014	90,940
2015	100,647
Total	$ 418,773

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet77.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Collaborative Arrangements (Details)	12 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended	1 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended
Dec. 31, 2010 USD ( $)	Dec. 31, 2009 USD ( $)	Dec. 31, 2008 USD ( $)	Jul. 31, 2008 Renexa Product [Member] Roche [Member] USD ( $)	Jan. 31, 2006 Renexa Product [Member] Roche [Member] USD ( $)	Mar. 31, 2009 Hespera Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2008 Hespera Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2007 Hespera Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2010 Volibris Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2009 Volibris Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2008 Volibris Product [Member] GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2010 Lexiscan Product [Member] Astellas US LLC and Astellas Pharma US, Inc. [Member] USD ( $)	Dec. 31, 2009 Lexiscan Product [Member] Astellas US LLC and Astellas Pharma US, Inc. [Member] USD ( $)	Dec. 31, 2010 TCM278 Product [Member] Tibotec Pharmaceuticals [Member] USD ( $)	Dec. 31, 2010 TCM278 Product [Member] Tibotec Pharmaceuticals [Member] EUR ( €)	Dec. 31, 2009 TCM278 Product [Member] Tibotec Pharmaceuticals [Member] USD ( $)	Dec. 31, 2009 TCM278 Product [Member] Tibotec Pharmaceuticals [Member] EUR ( €)	Dec. 31, 2009 Tamiflu Royalty Arrangement [Member] Roche [Member]	Aug. 31, 2007 Up-front Payments [Member] Parion Sciences, Inc. [Member] USD ( $)	Mar. 31, 2005 Up-front Payments [Member] Japan Tobacco Inc. [Member] USD ( $)	Nov. 30, 2007 PARI GmbH [Member] USD ( $)	Aug. 31, 2007 Parion Sciences, Inc. [Member] USD ( $)	Jul. 31, 2008 Japan Tobacco Inc. [Member] USD ( $)	Mar. 31, 2006 Japan Tobacco Inc. [Member] USD ( $)	Mar. 31, 2006 GlaxoSmithKline Inc. [Member] USD ( $)	Apr. 30, 2002 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2010 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2009 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2008 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2007 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2006 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2004 GlaxoSmithKline Inc. [Member] USD ( $)	Dec. 31, 2010 Roche [Member] USD ( $)	Dec. 31, 2009 Roche [Member] USD ( $)	Dec. 31, 2008 Roche [Member] USD ( $)	Dec. 31, 2010 Astellas US LLC and Astellas Pharma US, Inc. [Member] USD ( $)	Dec. 31, 2009 Astellas US LLC and Astellas Pharma US, Inc. [Member] USD ( $)	Dec. 31, 2008 Astellas US LLC and Astellas Pharma US, Inc. [Member] USD ( $)	Jul. 31, 2009 Tibotec Pharmaceuticals [Member] EUR ( €)	Jul. 31, 2009 Tibotec Pharmaceuticals [Member] USD ( $)
Total assets of the joint venture	$ 1,450,000,000	$ 1,400,000,000
Total liabilities of the joint venture	759,500,000	1,030,000,000
Amount paid to reduce the royalty rate																					13,500,000
Investment in the form of convertible debt																						5,000,000
Royalty agreement terms																		The royalties payable to us on net sales of Tamiflu sold by Roche remain the same under the amended agreement, which are as follows: (a) 14% of the first  $200.0 million in worldwide net sales in a given calendar year; (b) 18% of the next  $200.0 million in worldwide net sales during the same calendar year; and (c) 22% of worldwide net sales in excess of  $400.0 million during the same calendar year.
Payment in accordance with agreement				9,000,000	11,000,000
Number of years amortized over its useful patent life																																	11
Research and development expense														22,100,000	17,900,000	52,400,000	35,700,000		5,000,000	15,000,000			7,000,000	5,000,000
Milestone payments received																													20,000,000	11,000,000	10,000,000	17,000,000
Future milestone receivables																											80,000,000
Deferred revenue recognized						24,500,000	3,400,000	3,600,000	8,700,000	8,300,000	5,000,000
Gross sales limit for achievement																															75,000,000
Up-front payment received																									20,000,000	10,000,000
Number of years milestone and up-front license payments amortized																											6
Royalty revenue	545,970,000	491,818,000	218,180,000									43,200,000	19,700,000														48,000,000	32,400,000	31,700,000				386,500,000	392,700,000	155,500,000	10,200,000	9,400,000	9,500,000
Research and development reimbursement contract, maximum																																							€ 71,500,000	$ 100,000,000

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet78.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Narrative) (Details) (USD  $) Share data in Millions, except Per Share data, unless otherwise specified	1 Months Ended	12 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended
May 31, 2010	Apr. 30, 2009	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010 Warrants Expiring in 2011 [Member]	Dec. 31, 2010 Warrants Expiring in 2013 [Member]	Dec. 31, 2010 Warrants Expiring in 2014 [Member]	Dec. 31, 2010 Warrants Expiring in 2016 [Member]	Apr. 30, 2006 Warrants Expiring in 2011 and 2013 [Member]	Jul. 31, 2010 Warrants Expiring in 2014 and 2016 [Member]	Apr. 30, 2006 2011 and 2013 Convertible Note Hedges [Member]	Jul. 31, 2010 2014 and 2016 Convertible Note Hedges [Member]	Apr. 30, 2006 2014 and 2016 Convertible Note Hedges [Member]	Jul. 31, 2010 Convertible Notes Hedges and Warrants [Member]	Apr. 30, 2006 Convertible Notes Hedges and Warrants [Member]	Apr. 30, 2006 2011 Convertible Senior Notes [Member]	Dec. 31, 2010 2011 Convertible Senior Notes [Member]	Apr. 30, 2006 2013 Convertible Senior Notes [Member]	Dec. 31, 2010 2013 Convertible Senior Notes [Member]	Jul. 31, 2010 2014 Convertible Senior Notes [Member]	Dec. 31, 2010 2014 Convertible Senior Notes [Member]	Apr. 30, 2006 2011 and 2013 Convertible Senior Notes [Member]	Dec. 31, 2010 2011 and 2013 Convertible Senior Notes [Member]	Dec. 31, 2009 2011 and 2013 Convertible Senior Notes [Member]	Dec. 31, 2008 2011 and 2013 Convertible Senior Notes [Member]	Jul. 31, 2010 2016 Convertible Senior Notes [Member]	Dec. 31, 2010 2016 Convertible Senior Notes [Member]	Jul. 31, 2010 2014 and 2016 Convertible Senior Notes [Member]	Dec. 31, 2010 2014 and 2016 Convertible Senior Notes [Member]
Convertible senior notes																$ 650,000,000		$ 650,000,000		$ 1,250,000,000						$ 1,250,000,000
Convertible senior notes, effective interest rate																	5.70%		5.80%		3.50%						4.00%
Convertible senior notes, stated interest rate																0.50%		0.63%		1.00%						1.63%
Initial conversion ratio																25.8048		26.246		22.1845						22.0214
Principle amount applied to initial conversion ratio																1,000		1,000		1,000						1,000
Payments of debt issuance costs																						23,800,000						37,500,000
Debt instrument conversion price per share																38.75	38.75	38.1	38.1	45.08	45.08					45.41	45.41
Debt instrument, convertible, terms of conversion feature																						The 2011 and 2013 notes may be converted, subject to adjustment, only under the following circumstances: 1) during any calendar quarter beginning after September 30, 2006 if the closing price of our common stock for at least 20 trading days during the last 30 consecutive trading day period of the previous quarter is more than 130% of the applicable conversion price per share, 2) if we make specified distributions to holders of our common stock or if specified corporate transactions occur, or 3) during the last month prior to maturity of the applicable notes. Upon conversion, a holder would receive an amount in cash equal to the lesser of (i) the principal amount of the note or (ii) the conversion value for such note. If the conversion value exceeds the principal amount, we may also deliver, at our option, cash or common stock or a combination of cash and common stock for the conversion value in excess of the principal amount. If the 2011 and 2013 notes are converted in connection with a change in control, we may be required to provide a make whole premium in the form of an increase in the conversion rate, subject to a stated maximum amount. In addition, in the event of a change in control, the holders may require us to purchase all or a portion of their notes at a purchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any.						The 2014 and 2016 notes may be converted prior to April 1, 2014 and April 1, 2016, respectively, only under the following circumstances: 1) during any calendar quarter commencing after September 30, 2010, if the closing price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than 130% of the applicable conversion price on each applicable trading day, or 2) during the five business day period after any measurement period of ten consecutive trading days in which, for each trading day of such period, the trading price per  $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of Gilead common stock and the applicable conversion rate on such trading day, or 3) upon the occurrence of specified corporate transactions, such as the distribution of certain stock rights, cash amounts, or other assets to all Gilead shareholders or the occurrence of a change in control. On and after April 1, 2014, in the case of the 2014 Notes, and April 1, 2016, in the case of the 2016 Notes, holders may convert their notes at any time, regardless of the foregoing circumstances. Generally, upon conversion, a holder would receive an amount in cash equal to the lesser of (i) the principal amount of the note or (ii) the conversion value for such note, as measured under the indenture governing the relevant notes. If the conversion value exceeds the principal amount, we may also deliver, at our option, cash or common stock or a combination of cash and common stock for the conversion value in excess of the principal amount. If the 2014 and 2016 notes are converted in connection with a change in control, we may be required to provide a make whole premium in the form of an increase in the conversion rate, subject to a stated maximum amount. In addition, in the event of a change in control, the holders may require us to purchase all or a portion of their notes at a purchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any.
Payments to acquire convertible note hedges			362,622,000								379,100,000	362,600,000
Proceeds from sale of warrants			155,425,000						235,500,000	155,400,000
Net cost of convertible note hedge and warrant transactions														207,200,000	143,700,000
Effective conversion price																$ 50.8		$ 53.9		$ 56.76						$ 60.1
Common stock covered by the Convertible Note Hedges, subject to anti-dilution adjustments											33.8		55.3
Common stock underlying the warrants, subject to anti-dilution adjustments									33.8	55.3
Repurchase of common stock relating to sale of notes, shares																						16.7
Repurchase of common stock relating to sale of notes, value																						544,900,000
Interest expense, long-term debt																							67,900,000	64,600,000	61,500,000				34,900,000
Borrowing under the credit agreement			5,000,000
Proceeds from credit facility	500,000,000	400,000,000	500,000,000	400,000,000
Amount available under the credit agreement			1,250,000,000
Warrants strike price					$ 50.8	$ 53.9	$ 56.76	$ 60.1
Repayments of Lines of Credit			$ 500,000,000	$ 400,000,000
Line of credit facility, description			The credit agreement also includes a sub-facility for swing-line loans and letters of credit. Loans under the credit agreement bear interest at an interest rate of either LIBOR plus a margin ranging from 20 basis points to 32 basis points or the base rate, as described in the credit agreement. We may reduce the commitments and may prepay loans under the credit agreement in whole or in part at any time without penalty, subject to certain conditions. The credit agreement will terminate in December 2012 and all unpaid borrowings thereunder shall be due and payable at that time.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet79.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Schedule of Carrying Amount of Convertible Senior Notes) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Total convertible senior notes, net	$ 3,477,564	$ 1,155,266
Less current portion (2011 convertible senior notes)	638,991
Total non-current convertible senior notes, net	2,838,573	1,155,266
2011 Convertible Senior Notes [Member]
Total convertible senior notes, net	638,991	606,786
2013 Convertible Senior Notes [Member]
Total convertible senior notes, net	576,884	548,480
2014 Convertible Senior Notes [Member]
Total convertible senior notes, net	1,153,805
2016 Convertible Senior Notes [Member]
Total convertible senior notes, net	$ 1,107,884

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet80.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Schedule of Information about Equity and Liability Components of Convertible Senior Notes 2011 and 2013 Notes) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2010 2011 and 2013 Convertible Senior Notes [Member]	Dec. 31, 2009 2011 and 2013 Convertible Senior Notes [Member]	Dec. 31, 2010 2011 Convertible Senior Notes [Member]	Dec. 31, 2009 2011 Convertible Senior Notes [Member]	Dec. 31, 2010 2013 Convertible Senior Notes [Member]	Dec. 31, 2009 2013 Convertible Senior Notes [Member]
Carrying Value of Equity Component	$ 255,517	$ 340,712	$ 340,712	$ 147,481	$ 147,481	$ 193,231	$ 193,231
Net Carrying Amount of Liability Component		1,215,875	1,155,266	638,991	606,786	576,884	548,480
Unamortized Discount of Liability Component		$ (83,979)	$ (144,588)	$ (10,996)	$ (43,201)	$ (72,983)	$ (101,387)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet81.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Schedule of Information about Equity and Liability Components of Convertible Senior Notes 2014 and 2016 Notes) (Details) (USD  $) In Thousands	Dec. 31, 2010
Carrying Value of Equity Component	$ 255,517
2016 Convertible Senior Notes [Member]
Carrying Value of Equity Component	152,039
Net Carrying Amount Of Liability Component	1,107,884
Unamortized Discount of Liability Component	(142,116)
2014 Convertible Senior Notes [Member]
Carrying Value of Equity Component	107,496
Net Carrying Amount Of Liability Component	1,153,805
Unamortized Discount of Liability Component	(96,195)
2014 and 2016 Convertible Senior Notes [Member]
Carrying Value of Equity Component	259,535
Net Carrying Amount Of Liability Component	2,261,689
Unamortized Discount of Liability Component	$ (238,311)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet82.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Commitments and Contingencies (Narrative) (Details) (USD  $) In Millions	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Commitments and Contingencies
Description of lessee leasing arrangements, operating leases	We have entered into various long-term non-cancelable operating leases for equipment and facilities. We lease facilities in Foster City, Palo Alto and San Dimas, California; Durham, North Carolina; Boulder, Colorado; Seattle, Washington; the Dublin and Cork areas of Ireland and the London area of the United Kingdom. We also have operating leases for sales, marketing and administrative facilities in Europe, Canada and Asia Pacific. Our leases expire on various dates between 2011 and 2029, with many of our leases containing options to renew. Certain facility leases also contain rent escalation clauses. Our most significant lease, related to a facility in Seattle, Washington, expires in 2020 and has a 10-year term. The lease provides us with three consecutive rights to extend the term of the lease through 2035 and contains an annual three percent rent escalation clause. The lease also requires us to pay additional amounts for operating expenses and maintenance. We also have leases for three corporate aircraft, with varying terms, with renewal options upon expiration of the lease terms.
Lease expense under our operating leases	$ 41.7	$ 37.3	$ 29.3
Purchase Commitments, 2011	640.3
Purchase Commitments, 2012	149.3
Purchase Commitment, 2013	57.5
Purchase Commitment, 2014	20.2
Purchase Commitment, 2015	3.1
Actual payments for purchases related to active pharmaceutical ingredients	$ 835.7	$ 1,030	$ 1,040

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet83.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Commitments and Contingencies (Future Minimum Rental Payments Under Operating Leases) (Details) (USD  $) In Thousands	Dec. 31, 2010
Commitments and Contingencies
2011	$ 45,887
2012	37,733
2013	29,648
2014	21,477
2015	19,078
Thereafter	57,344
Total	$ 211,167

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet84.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity (Narrative) (Details) (USD  $)	1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended		12 Months Ended	1 Months Ended	5 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	8 Months Ended	12 Months Ended	1 Months Ended
Jan. 31, 2010	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Jan. 31, 2010 Performance Based Share Awards [Member]	Jan. 31, 2009 Performance Based Share Awards [Member]	Jan. 31, 2008 Performance Based Share Awards [Member]	Dec. 31, 2010 Performance Based Share Awards [Member]	Dec. 31, 2009 Performance Based Share Awards [Member]	Dec. 31, 2008 Performance Based Share Awards [Member]	Dec. 31, 2010 Performance Based Share Awards [Member] Three Years Vesting [Member]	Dec. 31, 2010 Time-Based Restricted Stock Awards [Member]	Dec. 31, 2010 Time-Based Restricted Stock Awards [Member] Five Years Period [Member]	Dec. 31, 2010 Employee Stock Purchase Plan [Member]	Dec. 31, 2010 Stock Option Plans [Member]	Dec. 31, 2010 Two Thousand Four Plan [Member]	Dec. 31, 2009 Open Market Transactions [Member]	Dec. 31, 2008 Open Market Transactions [Member]	Dec. 31, 2007 Open Market Transactions [Member]	Jun. 30, 2008  $500M Accelerated Repurchase [Member] Stock Repurchase Program;  $3B 3-Year [Member]	Feb. 29, 2008  $500M Accelerated Repurchase [Member] Stock Repurchase Program;  $3B 3-Year [Member]	Mar. 31, 2009  $750M Accelerated Repurchase [Member] Stock Repurchase Program;  $3B 3-Year [Member]	Oct. 31, 2008  $750M Accelerated Repurchase [Member] Stock Repurchase Program;  $3B 3-Year [Member]	Mar. 31, 2009  $750M Accelerated Repurchase [Member] Stock Repurchase Program;  $3B 3-Year [Member]	Oct. 31, 1999 First Amendment of Rights Plan [Member] Series A Junior Participating Preferred Stock [Member]	Oct. 31, 2003 Second Amendment of Rights Plan [Member] Series A Junior Participating Preferred Stock [Member]	Dec. 31, 2010 CV Therapeutics Plans [Member]	Oct. 31, 2007 Stock Repurchase Program;  $3B 3-Year [Member]	Jan. 31, 2011 Stock Repurchase Program;  $5B, 3-Year [Member]	May 31, 2010 Stock Repurchase Program;  $5B, 3-Year [Member]	Dec. 31, 2010 Stock Repurchase Program;  $5B, 3-Year [Member]	Dec. 31, 2010 Stock Repurchase Program;  $5B, 3-Year [Member]	Nov. 30, 1994 Series A Junior Participating Preferred Stock [Member]	Dec. 31, 2010 Series A Junior Participating Preferred Stock [Member]
Authorized common stock repurchase program	$ 1,000,000,000																											$ 3,000,000,000	$ 5,000,000,000	$ 5,000,000,000
Aggregate purchase price of the stock repurchased and retired under the stock repurchase programs																	998,100,000	719,300,000	32,700,000												3,020,000,000	4,020,000,000
Number of stock repurchased and retired under the stock repurchase programs																	21,845,929	14,696,449	705,600													109,900,000
Incremental common shares attributable to accelerated share repurchase agreements																				239,612	9,373,548	1,356,337	14,874,519	16,230,856
Average purchase price per share of the stock repurchased and retired under the stock repurchase programs																	$ 45.69	$ 48.94	$ 46.28													$ 36.57
Accelerated share repurchases, settlement payment or receipt																					500,000,000		750,000,000
Accelerated share repurchases, initial price paid per share																					$ 53.34		$ 50.42
Accelerated share repurchases, final price paid per share																				$ 52.01		$ 46.21
Remaining authorized amount of stock repurchases																																1,980,000,000
Decrease in common stock and APIC		319,800,000	61,700,000	95,800,000
Excess of purchase price over par value charged against retained earnings		3,710,000,000	940,800,000	1,880,000,000
Preferred stock, shares authorized		5,000,000	5,000,000																															800,000
Preferred stock, shares outstanding		0	0
Preferred Stock, Participation Rights																									The first amendment provided, among other things, for an increase in the exercise price of a right under the plan from  $15 to  $100 and an extension of the term of the plan from November 2004 to October 2009.	The second amendment provides, among other things, for an increase in the exercise price of a right under the plan from  $100 to  $400 and an extension of the term of the Rights Plan to October 2013.							The Rights Plan provides for the distribution of a preferred stock purchase right as a dividend for each share of our common stock. The purchase rights are not currently exercisable. Under certain conditions involving an acquisition or proposed acquisition by any person or group of 15% or more of our common stock, the purchase rights permit the holders (other than the 15% holder) to purchase our common stock at a 50% discount from the market price at that time, upon payment of a specified exercise price per purchase right. In addition, in the event of certain business combinations, the purchase rights permit the purchase of the common stock of an acquirer at a 50% discount from the market price at that time. Under certain conditions, the purchase rights may be redeemed by our Board in whole, but not in part, at a price of  $0.0025 per purchase right. The purchase rights have no voting privileges and are attached to and automatically trade with our common stock.
Number of shares authorized for future issuance																51,793,307											0
Options assumed from acquisition and converted into options to purchase common stock																											1,800,000
Number of shares authorized for grant																121,594,183
Purchase of shares converted under the option plan		45,018,000	47,090,000	45,235,000
Purchase of shares converted under the option plan																											1,800,000
Total intrinsic value of options exercised		262,300,000	379,800,000	551,700,000
Total fair value of stock options vested		124,600,000	162,900,000	169,200,000
Number of options outstanding that are expected to vest		13,302,022
Weighted average exercise price of options outstanding that are expected to vest		$ 43.12
Intrinsic Value of options outstanding that are expected to vest		9,600,000
Weighted average remaining contractual life of options outstanding that are expected to vest		7.62
Aggregate intrinsic value of stock options outstanding		564,200,000
Aggregate intrinsic value of stock options exercisable		554,000,000
Weighted-average remaining contractual life for options outstanding		5.3
Weighted-average remaining contractual life for options exercisable		4.5
Unrecognized compensation cost related to stock options														22,100,000	260,800,000
Unrecognized compensation costs, weighted-average period of recognition														1	2.7
Share based awards granted					412,505	426,305	219,690
Payout percentage, minimum								0.00%
Payout percentage, maximum								200.00%
Share based awards weighted-average grant date fair values								$ 54.25	$ 61.89	$ 56.61
Stock-based compensation expense		200,041,000	185,758,000	153,364,000				21,300,000	14,900,000	7,500,000		19,500,000
Awards vesting period											three		five
Time-based restricted stock awards to employees												2,189,903
Percentage of purchase price lower than fair market value of common stock														85.00%
Shares issued under Employee Stock Purchase Plan														1,110,485
Value of shares issued under Employee Stock Purchase Plan		$ 32,307,000	$ 34,873,000	$ 30,386,000
Shares reserved for issuance														33,280,000
Shares available for issuance														6,567,411

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet85.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity (Schedule of Summary of Activity Under Stock Option Plans) (Details) (USD  $) In Thousands, except Per Share data	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Stockholders' Equity
Outstanding, beginning of year	69,193	76,811	84,977
Granted and assumed	4,836	7,286	9,807
Forfeited	(2,348)	(2,393)	(2,471)
Expired	(759)	(440)	(59)
Exercised	(10,671)	(12,071)	(15,443)
Outstanding, end of year	60,251	69,193	76,811
Exercisable, end of year	45,018	47,090	45,235
Outstanding, beginning of year	$ 28.09	$ 24.7	$ 20.33
Granted and assumed	$ 44.27	$ 48.87	$ 47.11
Forfeited	$ 43.16	$ 39.33	$ 30.61
Expired	$ 53.27	$ 64.08	$ 11.72
Exercised	$ 17.68	$ 15.56	$ 13.97
Outstanding, end of year	$ 30.32	$ 28.09	$ 24.7
Exercisable, end of year	$ 25.92	$ 22.36	$ 17.29
Weighted-average grant date fair value of options granted during the year	$ 14.24	$ 17	$ 16.95

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet86.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation (Narrative) (Details) (USD  $) In Millions	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Stock-Based Compensation
Capitalized amount of stock-based compensation costs to inventory	$ 10.9	$ 11.4	$ 9.9

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet87.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation (Schedule of Stock-Based Compensations Expenses Included in Consolidated Statements of Income) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Stock-based compensation expense included in total costs and expenses	$ 200,041	$ 185,758	$ 153,364
Income tax effect	(52,331)	(46,486)	(40,565)
Stock-based compensation expense included in net income	147,710	139,272	112,799
Cost of Goods Sold [Member]
Stock-based compensation expense included in total costs and expenses	10,180	10,859	10,312
Research and Development Expenses [Member]
Stock-based compensation expense included in total costs and expenses	84,048	82,893	66,523
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense included in total costs and expenses	$ 105,813	$ 92,006	$ 76,529

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet88.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation (Schedule of Assumptions to Calculate the Estimated Fair Value of the Awards) (Details)	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Expected dividend yield	0.00%	0.00%	0.00%
ESPP [Member]
Expected volatility	35.00%	37.00%	31.00%
Expected term in years	1.3	1.3	1.2
Risk-free interest rate	0.40%	0.70%	2.10%
Stock Options [Member]
Expected volatility	31.00%	35.00%	34.00%
Expected term in years	5.4	5.3	5.3
Risk-free interest rate	2.30%	2.10%	2.80%

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet89.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income (Loss) (Net Realized Gains (Losses) on Sale of Securities and Cash Flow Hedges) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Comprehensive Income (Loss)
Net unrealized gain (loss) related to available-for-sale securities, net of tax impact of  $(6,624),  $(11,724) and  $11,487 for 2010, 2009 and 2008, respectively	$ 13,450	$ 21,689	$ (21,607)
Net unrealized gain (loss) related to cash flow hedges, net of tax impact of  $(9,149),  $10,682 and  $(40,681) for 2010, 2009 and 2008, respectively	105,924	(19,016)	93,962
Reclassification adjustments, net of tax impact of  $9,028,  $32,532 and  $1,805 for 2010, 2009 and 2008, respectively	(74,289)	(58,130)	(5,603)
Other comprehensive income (loss)	45,085	(55,457)	66,752
Net unrealized gain (loss) related to available-for-sale securities, tax	(6,624)	(11,724)	11,487
Net unrealized gain (loss) related to cash flow hedges, tax	(9,149)	10,682	(40,681)
Reclassification adjustment, tax	$ 9,028	$ 32,532	$ 1,805

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet90.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Comprehensive Income (Loss) (Accumulated Other Comprehensive Income (Loss), Net of Taxes) (Details) (USD  $) In Thousands	Dec. 31, 2010	Dec. 31, 2009
Comprehensive Income (Loss)
Net unrealized gain on available-for-sale securities	$ 16,528	$ 9,509
Net unrealized gain (loss) on cash flow hedges	21,615	(16,450)
Cumulative foreign currency translation adjustment	(7,232)	1,183
Accumulated other comprehensive income (loss)	$ 30,911	$ (5,758)

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet91.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Narrative) (Details) (USD  $) In Millions, unless otherwise specified	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Major customers percentage of total revenues, minimum	10.00%
Property, plant and equipment percentage in major reporting geographical segment	At December 31, 2010, the net book value of our property, plant and equipment in the United States, Ireland and Canada was  $519.4 million,  $112.2 million and  $53.9 million, respectively, which comprised approximately 98% of the total net book value of our property, plant and equipment.	At December 31, 2009, the net book value of our property, plant and equipment in the United States, Ireland and Canada was  $510.0 million,  $115.3 million and  $57.0 million, respectively, which comprised approximately 97% of the total net book value of our property, plant and equipment.
United States [Member]
Property, plant and equipment, net	$ 519.4	$ 510
Ireland [Member]
Property, plant and equipment, net	112.2	115.3
Canada [Member]
Property, plant and equipment, net	$ 53.9	$ 57

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet92.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Product Sales) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Product sales	$ 7,389,921	$ 6,469,311	$ 5,084,796
Antiviral Products Atripla [Member]
Product sales	2,926,579	2,382,113	1,572,455
Antiviral Products Truvada [Member]
Product sales	2,649,908	2,489,682	2,106,687
Antiviral Products Viread [Member]
Product sales	732,240	667,510	621,187
Antiviral Products Hepsera [Member]
Product sales	200,592	271,595	341,023
Antiviral Products Emtriva [Member]
Product sales	27,679	27,974	31,080
Total Antiviral Products [Member]
Product sales	6,536,998	5,838,874	4,672,432
AmBisome [Member]
Product sales	305,856	298,597	289,651
Letairis [Member]
Product sales	240,279	183,949	112,855
Ranexa [Member]
Product sales	239,832	131,062
Other Products [Member]
Product sales	$ 66,956	$ 16,829	$ 9,858

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet93.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Schedule of total Revenues From External Customers and Collaboration Partners by Geographic Region) (Details) (USD  $) In Thousands	3 Months Ended	12 Months Ended
Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Mar. 31, 2009	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Total revenues	$ 1,998,687	[1]	$ 1,937,656	[1]	$ 1,927,224	[1]	$ 2,085,853	[1]	$ 2,032,379	$ 1,801,389	$ 1,647,155	$ 1,530,460	$ 7,949,420	$ 7,011,383	$ 5,335,750
United States [Member]
Total revenues													4,224,035	3,599,313	2,857,472
France [Member]
Total revenues													519,700	468,314	395,672
Spain [Member]
Total revenues													456,647	451,115	356,607
United Kingdom [Member]
Total revenues													450,368	393,036	297,276
Italy [Member]
Total revenues													345,189	323,709	277,441
Germany [Member]
Total revenues													274,991	293,111	242,193
Switzerland [Member]
Total revenues													458,606	448,203	193,314
Other European Countries [Member]
Total revenues													665,237	603,068	346,722
Other Countries [Member]
Total revenues													554,647	431,514	369,053
Total Revenues Outside of the United States [Member]
Total revenues													$ 3,725,385	$ 3,412,070	$ 2,478,278
[1]	During 2010, we recorded  $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet94.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Schedule of Revenues from Each Customer Who Individually Accounted for 10% or More as a % of Total Revenues) (Details)	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Cardinal Health, Inc. [Member]
The percentage of total revenues from the customers	17.00%	18.00%	21.00%
McKesson Corp. [Member]
The percentage of total revenues from the customers	14.00%	13.00%	16.00%
AmerisourceBergen Corp. [Member]
The percentage of total revenues from the customers	12.00%	11.00%	11.00%

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet95.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Narrative) (Details) (USD  $)	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Foreign pre-tax income	$ 1,370,000,000	$ 1,330,000,000	$ 900,000,000
Cumulative unremitted foreign earnings that are permanently invested	4,480,000,000	3,190,000,000
Tax liability if remitted	1,600,000,000	1,140,000,000
Change in valuation allowance	11,900,000	1,100,000	(23,500,000)
Total federal, state and foreign unrecognized tax benefits	126,516,000	106,506,000	121,424,000	115,087,000
Unrecognized tax benefits that would impact effective tax rate	106,500,000	72,600,000
Unrecognized tax benefits, accrued interest and penalties	12,300,000	5,400,000
Reasonably possible estimated decrease in unrecognized tax benefits in the next 12 months	6,000,000
U.S. Federal [Member]
Net operating loss carryforwards	732,500,000
Tax credit carryforwards	26,200,000
Operating loss carryforwards, expiration dates	2016
State [Member]
Net operating loss carryforwards	1,400,000,000
Tax credit carryforwards	$ 3,300,000
Operating loss carryforwards, expiration dates	2011
Tax credit carryforwards, expiration dates	2016

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet96.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Provision for Income Taxes) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Income Taxes
Current	$ 852,822	$ 719,777	$ 585,075
Deferred	(29,854)	(47,608)	6,099
Federal Total	822,968	672,169	591,174
Current	139,819	153,376	56,223
Deferred	17,464	9,150	24,333
State Total	157,283	162,526	80,556
Current	43,094	42,860	38,738
Deferred	454	(1,191)	(8,105)
Foreign Total	43,548	41,669	30,633
Provision for income taxes	$ 1,023,799	$ 876,364	$ 702,363

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet97.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Difference Between the Provision for Income Taxes and Federal Statutory Income Tax Rate Before Income Tax) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Income Taxes
Income before provision for income taxes	$ 3,913,548	$ 3,501,956	$ 2,672,698
Tax at federal statutory rate	1,369,742	1,225,685	935,444
State taxes, net of federal benefit	106,250	111,095	58,166
Foreign earnings at different rates	(435,767)	(399,993)	(257,835)
Research and other credits	(33,072)	(43,045)	(32,270)
Net unbenefitted stock compensation	13,188	4,269	5,224
Other	3,458	(21,647)	(6,366)
Provision for income taxes	$ 1,023,799	$ 876,364	$ 702,363

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet98.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Components Deferred Tax Assets and Liabilities) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009
Income Taxes
Net operating loss carryforwards	$ 308,854	$ 377,058
Stock-based compensation	142,242	117,019
Reserves and accruals not currently deductible	109,806	90,760
Deferred revenue	49,194	67,389
Depreciation related	58,875	44,166
Research and other credit carryforwards	25,151	28,980
Capitalized intangibles	5,839	12,086
Other, net	88,669	64,881
Total deferred tax assets before valuation allowance	788,630	802,339
Valuation allowance	(13,040)	(1,078)
Total deferred tax assets	775,590	801,261
Intangibles	(322,168)	(384,480)
Unremitted foreign earnings	(15,928)	(15,928)
Other	(20,774)	(17,053)
Total deferred tax liabilities	(358,870)	(417,461)
Net deferred tax assets	$ 416,720	$ 383,800

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet99.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Total Gross Unrecognized Tax Benefit Liabilities) (Details) (USD  $) In Thousands	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Income Taxes
Balance, beginning of period	$ 106,506	$ 121,424	$ 115,087
Additions	24,320	25,036	37,495
Reductions	(3,303)	(8,380)
Additions	25,581	37,014	4,298
Reductions	(23,474)	(36,277)	(23,307)
Settlements	(2,160)	(31,517)	(10,252)
Lapse of statute of limitations	(954)	(794)	(1,897)
Balance, end of period	$ 126,516	$ 106,506	$ 121,424

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet100.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Deferred Compensation Plans (Details) (USD  $) In Millions, except Share data	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Deferred compensation arrangement with individuals, maximum contractual term	We maintain a retirement savings plan under which eligible employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (Gilead Plan). Under the Gilead Plan, employees may contribute up to 60% of their eligible annual compensation, subject to IRS plan limits. We make matching contributions under the Gilead Plan. In 2010, 2009 and 2008, we contributed up to 50% of an employee's contributions up to an annual maximum match of  $5,000.
Total matching contribution expense under Gilead plan	$ 11.2	$ 10.2	$ 7.8
Phantom shares outstanding	31,682
Management [Member]
Deferred compensation arrangement with individuals, maximum contractual term	We maintain a deferred compensation plan under which our directors and key employees may defer compensation for income tax purposes. The deferred compensation plan is a non-qualified deferred compensation plan which is not subject to the qualification requirements under Section 401(a) of the Internal Revenue Code. Compensation deferred after December 31, 2004 is subject to the requirements of Section 409A of the Internal Revenue Code. Under the plan, officers and other senior grade level employees may contribute up to 70% of their annual salaries and up to 100% of their annual bonus while directors may contribute up to 100% of their annual retainer fee. Amounts deferred by participants are deposited in a rabbi trust and are recorded in other noncurrent assets in our Consolidated Balance Sheets. Beginning in 2004, directors may also elect to receive all or a portion of their annual cash retainer in phantom shares, which gives the participant the right to receive an amount equal to the value of a specified number of shares over a specified period of time and which will be payable in shares of our common stock (with fractional shares paid out in cash) as established by the plan administrator.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet101.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Subsequent Events (Details) (USD  $)	1 Months Ended		1 Months Ended
Jan. 31, 2010	Jan. 31, 2011 Stock Repurchase Program;  $5B, 3-Year [Member]	May 31, 2010 Stock Repurchase Program;  $5B, 3-Year [Member]	Jan. 14, 2011 Arresto Biosciences, Inc. [Member]	Feb. 28, 2011 Calistoga Pharmaceuticals, Inc. [Member]
Authorized common stock repurchase program	$ 1,000,000,000	$ 5,000,000,000	$ 5,000,000,000
Potential cash payment at acquisition related to acquisition tender offer					375,000,000
Total cash paid for acquisition				225,000,000
Potential future payments related to acquisition tender offer					$ 225,000,000

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet102.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Quarterly Results of Operations (Details) (USD  $) In Thousands, except Per Share data	3 Months Ended	12 Months Ended
Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Mar. 31, 2009	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Quarterly Results of Operations
Total revenues	$ 1,998,687	[1]	$ 1,937,656	[1]	$ 1,927,224	[1]	$ 2,085,853	[1]	$ 2,032,379	$ 1,801,389	$ 1,647,155	$ 1,530,460	$ 7,949,420	$ 7,011,383	$ 5,335,750
Gross profit on product sales	1,433,901	[1]	1,387,975	[1]	1,350,536	[1]	1,347,633	[1]	1,330,999	1,239,255	1,185,333	1,118,166
Net income	626,365	[1]	702,163	[1]	709,127	[1]	852,094	[1]	799,393	670,478	569,145	586,576	2,889,749	2,625,592	1,970,335
Net income attributable to Gilead	629,419	[1]	704,876	[1]	712,061	[1]	854,901	[1]	802,212	673,033	571,398	589,112	2,901,257	2,635,755	1,978,899
Net income per share attributable to Gilead common stockholders-basic	$ 0.78	[1]	$ 0.85	[1]	$ 0.81	[1]	$ 0.95	[1]	$ 0.89	$ 0.75	$ 0.63	$ 0.65	$ 3.39	$ 2.91	$ 2.15
Net income per share attributable to Gilead common stockholders-diluted	$ 0.76	[1]	$ 0.83	[1]	$ 0.79	[1]	$ 0.92	[1]	$ 0.87	$ 0.72	$ 0.61	$ 0.63	$ 3.32	$ 2.82	$ 2.06
In-process research and development impairment charges													$ 136,000
[1]	During 2010, we recorded  $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/Sheet103.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Schedule II Valuation and Qualifying Accounts (Details) (USD  $)	12 Months Ended
Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010 Accounts Receivable Allowances [Member]	Dec. 31, 2009 Accounts Receivable Allowances [Member]	Dec. 31, 2008 Accounts Receivable Allowances [Member]	Dec. 31, 2010 Valuation Allowance for Deferred Tax Assets [Member]	Dec. 31, 2009 Valuation Allowance for Deferred Tax Assets [Member]	Dec. 31, 2008 Valuation Allowance for Deferred Tax Assets [Member]
Balance at Beginning of Period			$ 132,810,000	[1]	$ 90,694,000	[1]	$ 72,217,000	[1]	$ 1,078,000	[2]		[2]	$ 23,498,000
Additions/Charged to Expense			818,132,000	[1]	606,504,000	[1]	500,037,000	[1]	12,127,000	[2]	15,103,000	[2]	965,000
Deductions			800,000,000	[1]	564,388,000	[1]	481,560,000	[1]	165,000	[2]	14,025,000	[2]	24,463,000
Balance at End of Period			150,942,000	[1]	132,810,000	[1]	90,694,000	[1]	13,040,000	[2]	1,078,000	[2]		[2]
Valuation allowance for deferred tax assets, acquisitions	$ 9,900,000	$ 1,100,000
[1]	Allowances are for doubtful accounts, sales returns, cash discounts and chargebacks.
[2]	Valuation allowance for deferred tax assets includes  $9.9 million and  $1.1 million as of December 31, 2010 and 2009, respectively, related to our acquisitions.

------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877 Content-Location: file:///C:/443b7a86_03ad_4718_a33a_b661e92b5877/Worksheets/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" ------=_NextPart_443b7a86_03ad_4718_a33a_b661e92b5877--